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Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy, 
despite advances in treatment. The most common histological type, high grade serous 
carcinoma (HGSC) is usually diagnosed at an advanced stage, and although this type of 
tumors frequently responds to surgery and platinum-based chemotherapy, they 
usually recur. Ovarian clear cell carcinoma (CCC) is an unusual histological type, which 
is known to be intrinsically chemoresistant and is associated with poor prognosis in 
advanced stages. Hence, the discovery of new therapeutic strategies urges and the fact 
that histone deacetylases (HDACs) expression is increased in ovarian cancer points out 
HDAC inhibitors (HDACIs) as an attractive approach. 
Our hypothesis is that HDACIs are useful drugs to treat ovarian cancer. So, the 
main goal was to disclose the molecular mechanisms underlying the action of HDACIs 
in ovarian cancer. 
We investigated the expression profile of HDAC, class I (HDAC1, 2, 3) and class II 
(HDAC4, 6 and phosphoHDAC4/5/7) in ovarian cancer. HDACs protein expression was 
analyzed by immunohistochemistry on tissue microarrays (TMA) from 64 patients with 
ovarian cancer (49 cases of HGSC and 15 cases of CCC). Our results showed that HGSC 
expressed HDAC1, 2, 3, 4, 6 and phosphoHDAC4/5/7 whereas CCC expressed HDAC1, 2 
and 6. HDAC2, 3, 4 and pHDAC4/5/7 were associated with HGSC type. Kaplan-Meier 
curves showed that HDACs expression was not associated with survival. We also 
evaluated the association of HDACs expression profile with the cell cycle markers and 
we found that HDAC1 expression was statistically associated with p21 expression in 
HGSC.  
In order to understand the effects of HDACIs we used cancer cell lines (OVCAR3 
and ES2) exposed to HDACIs, butyric acid and vorinostat, 5-aza-2´-deoxycytidine (DNA 
methylation inhibitor) and carboplatin and paclitaxel (standard chemotherapy) alone 
and combined. Analysis of cell death, proliferation and migration in cancer cell lines 
was performed. Our results showed, that both HDACIs induced cell death, mainly 
through apoptosis in the two cell lines. This result was further confirmed in ES2 cell 
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line exposed to vorinostat, by the study of immunofluorescence of cleaved caspase 3 
and the ratio of BAX/BCL-2 proteins, which increased after vorinostat exposure. Cell 
migration was decreased by vorinostat in both cancer cell lines. Our results also 
indicated that the association of different drugs were able to potentiate the effect of 
standard chemotherapy, mainly in ES2 cell line (CCC), supporting that EOC treatment 
can benefit from combined chemical and epigenetic therapy.  
Considering that CCC is a unique clinical, histopathological and molecular entity 
within ovarian cancer and having HNF1β as a pivotal pro-survival gene we evaluate the 
role of HNF1β in cell cycle arrest and apoptosis in CCC upon vorinostat exposure. Our 
results showed that vorinostat induced increased levels of HNF1β and at the same 
time cell cycle arrest and apoptosis in ES2 cells. This effect on HNF1β is associated with 
increased acetylation load of HNF1β. This study confirms that epigenetic modulation 
affects not only the conformation of chromatin and gene expression, but also it may 
alter the function and the turnover of proteins other than histones. 
Also, epigenetic modulation of signaling pathways have been reported in HGSC 
and CCC, including the overexpression of Notch pathway elements and we investigated 
the modulation of the Notch pathway by vorinostat in ovarian cancer. Using 
immunofluorescence and quantitative polymerase chain reaction, our results revealed 
that vorinostat activated the Notch pathway in CCC and HGSC cell lines, through 
different Notch ligands. The activation of Notch pathway by vorinostat, in CCC and 
HGSC cell lines, culminated in the increased expression of the same downstream 
transcription factors, hairy enhancer of split (Hes1) 1 and 5, and Hes-related proteins 1 
and 2. Therefore, vorinostat modulates the expression of several downstream targets 
of the Notch pathway and independent Notch receptors and ligands that are 
expressed in HGSC and CCC. This upregulation of the Notch pathway may explain why 
vorinostat therapy fails in ovarian carcinoma treatment, as shown in certain clinical 
trials.   
We also established a cell line from ascitic fluid from a patient with HGSC, who 
had been previously treated with neoadjuvant chemotherapy. The cell spontaneous 




and 3D cell cultures. Characterization studies confirmed that IPO-SOC43 cell line is of 
EOC origin and maintains morphological and molecular features of the primary tumor. 
The success of the cell line growth in a 3D systems, allows it to be used in more 
complex assays than those performed in 2D models. IPO-SOC43 is available for public 
research and we hope it can contribute to enrich the in vitro models addressing EOC 
heterogeneity, being useful to investigate EOC and to develop new therapeutic 
modalities.  
In conclusion, the results in vitro proved that there is benefits of combined 
therapy, using drugs with action of epigenetic modulation and conventional therapy. 
This thesis also pave the path for future studies on the role of HDACs cancer cells 
pathophysiology, serving as markers for the design of personalized and specific 
therapeutic strategies. 















































O carcinoma do ovário é a neoplasia ginecológica mais letal. Vários fatores são 
identificados como responsáveis pela baixa eficácia no tratamento do carcinoma do 
ovário. Assim, é postulado que a elevada taxa de mortalidade se deve principalmente, 
a dificuldades no diagnóstico da doença numa fase inicial e à resistência à terapêutica 
convencional. Deste modo, a investigação de novas estratégias terapêuticas é 
essencial e urgente. 
A expressão aumentada das desacetilases de histonas (HDAC) identificada em 
carcinomas do ovário pode indicar que os inibidores de HDACs (HDACIs) possam ser 
uma alternativa terapêutica. Os HDACIs são uma classe de agentes anti-neoplásicos, 
que bloqueiam a desacetilação de histonas e outras proteínas, causando paragem do 
ciclo celular, diferenciação e/ou apoptose das células neoplásicas. Vários HDACIs estão 
a ser testados em ensaios clínicos, quer como agentes únicos quer em terapias 
combinadas, apresentando alguns resultados positivos no combate a vários tumores 
sólidos e hematológicos. Os mecanismos moleculares do efeito anti-tumoral dos 
HDACIs não estão completamente esclarecidos, nem a avaliação da sensibilidade e/ou 
resistência das células a fármacos com influência na regulação epigenética. 
O cancro do ovário é um conjunto vasto de neoplasias distintas sendo os 
carcinomas o grupo mais prevalente. Atualmente, não é possível, de modo fiável 
prever o curso clínico da doença nem a resposta individual à quimioterapia. No 
entanto, a identificação morfológica do tipo de carcinoma do ovário tem valor 
prognóstico independente em análise multivariada, pelo que a avaliação de potenciais 
biomarcadores que possam constituir alvos terapêuticos deverá ser efetuada de modo 
independente, pois previsivelmente cada tipo histológico deverá ter uma resposta 
específica ao tratamento. 
Por estas razões, a hipótese geral desta tese é que os HDACIs são fármacos úteis 
no tratamento do cancro do ovário, sendo o objetivo a avaliação de mecanismos 
subjacentes à ação destes fármacos em carcinomas de ovário de modo a permitir uma 
terapêutica mais eficaz.  
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Neste projeto foram estudados apenas dois tipos histológicos de carcinoma do 
ovário: seroso de alto grau (HGSC), que é o mais frequente e o carcinoma de células 
claras (CCC) que apesar de pouco frequente é atualmente resistente à terapia 
convencional. 
Assim, um dos primeiros objetivos desta tese foi caracterizar o perfil de 
expressão das HDACs em carcinomas do ovário e validar a relevância de testar HDACIs 
como agentes de regulação epigenética, no tratamento do carcinoma do ovário. Os 
resultados em doentes com cancro do ovário mostram que o perfil de expressão das 
HDACs se associa ao tipo histológico. No HGSC verifica-se uma associação das HDACs 2, 
3, 4 e das HDAC4/5/7 fosforiladas, enquanto que no carcinoma de células claras (CCC), 
as HDAC1, 2 e 6 apresentam níveis elevados de expressão e verifica-se uma diminuição 
da expressão da HDAC3, HDAC4 e das HDAC4/5/7 fosforiladas. A expressão das HDACs 
2, 3, 4 e das HDAC4/5/7 fosforiladas estão associadas ao tipo histológico sendo mais 
expressas no HGSC. A expressão da HDAC3 está ainda associada a parâmetros clínicos, 
nomeadamente ao estádio mais avançado e à metastização; bem como a HDAC4c e a 
HDAC4/5/7 fosforiladas. 
Considerando que as HDACs estão sobre-expressas nestes tipos histológicos de 
carcinomas do ovário, seguidamente, pretendemos avaliar o efeito epigenético dos 
HDACIs em modelos in vitro de carcinoma de ovário e compreender as alterações 
decorrentes da exposição aos HDACIs, bem como perceber o efeito destes na dinâmica 
molecular e viabilidade celular. Para tal, usamos duas linhas celulares, de dois tipos 
histológicos já avaliados, uma linha de HGSC - OVCAR3 e uma linha celular de CCC - 
ES2.  
Os resultados indicam que os HDACI induzem a morte celular em ambas as linhas 
celulares, principalmente através da apoptose, avaliada por citometria de fluxo. Este 
resultado foi evidenciado na linha celular ES2 exposta ao vorinostat, pelo estudo da 
imunofluorescência da caspase 3 clivada e da avaliação da razão das proteínas 
BAX/BCL-2, que aumentou após a exposição ao vorinostat. Os resultados também 
indicam que a associação de diferentes tipos de fármacos potencia o efeito da 




cumulativo na morte celular, principalmente na linha celular ES2 (CCC). A migração 
celular também é afetada pelo vorinostat em ambas as linhas celulares de carcinoma 
de ovário. 
Os resultados mostram também que o vorinostat induz aumento do HNF1β e ao 
mesmo tempo paragem do ciclo celular e apoptose nas células ES2. O aumento da 
expressão do HNF1β é acompanhado pelo aumento dos seus níveis da acetilação. 
Este estudo confirma que a modulação epigenética afeta a conformação da 
cromatina e da expressão genética, mas também pode alterar a função e o turnover de 
outras proteínas além das histonas. Pela primeira vez é observado que a proteína 
HNF1β pode ser acetilada, contudo serão necessários mais estudos para validar o 
papel da acetilação na função e degradação da proteína HNF1β. 
Nesta tese foi avaliado também a modulação de outras vias de sinalização 
importantes no carcinoma do ovário, como por exemplo a via Notch através da 
exposição a HDACIs, nomeadamente vorinostat e ácido butírico. E os nossos resultados 
mostram que o vorinostat ativa a via Notch nas linhas celulares de CCC e HGSC, através 
de diferentes ligandos da via Notch. No CCC, a ativação da via Notch parece ocorrer 
através dos ligandos Delta (Dll) 1, 2 e 3, enquanto nos HGSC, os ligandos Dll1, Jagged 1 
e 2 são os mais expressos. A ativação da via Notch pelo vorinostat, em ambas linhas 
celulares, culminou na expressão aumentada dos mesmos genes alvo da via Notch, 
Hes1 e 5 e Hey 1 e 2. 
Assim, o vorinostat modula a expressão de vários fatores de transcrição da via 
Notch, independentemente do painel de receptores e dos ligandos expressos nas 
linhas de HGSC e CCC. Esta redundância da via Notch pode explicar porque a 
terapêutica isolada com vorinostat falha no tratamento do carcinoma do ovário, como 
observado em vários ensaios clínicos. 
Por fim, no decorrer dos trabalhos apresentados, e considerando a importância 
das linhas celulares na compreensão da biologia do cancro e nos mecanismos de 
sensibilidade e resistência das células aos fármacos, foi estabelecida uma linha celular, 
IPO-SOC43 a partir de líquido ascítico de uma doente com HGSC que havia sido 
previamente tratada com quimioterapia neoadjuvante. 
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Foram efetuados estudos de caracterização desta linha que demonstram que a 
linha celular IPO-SOC43 é de origem epitelial e que mantém características 
morfológicas e moleculares do tumor primário. As células mantêm-se em cultura em 
monocamada (2D) e em agregados em 3D, com taxas de proliferação e viabilidade 
dentro do esperado para uma linha neoplásica maligna. O sucesso da viabilidade em 
culturas 3D permite o seu uso em ensaios mais complexos, nomeadamente, na análise 
da contribuição dos vários componentes do microambiente tumoral na progressão da 
doença e resposta à terapêutica. 
A linha celular IPO-SOC43 está disponível para ser utilizada experimentalmente e 
esperamos que possa contribuir para enriquecer os modelos in vitro que abordam a 
heterogeneidade dos EOC e desenvolver novas modalidades terapêuticas. 
Em suma, os resultados contribuem para a implementação racional de novas e 
diferentes abordagens terapêuticas. Os resultados mostram que in vitro há benefício 
de terapêutica combinada, utilizando fármacos com ação de modelação epigenética e 
terapia convencional. Esta tese também abre caminho para estudos futuros mais 
detalhados sobre a função das HDACs na dinâmica celular e não só na regulação 
epigenética, bem como também na análise de mecanismos subjacentes à ação de 
proteínas codificadas por genes relevantes em cada tipo histológico de carcinoma do 
ovário. 
Espera-se assim, que a compreensão dos mecanismos subjacentes à ação dos 
fármacos envolvidos na regulação epigenética possa fornecer orientações para 
estratégias terapêuticas mais específicas e personalizadas. 











Figure 1. 1 - Representative examples of the five main types of ovarian carcinoma stained with 
hematoxylin and eosin (H&E) ...................................................................................................................... 5 
Figure 1. 2 - Ovarian cancer signaling pathways scheme ......................................................................... 21 
Figure 1. 3 – Cytosine metylation .............................................................................................................. 31 
 
Figure 2. 1- Representative pattern of HDACs protein expression in HGSC in tissue microarray (TMA) 
sections. ..................................................................................................................................................... 54 
Figure 2. 2 - Representative pattern of HDACs protein expression in CCC in tissue microarray (TMA) 
sections ...................................................................................................................................................... 55 
Figure 2. 3 - Representative examples of immunostaining for p16, p21, p53 and cyclin D1 in different 
histological types of ovarian cancer .......................................................................................................... 61 
 
Figure 3. 1 - Mechanism of action of HDAC inhibitors (HDACI) ................................................................ 74 
Figure 3. 2 - Cell death in ES2 cell line exposed to HDACIs and 5-aza-dC ................................................. 80 
Figure 3. 3 - Cell death in OVCAR3 cell line exposed to HDACIs and 5-aza-dC ......................................... 81 
Figure 3. 4 - mRNA expression of BCL-2 and BAD in ES2 cell line ............................................................. 82 
Figure 3. 5 - Expression of BCl-2 and BAX by Western blot ...................................................................... 83 
Figure 3. 6 - Expression of cleaved caspase 3 by immunofluorescence in EOC cell lines......................... 84 
Figure 3. 7 - mRNA expression of BECLIN-1 and ATG-7 in ES2 cell line .................................................... 85 
Figure 3. 8 - Cell death in ES2 cell line exposed to vorinostat, 5-aza-dC, carboplatin and/or paclitaxel 86 
Figure 3. 9 - Cell death in HGSC-OVCAR3 cell line exposed to vorinostat, 5-aza-dC, carboplatin ........... 87 
Figure 3. 10 - Cell proliferation curve for ES2 and OVCAR3 cells exposed to HDACIs and 5-aza-dC ....... 88 
Figure 3. 11 - Wound healing assay in ES2 cells and OVCAR3 cells exposed to vorinostat. .................... 89 
 
Figure 4. 1 - Vorinostat affects cell proliferation of clear cell carcinoma (ES2) but not of serous 
carcinoma (OVCAR3) ............................................................................................................................... 104 
Figure 4. 2 - Long term exposure of Vorinostat induces p21 expression and cell cycle arrest in clear cell 
carcinoma (ES2) ....................................................................................................................................... 105 
Figure 4. 3 - The expression of mutant p53 increases in ES2 upon vorinostat removal, after long term 
exposure ................................................................................................................................................... 106 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
xv 
 
Figure 4. 4 - Vorinostat increases cell death in clear cell carcinoma (ES2) ............................................. 107 
Figure 4. 5 - Vorinostat exposure increase the levels of HNF1β in clear cell carcinoma (ES2), both in 
short and long term exposure ................................................................................................................. 108 
 
Figure 5.1 – Vorinostat increases the expression of mRNA of Notch receptors, Delta/Jagged ligands 
and Hey/Hes downstream target genes ................................................................................................. 118 
Figure 5. 2 – Vorinostat increases the mRNA expression of Notch receptors, ligands and downstream 
targets in ovarian serous carcinoma OVCAR3 cell line ........................................................................... 120 
Figure 5. 3 - Schematic representation of Notch pathway in ovarian cancer ........................................ 123 
 
Figure 6. 1 – Morphological characterization of cells from ascitic fluid ................................................. 136 
Figure 6. 2 - Characterization of the primary ovarian carcinoma of the patient from whose ascitic fluid 
IPO-SOC43 was established ..................................................................................................................... 137 
Figure 6. 3 - Detection of cytokeratins and vimentin in IPO-SOC43 cell line by flow cytometry .......... 138 
Figure 6. 4 - Ovarian biomarkers in IPO-SOC43 cell line ......................................................................... 139 
Figure 6. 5 - Expression of biological markers in 2D cell culturing models in IPO-SOC43 cell line ........ 140 
Figure 6. 6 - Characterization of IPO-SOC43 cell line in 2D model .......................................................... 141 
Figure 6. 7 - Proliferation curve of IPO-SOC43 cell line ........................................................................... 142 
Figure 6. 8 - Wound healing assay to determine the migration rate of IPO-SOC43. ............................. 143 
Figure 6. 9 - cCGH profiles of cells from ascitic fluid and IPO-SOC43 cell line ........................................ 144 
Figure 6. 10 - Sanger sequencing histogram of TP53 exon 5 .................................................................. 147 
Figure 6. 11 - Aggregation of IPO-SOC43 with and without ROCK Inhibitor in 3D culture system ........ 148 
Figure 6. 12 - 3D Culture progression with measurement of aggregates area and growth curve of IPO-
SOC43 cells with ROCK Inhibitor ............................................................................................................. 149 
Figure 6. 13 - Characterization of IPO-SOC43 cell line in 3D model........................................................ 150 
Figure 6. 14 - Expression of biological markers relevant for the establishment of 3D cell culturing 









Table 1. 1 - TNM and FIGO classifications for Ovarian, Fallopian Tube and Peritoneal Cancer Staging 
System ........................................................................................................................................................ 15 
Table 1. 2 - Classes of histone deacetylases; localization in the cell, length, chromosomal localization 
and function ............................................................................................................................................... 35 
 
Table 2. 1 - Antibodies used for imunohistochemical study ..................................................................... 50 
Table 2. 2 - Clinical and pathological characteristics of the EOC patients ................................................ 52 
Table 2. 3 - Expression of HDACs in EOC commercial lines ....................................................................... 53 
Table 2. 4 - Expression of HDACs in EOC samples and its association with the histological type ........... 54 
Table 2. 5 - Association of HDACs expression and clinicopathological parameters in EOC ..................... 57 
Table 2. 6 - Multivariate analysis of HDAC3, HDAC4c and phosphoHDAC4/5/7 expression for 
histological type and metastasis ............................................................................................................... 59 
Table 2. 7 - Expression of cell cycle markers in EOC commercial cell lines .............................................. 59 
Table 2. 8 - Expression of cell cycle markers in EOC samples ................................................................... 60 
Table 2. 9 - Expression of HDACs expression and cell cycle markers in EOC ............................................ 62 
 
Table 3. 1 - Chemicals used in ovarian cancer cell lines ............................................................................ 76 
  
Table 6. 1 - Antigens evaluated and antibodies used to characterize IPO-SOC43 cell line .................... 130 
Table 6. 2 - Primers for PCR of the TP53 gene (Exons 4-9) ...................................................................... 133 








































This PhD thesis would not be possible without a large number of contributions, 
and for this reason I would like to express my gratitude to my supervisors, Ana Félix, 
for all the precious mentoring, guidance and motivation and to Jacinta Serpa for 
guiding me in the field of molecular biology, teaching me professional attitude towards 
designing, conducting and evaluating laboratory experiments. Both of them generously 
shared their time and expertise with me, were always open to answer my questions 
and discuss my ideas and were critical and supportive at the same time. I am deeply 
indebted to them for helping me. 
I am also thankful for all former and present members of the UIPM with a very 
special thanks to Leonor Remédio, Francisco Caiado, Germana Domingues, Lídia Silva, 
Sofia Gouveia and Filipa Coelho for all the good work environment, great friendship 
and helpful discussions. 
I would like to thank to the director José Cabeçadas, doctors and all colleagues of 
the Pathology Department of IPOLFG, especially to Teresa Pereira, Sónia Araújo, Filipa 
Areia, Cátia Teixeira, Arsénia Manhita and Filipa Antunes for creating a motivating and 
pleasant working atmosphere. From IPOLFG, I also thank Carmo Martins for her 
precious help with CGH and to António Guimarães for the valuable clinical data. 
I would like to thank to Vitor Espírito Santo and Catarina Brito, from IBET for 
sharing your knowledge of 3D cultures.   
Last, but not least, I would like to thank my parents and my family for their 
continuous support and encouragement. To my husband, for his patience and caring 



































LIST OF PUBLICATIONS 
 
The author declares that has designed and performed research, collected and 
analyzed data, and wrote the text of the published paper, and the manuscripts in 
preparation, which are part of this dissertation. 
 
Published original paper: 
Silva, F., Félix, A. & Serpa, J. Functional redundancy of the Notch pathway in 
ovarian cancer cell lines. Oncol. Lett. 12, 2686–2691 (2016). 
 
Published in proceedings (Poster): 
Silva, F., Serpa, J., Domingues, G., Silva, G., Almeida, A., Félix, A. Cell death 
induced by HDACS inhibitors in ovarian cancer cell lines (serous and clear cells 
carcinomas) – role of NOTCH, TP53 and FN1. BMC Proceedings, 4(Suppl 2):P36 (2010). 
Silva, F., Serpa, J., Fernandes, S., Dias, S., Félix, A. HDACS inhibitors effects in 
Ovarian Clear Cell Carcinoma. SINAL, 6th National Meeting, April, UMinho (2012). 
Silva, F., Fernandes, S., Félix, A., Serpa, J., Vorinostat Increases ARID1A splicing 
variant expression which may regulate HNF1β and cell survival, in Ovarian Clear Cell 
Carcinoma (CCC). International Journal of Gynecological Cancer, 23 (8) (2013) 
Silva, F., Coelho, F., Fernandes, S., Félix, A., Serpa, J., Vorinostat induces HNF1β 
expression and latency in ovarian clear cell carcinoma (OCCC) and resistance in ovarian 
serous carcinoma (OSC), EACR-AACR-SIC, Anticancer Drug Action and Drug Resistance: 



































ARID1A  adenine thymine-rich interactive domain 1A gene 
AKT  akt serine/Threonine kinase 
ATCC  American Type Culture Collection 
BAX  BCL-2 associated X protein 
BCL-2  B-cell lymphoma 2 
BAD  BCL-2 associated agonist of cell death 
BRAF  v-Raf murine sarcoma viral oncogene homolog B1 
BRCA1  breast cancer 1 gene 
BRCA2  breast cancer 2 gene 
CA125  cancer antigen 125 
CCNE1  cyclin E1 
CDKN1A  cyclin dependent kinase inhibitor 1A 
CTNNB1  catenin beta 1 
EOC  epithelial ovarian cancer 
ER  estrogen receptor 
FACS   fluorescence-activated cell sorting 
FBS  fetal bovine serum 
FIGO  Féderation Internationale de Gynécologie et d’Obstétrique 
FITC  fluorescein isothiocyanate 
FOXM1  forkhead box M1 
GSH  glutathione peroxidase 
HAT  histone acetyltransferases 
HDAC  histone deacetylases 
HDACI  histone deacetylases inhibitors 
HES  human hairy and enhancer of split 
HEY  hairy/enhancer of split related with YRPW motif 
HER-2  human epidermal growth factor receptor 2 
HPRT  hypoxanthine-guanine phosphoribosyl transferase 
HNF1β  hepatocyte nuclear factor 1β 
γ-H2AX  gamma-H2A histone family member X 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
xxiii 
 
LOH  heterozygosity 
MAPK  mitogen-activated protein kinase 
MLH1  mutL homolog 1 
MSH2  mutS homolog 2 
MSH6  mutS homolog 6 
IHC  immunohistochemistry 
KRAS  kirsten rat sarcoma viral oncogene homolog 
MAPK  mitogen-activated protein kinase 
mTOR  mammalian target of rapamycin 
NICD  notch intracellular domain 
NF1  neurofibromin 1 
PAX  paired box 2 
p16INK4A  cyclin-dependent kinase inhibitor 2A 
p21  cyclin-dependent kinase inhibitor 1A 
p53  tumor protein/suppressor p53 
PBS  phosphate-buffered saline 
PCR  polymerase chain reaction 
PFA  paraformaldehyde 
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic 
subunit alpha 
PMS2  PMS1 homolog 2, mismatch repair endonuclease 
PPP2R1A protein phosphatase 2, regulatory subunit A 
PTEN  phosphatase and tensin homolog 
ROMA  risk of ovarian malignancy algorithm 
ROS  reactive oxygen species 
RB1  retinoblastoma transcriptional corepressor 1 
RSF1  remodeling and spacing factor 1 
SAHA  suberoylanilide hydroxamic acid 
TCGA  The Cancer Genome Atlas 
TMA  tissue microarray 
TP53  gene encoding tumor protein p53 
WHO  World Health Organization 





















Cancer is a group of distinct diseases in which cells proliferate out of control and 
invade other tissues. Cancer cells no longer respond to genes that regulate cell cycle, 
function, differentiation and death. Tumor cell invasion of surrounding tissues and 
distant organs is the main cause of morbidity and mortality for most cancer patients1. 
The biological process by which normal cells are transformed into malignant cancer 
cells has been the subject of a large research in the biomedical sciences for many 
decades1. Cancer is the leading cause of mortality worldwide, being responsible for 8.2 
million cancer related deaths in 20122. 
1.1 Epithelial ovarian cancer (EOC) 
1.1.1 Epidemiology and Risk factors 
Epithelial ovarian cancer (EOC) is the most lethal gynecology malignancy3–5 and 
the seventh most common in women worldwide. Nearly 240,000 women6 were 
estimated to have been diagnosed with ovarian cancer in 2012 with incidence rates 
varying across the world. Although ovarian cancer accounts for only 4% of all cancers 
in women7, it has one of the highest death-to-incidence ratios, due to difficulties in 
detection, diagnosis and therapy of the disease8. Like most cancers, the risk of ovarian 
cancer rises with age: the median age of patients at diagnosis is 60 years, and the 
average lifetime risk for women in developed countries is around one in 709,10. 
Most ovarian carcinomas occur after menopause when the ovaries have little or 
no physiological role. As a consequence of the absence of abnormal ovarian function 
associated with major symptoms and the anatomical location (deep in the pelvis) 
about 70% of the patients are diagnosed with advanced-stage (extra-ovarian) disease 
and 5-years survival rates are between 20-40%11,12. Although most advanced stage 
cancers respond to standard therapy, relapse occurs in over 70% of patients, with 





In Portugal, the incidence of ovarian cancer is 490/100.000 (2008) and 5-year 
survival rate is 40%. Every year, in Portugal, the disease accounts for more than 371 
deaths12. 
There are several factors that can affect the risk of developing ovarian cancer 
and therefore ensuring a primary prevention, screening and early detection. One 
important risk factor is the familial history of ovarian or breast cancer, present in only 
10–15% of patients and mainly associated with germline mutations in BRCA1 and 
BRCA2 (breast cancer 1, 2 gene) genes14, and also with Lynch syndrome (a group of 
hereditary nonpolyposis colorectal cancer), having germline mutations in DNA 
missmatch repair genes MLH1 (MutL homolog1), MSH2 (MutS homolog 2), MSH6 
(MutS homolog 6) and PMS2 (PMS1 homolog 2)15,16. Women with a BRCA1 mutation, 
the risk of epithelial ovarian cancer is 39–46%17, and with a BRCA2 mutation is 
between 12–20%9,14. Whereas, for women with Lynch syndrome a 3-14% risk of 
ovarian cancer is estimated. The management of women with genetic predisposition 
for ovarian cancer includes surveillance and risk-reducing surgery18.  
Moreover, nulliparity, early menarche, late menopause, and increasing age are 
associated with increased risk, whereas oral contraceptive use, pregnancy, lactation, 
and tubal ligation are associated with reduced risk19. Several studies have 
demonstrated that the use of oral contraceptives for more than five years decreases 
the risk of ovarian cancer by 20%19. The prophylactic salpingo-oophorectomy may 
reduce the risk of ovarian cancer by 80 to 95% and can be recommended for women 
with high risk of developing the disease20. Survival of ovarian cancer patients has 
improved due to the increased use of platinum-based therapy and a greater 
determination to treat recurrent disease. As mentioned above, the majority of patient 
firstly respond to chemotherapy, but most will relapse, contributing to around 152,000 









1.1.2 Histological Types 
Ovarian tumors mainly arise from three different cell types; epithelial, germ, and 
sex cord stromal cells21 and several studies have contributed to confirm the 
heterogeneous nature of EOC based on their clinicopathological and molecular 
features and possible putative precursor lesions22–24. EOC represent 90% of ovarian 
malignant tumors21 and is a very heterogeneous group of neoplasms that exhibit a 
wide range of tumor morphology, clinical manifestations and underlying genetic 
alterations25. 
Current investigations support the general view that serous tumors develop, at 
least in 50%, from the fallopian tube; endometrioid and clear cell tumors are 
postulated to arise from endometrial tissue in the ovary (most probably by passing 
through the fallopian tube) that results in endometriosis and tumors23,24. 
 According to the latest classification by World Health Organization2 in 2014 and 
based on histopathology, immunohistochemistry, and molecular genetic analysis, 
ovarian epithelial tumors are grouped into seven different types. Low grade tumors 
include low grade serous carcinoma (LGSC<5%), endometrioid carcinomas (EC; 10%), 
mucinous carcinomas (MC; 3%), and a subset of clear cell carcinomas (CCC; 10%)26–29. 
These tumors develop slowly and in general are confined to the ovary30, genetically 
stable, and each histological type has a distinct genetic profile27,29,30. In contrast, high 
grade tumors progress rapidly and include high grade serous carcinoma (HGSC), 
seromucinous tumors (probably), undifferentiated carcinoma and some clear cell 
carcinomas28 (Figure 1.1). HGSC is the most prevalent type and it is characterized by a 
very homogenous genetic profile characterized by tumor protein p53 (TP53) mutations 







Figure 1. 1 - Representative examples of the five main types of ovarian carcinoma stained 
with hematoxylin and eosin (H&E) 
High grade serous carcinoma, clear cell carcinoma, low grade serous carcinoma, endometrioid 
carcinoma and mucinous carcinoma. Scheme adapted from Jones & Drapkin32 and Karst & 
Drapkin33. 
1.1.2.1 Serous carcinoma 
Serous histology is the most common, representing 70% of EOC34. It is accepted 
that LGSC and HGSC are fundamentally different tumor types, and consequently, 
different diseases2. 
1.1.2.1.1 Low grade serous carcinomas (LGSC) 
LGSC are rare and account for <5% of all cases of ovarian carcinomas35. They 
frequently have a noninvasive serous borderline component (with or without 
micropapillary pattern) and probably they represent tumor progression of serous 
borderline tumors beyond microinvasion. Although the presence of small foci of LGSC 
Clear cell
PIK3CA, PTEN and ARID1A mutations, 














in an ovarian borderline tumor is associated with a good prognosis, patients with 
advanced stage disease fare less favorably. Typically, present as large masses that are 
confined to one ovary (stage Ia), are indolent, and have good prognosis2,28. They show 
a relative genetic stability and usually display a variety of somatic alterations that 
include mutations in v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) or 
kirsten rat sarcoma viral oncogene homolog (KRAS) genes, in 33-50% and 27-36%36, 
respectively. 
Microscopically, LGSC has small papillae of tumor cells exhibiting uniform nuclei 
within hyalinized stroma, which often contains psammoma bodies. Distinction of LGSC 
from HGSC relies on cell atypia and mitotic activity. Ki-67 immunoreaction differs 
between the two tumor types, being the median Ki-67 labeling index lower (2.5%) in 
LGSC than in HGSC (22.4%)37. The most useful immunomarker is p53 as this tumor type 
shows a wild type positivity in the nuclei in contrast with HGSC2.  
1.1.2.1.2 High grade serous carcinomas (HGSC) 
HGSC are aggressive tumors that are usually diagnosed at an advanced stage, 
and although they frequently respond to surgery and platinum-based chemotherapy, 
they eventually recur. Microscopically, HGSC show neoplastic cells displaying papillary 
and solid growth with slit-like glandular lumens. The tumor cells are usually of 
intermediate size, with spotted bizarre mononuclear giant cells exhibiting prominent 
nucleoli26. In contrast to LGSC, these tumors show more than threefold variation in 
nuclear size26,38. 
In contrast to LGSCs, HGSCs are not associated with serous borderline tumors 
and typically exhibit TP53 mutations and BRCA alterations39, and most of these tumors 
show immunoexpression for p53, BRCA1, WT1 (Wilm’s tumor 1 factor), p16 and have 
estrogen receptors (ER) in approximately two-thirds of HGSC cases40. 
HGSC show considerable genetic instability, harbor mutations and show an 
association of TP53 mutations with increased expression of gamma-H2A histone family 
member X (-H2AX), a marker of DNA damage, expression of Ki-67, a proliferation 





overexpression/amplification of HER2/neu, AKT (AKT serine/ threonine kinase) and loss 
of heterozygosity (LOH) on chromosomes 7q and 9q are common4. Profiling of mRNA 
and miRNA (micro RNA) of 489 Type II tumors, in particular HGSC, performed by The 
Cancer Genome Atlas (TCGA)31 revealed that almost all samples comprised TP53 
mutations (in almost 98% of the cases ) and significant recurring somatic mutations in 
NF1 (neurofibromin 1), BRCA1, BRCA2, RB1 (RB transcriptional corepressor 1), 
CDK1227–31 (cyclin dependent kinase 12), CCNE1 (cyclin E1), AKT2 (AKT serine/ 
threonine kinase 2), RSF1 (remodeling and spacing factor 1) and PIK3CA 
(phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)31,41. 
KRAS mutations are rare and BRAF mutations have not been described in HGSC36. In 
addition, Notch3 and FoxM1 (forkhead box M1) were found to be involved in HGSC 
pathophysiology. More recently, the results of the TCGA study were highlighted in 
another genome-wide report42. 
As a result of the chromosomal instability, HGSC are typically aneuploid, with 
very complex karyotypes. The aCGH (array Comparative Genomic Hybridization) 
findings of the TCGA study31 reveal gains/amplifications of 1q, 3q 6p 7q, 8q, 12p, 20p 
and 20q; and losses of 4p, 4q, 5q, 6q, 8p, 9p, 9q, 11p, 11q ,13q, 14q, 15q, 16p, 16q, 
17p, 17q, 18p, 18q, 19p, 19q and 22q some of them already reported in other 
studies43. Other genetic alterations observed, suggest a co-operative effect, for 
example, associations have been found between CCNE1 (cyclin E1) and 12p 
amplification41, and between MYC (V-Myc Avian Myelocytomatosis viral oncogene 
homolog) and 20q amplification by fluorescence in situ hybridization (FISH). Also, 
positive associations were identified between gains on 19 and 20q, gain of 20q and 
loss of X, and between the loss of several regions, particularly 17q.  
1.1.2.2 Endometrioid carcinomas (EC) 
After HGSC, EC and clear cell carcinomas (CCC) are the most frequent types of 
EOC accounting for approximately 10-15% of all ovarian carcinomas23. The molecular 
and genetic alterations that underlie the development of these tumors are beginning 





CCC and a direct transition from ovarian atypical endometriosis to EC or CCC, in 15%-
32% of cases44.   
EC occur most frequently in women of perimenopausal age, and most of them 
are found at an early stage45. These ovarian tumors are bilateral in 28% of cases and 
are associated in 15%–20% of cases with a carcinoma of the endometrium45,46. In the 
former presentation, both tumors are endometrioid in type in the majority of cases2. 
Up to 42% of cases, evidences of bilateral ovarian or pelvic endometriosis is present. 
Squamous differentiation inside the tumor occurs in 50% of cases45. Somatic mutations 
in CTNNB1 (β-catenin) and PTEN (phosphatase and tensin homolog) genes are the 
most common genetic alterations identified in ECs, being CTNNB1 mutations 
associated with a favorable disease outcome47,48. Also PTEN is mutated in 20% of cases 
and its inactivation results in the lack of inhibition of PI3K-AKT signaling pathway that 
inhibits apoptosis and activates proliferation. The finding of LOH at 10q23 and 
somatic PTEN mutations in endometriotic cysts, adjacent to ECs with similar genetic 
alterations, provides additional evidence of the precursor role of endometriosis in 
ovarian carcinogenesis47. An alternative mechanism for the activation of PI3K signaling 
in EC is activating mutations of PIK3CA, which encodes the p110 catalytic subunit of 
PI3K. EC is the most frequently encountered type in patients with hereditary Lynch 
syndrome49. The reported frequency of microsatellite instability (MI) in ovarian ECs 
ranges from 12.5% to 19%50,51.  
Recent discovery of ARID1A mutations in ovarian EC as well as in adjacent 
endometriosis, is considered a particular feature of these tumors52, although it appears 
to be a late event in endometrial carcinoma53. EC have expression of vimentin, 
cytokeratins (CK7, 97%; CK20, 13%), epithelial membrane antigens (EMA), estrogen 
and progesterone receptors by immunohistochemical studies54. 
1.1.2.3 Clear cell carcinomas (CCC) 
CCC is a rare type known to be intrinsically chemoresistant and associate with 
very poor prognosis in advanced stages55. Tumors are commonly unilateral. As EC, they 
are also associated with endometriosis, and those tumors next to endometriotic 





predominantly in the architectural findings: solid, tubule-cystic and papillary areas 
mixed in varied proportions. Cytological features are characterized most commonly for 
polygonal to flattened cells with pale or clear cytoplasm, which is attributed to the 
accumulation of glycogen and lipids. Densely hyaline basement membrane material 
expanding the cores of the papillae or deposit between cells is a common feature. 
Mitoses are less frequent than in other types of EOC55.  
Based on genome-wide mutational analysis, the most common mutations 
identified in CCC include ARID1A mutation in nearly half of the CCC (46%-57%) and loss 
of BAF250a expression (protein encoded by ARID1A)44. ARID1A gene has been 
identified as a novel tumor suppressor44,57 and acts as a chromatin remodeling 
modifier, which stimulates cell signaling that can lead to cell cycle arrest and cell death 
in the event of DNA damage, consequently the dysfunction of ARID1A may result in 
susceptibility to CCC carcinogenesis through a defect in the repair or replication of 
damaged DNA58. A recent study indicated that the loss of ARID1A protein expression is 
related to short disease-free survival and chemoresistance in CCC59. 
Activating mutations of PIK3CA and deletion of PTEN, are found respectively in 
about 50% and 20% of tumors47, supporting the role of an aberrant PI3K/PTEN 
pathway in CCC60. In addition, the overexpression of Notch pathway elements has also 
been reported in these tumors61,62. In contrast to various other human tumor types, 
TP53 and Rb (retinoblastoma protein) mutations are rarely detected in CCC, but these 
cell cycle regulatory proteins may be involved in the carcinogenesis of CCC through 
inactivation by ARID1A58 for example. In CCC, no BRCA alterations, chromosomal 
instability, nor complex karyotypes as seen in HGSC63 have been reported, however 
epigenetic modulation of signaling pathways have been described64–66. 
Molecular alterations in CCC are mainly unknown and this histological type 
represent a distinct challenge with a unique and different histology, with de novo 
expression of HNF1β (hepatocyte nuclear factor 1β transcription factor). 
HNF1β is involved in the glycogen synthesis67 and regulates several specific 
genes, including those encoding dipeptidyl peptidase IV (protein degradation), 





iron deposition, and antiapoptosis), annexin 4 (calcium ion binding, epithelial cell 
differentiation), and UDP Glucuronosyltransferase 1 Family, Polypeptide A Complex 
(UGT1A1) (detoxifycation)68. It is postulated that HNF1β plays an important role in the 
pathogenesis and behavior of CCC69. Promoter hypomethylation of HNF1β, and active 
transcription, was previously reported in CCC70,71. Moreover, recently, we showed the 
role of HNF1 in the intrinsic chemoresistance exhibited by CCC72. 
 CCC tumor cells are usually positive for HNF1β (>90%) and are negative for ER 
and WT1 in >95% of cases37,40. In addition to its presence in CCC, HNF1β is also 
expressed in the majority of tumors with cytoplasmic clearing, including renal CCC, 
endometrial CCC69 and ovarian and endometrial carcinomas of mixed histology.  
1.1.2.4 Mucinous carcinomas (MC) 
Mucinous tumors account, approximately, for 3% of EOC. The cells of MC 
resemble cells of the gastric pylorus, or intestine45,46,73, showing gastrointestinal 
differentiation in  the majority of these tumors. Primary MC of the ovary are large, 
unilateral and usually confined to the ovary, without ovarian surface involvement or 
pseudomyxoma peritonei, while mucinous ovarian metastases are typically small (<10 
cm) and bilateral. Malignant mucinous ovarian tumors are often heterogeneous, 
showing the coexistence of benign-appearing, borderline, noninvasive carcinoma, and 
invasive components. This morphology suggests a step-wise progression from benign 
to borderline and from borderline to carcinoma74. The category of mucinous 
borderline tumor with intraepithelial carcinoma is used for those tumors that lack 
obvious stromal invasion but show unequivocally malignant areas75. Mucinous 
borderline tumors with intraepithelial carcinoma have a very low risk of recurrence 
(<5%)76. 
The gene expression profile of MC differs from the HGSC, EC and 
CCC77. KRAS mutations are frequent, (up to 75% of primary MC),  and seems to be an 
early tumorigenic event78. Using KRAS as a molecular marker, laser capture 
microdissection studies have shown the identical KRAS mutation in MC and adjacent 
mucinous cystadenomas and borderline tumors74 supports the morphological 





1.1.2.5 Other types of ovarian carcinomas 
Seromucinous carcinomas (SMC), Brenner carcinomas (BC) and 
Undifferenciated carcinomas (UC) 
Seromucinous carcinomas (SMC) are composed predominantly of serous and 
endocervical-type mucinous epithelium. These tumors are quite uncommon and data 
on the epidemiology is still insufficient2. 
Brenner carcinomas (BC) are extremely rare but Brenner benign tumor accounts 
for 5% of benign ovarian epithelial tumors2. BC histogenesis is not well characterized 
nor the genetic and molecular events. 
Another uncommon histological type is undifferentiated carcinomas (UC), usually 
appear as solid masses with extensive necrosis, and a deficient mismatch repair 
proteins have been found in almost half of the tumors2. 
In summary, each histological type of EOC is associated with a distinct profile of 
clinical, morphological, genetic and molecular alterations, which for the most common 
low-grade tumors are shared with their respective precursor lesions (borderline 
tumors and endometriosis) supporting their stepwise progression. In contrast, the high 
grade tumors, aside from a very high frequency of TP53 mutations and molecular 
alterations of BRCA1/2, are characterized by marked genetic instability.  
1.1.3 Clinical presentation 
Ovarian cancer is often described as a ‘silent killer’79 because the symptoms are 
non-specific and common to other diseases. Symptoms such as abdominal discomfort, 
bloating, gas, nausea, and urinary urgency, frequently lead to misdiagnosis80,81, and 
contribute for the high percentage of cases that are diagnosed at an advanced stage. 
In addition, there is no routine and reliable screening for ovarian cancer82, hence the 
majority of women are diagnosed at advanced stage exhibiting extraovarian and 






Approximately 70% of women with ovarian cancer are diagnosed at stage III or IV 
of the disease82. Ovarian cancer usually spreads to the opposite ovary/fallopian tube, 
and the uterus, and then intraperitoneally. Distant metastases are rare, but may occur 
in the liver, lungs, pleura, adrenal glands, and spleen76. The histological grade of 
tumors can affect treatment and prognosis. Low grade tumors have a more favorable 
prognosis than high grade tumors. 
Cancer spread can greatly cause the accumulation of fluid in the abdomen, called 
ascites, which is a common complication of ovarian cancer that can cause swelling, 
fatigue and shortness of breath82. 
CA125, the serum tumor marker carbohydrate antigen 125 also known as mucin 
16 (MUC16) is a secreted and membrane-associated glycoprotein expressed by 
coelomic and müllerian-derived epithelia, including the epithelium of the fallopian 
tube, endometrium and endocervix83. 
CA125 levels are low (< 35 U/mL) in the serum of healthy individuals, and CA125 
elevation is commonly associated with HGSC, the most common histological type of 
ovarian carcinoma83. CA125 can be used for monitoring disease recurrence84. Although 
it is elevated in only 50-60% of ovarian cancer patients it can also be elevated in other 
non-cancerous gynecological complications such as benign ovarian neoplasms, 
endometriosis, pelvis inflammatory disease, liver disease or other malignant 
conditions, including cancers of the pancreas, breast, lung and colon85. Nevertheless, 
CA125 cannot be used as a unique parameter in the prediction of malignancy. Usually, 
a combination of a patient's medical history, clinical examination results, imaging data 
and tumor marker profile is used to clinically differentiate malignant ovarian masses 
from their benign counterparts and perform a histological exam for diagnosis 
confirmation. However, CA125 assay detects circulating MUC16, is one of the most 
widely used cancer biomarkers for the follow-up of ovarian carcinoma. 
Recently Ricardo et al.86 demonstrated that detection of aberrant cancer-
associated glycoforms (Tn, STn, and T) of MUC16 as well as MUC1 in circulation, in 
ovarian cancer tissue using Proximity Ligation Assays (PLA), can improve the yield of 





serous tumors from benign lesions with a specificity of 100% and a sensitivity of 70-
80% on tissues. In fact, serous ovarian carcinomas selectively express Tn and STn 
glycoforms of MUC16 and MUC1, and these glycomucin profiles are likely to serve as 
more cancer-specific biomarkers than the mucins themselves. This study provides 
strong support for the use of PLAs to detect aberrant glycoforms of mucins and 
thereby improve cancer specificity of biomarker assays86. 
The human epididymis secretory protein 4 (HE4) gene was found to be 
overexpressed in ovarian cancer87 and is used as a potential serum biomarker. HE4 
belongs to the family of whey acidic four-disulfide core (WFDC) proteins with 
suspected trypsin inhibitor properties. HE4 was first determined in the epithelium of 
the distal epididymis88.  
Biomarker HE4 has very low expression in the epithelia of respiratory and female 
reproductive tissues including ovary, but high secreted levels can be found in the 
serum of ovarian cancer patients89 and also in ovarian cancer tissue88. Recently, Moore 
at al.90,91 published a series of papers that used a combination of CA125, HE4 and 
menopausal status to predict the presence of a malignant ovarian tumor. Originally, 
nine potential biomarkers were evaluated, from which HE4 was the most effective in 
detecting ovarian cancer. When CA125 was combined with HE4, the prediction rate 
was higher, showing a sensitivity for detecting malignant disease of 76.4% at a 
specificity of 95%90,92 in ovarian carcinoma vs endometriotic cysts. Measured values of 
HE4 and CA125 can be combined in an algorithm called ROMA (Risk of Ovarian 
Malignancy Algorithm), which additionally includes the menopausal status. Several 
published studies91,92 show that ROMA helps in the triage of pre and postmenopausal 
women suspected for ovarian cancer. This high accuracy helps to stratify patients into 
low-and-high risk groups and therefore contributes to better diagnosis, treatment and 
outcome. 
Non-invasive screening tools have been studied to help screening this cancer, 
such as transabdominal and transvaginal ultrasonography (TVS), since it is able to 
estimate ovarian size, detects masses as small as 1 cm and distinguishes solid lesions 





adnexal masses93, the specificity of ultrasonography is not adequate for its use as a 
single screening modality94.  
The majority of ovarian tumors are surgically staged to determine the presence 
of extraovarian disease, classified according to the terms of the staging scheme (I to IV) 
developed by the Fédération Internationale de Gynécologie et d’Obstétrique (FIGO) 
and the classification system prognosis helps to define treatment (Table 1.1). Staging is 
performed by examining histological sections of tissue samples and cytological 
assessment of fluid samples95. 
1.1.4 Treatment of ovarian cancer 
Ovarian cancer is highly curable when it is confined to the ovaries, with an 
expected 80–95% in 5-year survival73. Only about 20% of affected patients are found at 
this stage, and the diagnosis is often made incidentally during the study of another 
medical condition. Current therapies for advanced ovarian carcinomas are limited and 
not curative and the search for new therapeutic agents in the treatment of the disease 
and recurrence, have been disappointing22. 
The standard treatment for ovarian cancer patients includes cytoreductive 
surgery, during which adequate staging is performed by pathological examination of 
ovarian and other tissues to define the histological nature of the tumor and its stage. 
In patients diagnosed with early disease, surgery alone may be sufficient but in 
advanced disease, debulking surgery followed by chemotherapy is recommended96. 
Chemotherapy after surgery is referred to as ‘first-line’ treatment and involves a 
combination of a platinum and taxane-based chemotherapy (usually six cycles of 
carboplatin and paclitaxel) delivered intravenously (IV) or intraperitonealy (IP)97,98. 
Patients with advanced ovarian cancer who aren’t initially able to undergo surgery due 
to unressectable tumors can be treated with chemotherapy, being considered for 
surgery (neoadjuvant treatment)9 and then followed by platinum-based combination 
of chemotherapy, or not. Although initially the majority of patients become tumor 






Table 1. 1 - TNM and FIGO classifications for Ovarian, Fallopian Tube and Peritoneal Cancer 
Staging System  






TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 I Tumor limited to the ovaries (one or both) or fallopian tubes
T1a IA
Tumor limited to one ovary (capsule intact) or fallopian tube; no
tumor on ovarian or fallopian tube surface; no malignant cells in
the ascites or peritoneal washings.
T1b IB
Tumor limited to both ovaries (capsules intact) or fallopian tubes;
no tumor on ovarian or fallopian tube surface; no malignant cells in
the ascites or peritoneal washings.
T1c IC
Tumor limited to one or both ovaries or fallopian tubes, with any of
the following:
IC1: Surgically spill intraoperatively.
IC2: Capsule ruptured before surgery or tumor on ovarian or
fallopian tube surface.
IC3: Malignant cells present in the ascites or peritoneal washings.
T2 II
Tumor involves one or both ovaries or fallopian tubes with pelvic
extension or peritoneal cancer.
T2a IIA
Extension and/or implants on the uterus and/or fallopian tubes
and/or ovaries.
T2b IIB Extension to other pelvic intraperitoneal tissues.
T3 III
Tumor involves one or both ovaries, or fallopian tubes, or primary
peritoneal cancer, with cytologically or histologically confirmed
spread to the peritoneum outside of the pelvis and/or metastasis
to the retroperitoneal lymph nodes.
T3a IIIA
Metastasis to the retroperitoneal lymph nodes with or without
microscopic peritoneal involvement beyond the pelvis.
T3b IIIB
Macroscopic peritoneal metastases beyond the pelvic ≤2 cm in
greatest dimension, with or without metastasis to the
retroperitoneal lymph nodes.
T3c IIIC
Macroscopic peritoneal metastases beyond the pelvic >2 cm in
greatest dimension, with or without metastasis to the
retroperitoneal lymph nodes.
T4 IV Distant metastasis excluding peritoneal metastases.
T4c IVA Pleural effusion with positive cytology.
T4b IVB
Metastases to extra-abdominal organs (including inguinal lymph
nodes and lymph nodes outside of the abdominal cavity)
Regional lymph nodes (N)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 IIIC Regional lymph node metastasis
Distant metastasis (M)
M0 No distant metastasis





Similar to other malignancies, the management of ovarian cancer has evolved 
from single agent to combination of chemotherapy agents. The most frequently used 
combination as the first-line chemotherapy for ovarian cancer patients is the 
combination of platinum and taxane drugs. 
Two platinum compounds are most commonly used, cisplatin and carboplatin. 
Cisplatin is one of the most potent antitumor agent known, displaying clinical activity 
against a wide variety of solid tumors100,101. The toxic side effects associated with the 
use of this drug was the motion for the development of the second-generation 
platinum chemotherapeutic agent, carboplatin102,103. 
Besides their chemical similarity, cisplatin and carboplatin operate by same 
mechanisms: the formation of protein and DNA adducts (covalent bounds) and the 
generation of reactive oxygen species (ROS). Labile ligands in the coordination sphere, 
chloride for cisplatin and 1,1-cyclobutanedicarboxylate (CBDCA) for carboplatin, are 
displaced by water or other biological nucleophiles, and the activated cis-
diammineplatinum(II) moiety bind to purine bases in nuclear DNA104. The resulting 
platinum-DNA adducts, mainly 1,2-intrastrand cross-links, leads to death of cancer cells 
through the induction of errors in DNA, transcription inhibition and subsequent 
downstream effects105. Because cisplatin and carboplatin have the same NH3 non-
leaving group ligands, the resulting DNA adducts are identical106 and therefore the 
drugs exhibit the same spectrum of activity107. Its cytotoxic mode of action is mediated 
by its interaction with DNA to form DNA adducts, primarily intra-strand crosslink 
adducts, which activate several signal transduction pathways, including those involving 
ATR (serine/threonine-protein kinase ATR), p53, p73 and MAPK, ending with the 
activation of apoptosis100. 
Carboplatin, however, is significantly less toxic than cisplatin. The typical patient 
dose for carboplatin is approximately ten times greater than cisplatin (400 mg/m2 
versus 40 mg/m2), and the dose-limiting toxic side effect of carboplatin is 
myelosuppression in contrast to nephrotoxicity for cisplatin102. 
Taxanes are hydrophobic mitotic inhibitors and paclitaxel is one of the taxanes in 





poor penetration into the central nervous system108 and is eliminated via hepatic 
metabolism. Despite the initial effectiveness of the response to paclitaxel in most 
cases patients in due course become resistant and relapse109. At a higher dose, 
paclitaxel is known to suppress microtubule minus ends detachment from 
centrosomes110–112. The taxanes can also induce apoptosis and have anti-angiogenic 
properties113. In various studies it is showed as an effective anticancer agent against 
lung, breast, ovarian, leukemia and liver cancer114. 
Regarding the mechanism of action of taxanes, they bind to the β-subunit of 
tubulin, resulting in the formation of stable, non-functional microtubule bundles and 
thus interfering with mitosis, inducing a cell cycle arrest in G2 for paclitaxel and in S-
phase for docetaxel115. Recent studies showed that taxanes are also able to induce ROS 
production in cancer cells, and hydrogen peroxide (H2O2) was found to be involved in 
induced cancer cell death in vitro and in vivo116,117. 
Tumor resistance to chemotherapy may be present at the beginning of 
treatment, can develop during treatment, or become apparent on recurrence of 
disease118. Patient response to chemotherapy for ovarian cancer is in fact 
heterogeneous and there are no tools to aid the prediction of sensitivity or resistance 
to chemotherapy, treatment stratification and current use in clinical setting119. 
Resistance mechanisms that limit the extent of DNA damage associated with 
chemotherapy include decrease of intracellular drug accumulation, increased 
drug inactivation and increased DNA damage repair or inhibition of transmitted DNA 
damage recognition100. Increased glutathione levels is also a mechanism of resistance, 
since thiols are highly nucleophilic and besides being ROS scavengers they also react 
with platinum derived drugs as carboplatin and cisplatin72.  
ROS are naturally produced by cells through aerobic metabolism, and high levels 
of ROS in the cells are associated with many diseases including cancer120. However, 
under certain conditions, ROS increase proapoptotic molecules such as p53 and p38 
MAP kinase121. ROS-sensitive signaling pathways are persistently elevated in many 
types of cancers, where they participate in cell growth/proliferation, differentiation, 





as second messengers in cellular signaling123. H2O2 regulates protein activity through 
reversible oxidation of its targets including protein tyrosine phosphatases, protein 
tyrosine kinases, receptor tyrosine kinases and transcription factors122,123. The 
formation of ROS upon chemotherapy depends on the concentration of 
chemotherapeutic agents and the duration of exposure124. The efficiency of several 
chemotherapeutic agents depends on the alteration of redox state through the 
generation of ROS, inducing cell death125. 
One main explanation on tumor cell resistance to paclitaxel is the overexpression 
of P-glycoprotein (P-gp, MDR-1), which works as a drug efflux pump. However, clinical 
utility of P-gp inhibitors are often ineffective or toxic at the doses required to 
attenuate P-gp function126,127. Other possible mechanisms of resistance involve 
alterations in the drug-binding affinity of the microtubules128, changes in tubulin 
structure and cell cycle deregulation129. Thus, paclitaxel-resistant mechanisms are 
complicated and still not entirely clear. 
Summing up, ovarian cancer usually responds to chemotherapy, (the 
combination of carboplatin and paclitaxel is the most used) but, in the majority of 
cases the cancer recurs resulting in the death of eventually half of patients77 as a 
consequence of the development of drug resistance99. Therapeutic resistance can arise 
from tumor cells that are intrinsically resistant as well as those that have acquired 
resistance during treatment130. To date, there are no reliable clinical factors that can 
properly stratify patients for suitable chemotherapy strategies. 
1.2 Molecular features of ovarian cancer 
Alterations in cell cycle regulatory genes, mainly tumor suppressor genes and 
proto-oncogenes induce an unrestrained growth of cells and serve as precursors of 
immortality. Of the many regulators, tumor suppressor proteins play a pivotal role in 
the cell cycle regulation process and are highly deregulated in ovarian carcinomas131. 
Besides some cases integrated in hereditary cancer syndromes, most mutations seen 
in EOC are somatic mutations affecting cells by interfering with several signaling 





1.2.1 Pathways involved in ovarian cancer 
1.2.1.1 Notch Signaling Pathway 
Notch signaling pathway is an evolutionary conserved pathway that is required 
for embryonic development, and in adult tissues acts in homeostasis132. Notch 
signaling is a justacrine pathway that has been found to be deregulated in human 
hematological malignancies and solid tumors133,134. It has multiple roles in cell fate 
determination through regulation of proliferation, differentiation, survival and 
apoptosis135,136. Notch receptors (Notch1-4)  as well as their ligands Delta-like (Dll1, 3 
and 4) and Serrate-like Jagged1 and 2137–140 are single-pass transmembrane proteins 
with extracellular domains that consist of multiple epidermal growth factor (EGF)-like 
repeats. The extent of EGF-like repeat fucosylation by the fucosyltransferases, such as 
Fringe, determines the affinity strength between the receptors and their ligands. Notch 
receptors are synthesized in the endoplasmic reticulum as an inactive single peptide 
precursor141. 
Notch signaling is initiated by the binding of Notch Delta/Jagged ligands to Notch 
receptors (Figure 1.2). This interaction induces a first cleavage (S1) in the Notch 
receptor by furin-like convertases producing an extracellular N-terminal fragment and 
a transmembrane C-terminal fragment that also includes the Notch intracellular 
domain (NICD). A second cleavage (S2) occurs catalyzed by a member of disintegrin 
and metalloproteases (ADAM) family (ADAM17 or ADAM10), also known as the 
metalloproteinase tumor necrosis factor-α-converting enzyme (TACE). The remaining 
Notch fragment is then accessible to the presenilin-dependent γ-secretase protease 
complex and this complex carries out the third and final cleavage (S3) of the Notch 
protein135,142. This final cleavage event releases the active NICD into the cytoplasm and 
after translocation into the nucleus, binds to ubiquitous transcription factor CSL 
(CBF1/Suppressor of Hairless, and Longevity-Assurance Gene-1), and converts a large 
co-repressor complex into a transcriptional activating complex. The complex contains 
NICD, CSL, mastermind-like protein (MAML; a transcriptional coactivator), SKIP (Ski-
interacting protein as a CBF1 binding protein) and p300, and activates the transcription 





Enhancer of Split (HES) family proteins, HES related proteins (HEY)143 as well as cell 
cycle regulators such as p21, cyclin D1 and 3144, c-myc145, and HER2146.  
The Notch pathway has also been implicated as interacting with the EGFR/HER2 
tyrosine kinase receptor family, as well as phosphatidylinositol 3-kinase/AKT/mTOR 
signaling, two central growth pathways in the physiological and neoplastic setting147. 
Although interaction of Notch signaling with other pathways has been a focus of 
investigation, the exact mechanisms of this crosstalk remain largely unknown. It is 
evident that the interaction of Notch signaling with other pathways highly depends on 
the cellular context, and differs from one cellular microenvironment to another140. 
Elements of the Notch pathway are altered in more than 20% of HGSC, mostly as 
amplifications in the ligand Jagged 1 and 2 and Notch 331. Notch3 (mRNA and protein) 
was found to be overexpressed especially in serous ovarian carcinomas compared with 
the normal ovarian surface epithelium148 and correlation with aggressive tumors with 
poor prognosis148,149  have been described. 
Notch 3 was found to be active in some ovarian cancer cell lines, but according to 
observations by Hopfer and colleagues150 there were no differences in the expression 
of extracellular Notch3 between ovarian cancers and benign ovarian adenomas. Park 
et al.151 demonstrated that Notch3 expression is associated with post chemotherapy 
recurrence, probably as a result of upregulation of the ATP Binding Cassette Subfamily 
B Member 1 (ABCB1) that acts as a pump of xenobiotics. Chemoresistance to platinum-
based therapy was also associated with Notch3 activation152. In ovarian cancer cell 
lines Notch1 overexpression has also been shown to promote tumor cell 
proliferation153,154.  
Targeting the Notch pathway either with small molecule inhibitors primarily with 
γ-secretase inhibitors (GSIs) or monoclonal antibodies (mAbs) to Notch ligands and 







Figure 1. 2 - Ovarian cancer signaling pathways scheme 
Scheme adapted from Yap, 2013; Longuespée et al., 2012 and Toss et al., 2013 155–157. 
 
1.2.1.2 Mitogen-activated protein kinases (MAPK) pathway  
MAPK/ERK pathway activation and subsequent interactions are highly regulated 
events that become deregulated in cancer cells. The pathway begins with the 
activation of Kirsten rat sarcoma oncoprotein (KRAS), which initiates a multistep 
phosphorylation events that leads to the activation of RAF/MEK and MAPK pathways, 
and in conjunction with mammalian target of rapamycin (mTOR), a target of the 
protein AK strain thymoma (AKT) pathway, which ultimately regulate the transcription 


















































Point mutations in KRAS provide an advantage for the survival and progression of 
tumors161–163. KRAS somatic mutations have been implicated in the genesis of LGSC, 
inducing a mitogenic phenotype164. 
Patients with ovarian cancer frequently present activation of the MAPK/ERK 
pathway due to somatic mutations of KRAS or BRAF, which seem to occur early in 
malignant transformation36. KRAS and BRAF mutations are found in respectively 27-
36% and 33-50% of LGSC. In contrast, a study conducted on 489 HGSC, TCGA31 showed 
that in 45% of cases that contained altered PI3K/RAS signaling, less than 1% was due to 
mutations and only 11% were due to amplifications. Also, BRAF was mutated in 0.5% 
of HGSC cases. These mutations enhance kinase activity, becoming the mutated 
protein independent of the activation of the tyrosine kinase receptor, and 
hyperactivating the MAPK pathway during the initiation and progression of 
tumorigenesis158. 
1.2.1.3 PI3K/PTEN/AKT pathway 
The PI3K pathway is activated through transmembrane tyrosine kinase receptors 
(RTK). PI3K is a heterodimeric protein comprised of a regulatory subunit, p85, and a 
catalytic subunit, p110165,166. The p110 catalytic subunits exit as several isoforms α, β, γ 
and δ166. Recruitment of the PI3K complex to the inner surface of the plasma 
membrane juxtaposes it with its substrate phosphatidylinositol-4,5 diphosphate (PIP2) 
located in the inner lamina of the cell membrane. PIP2 is then phosphorylated by the 
p110 subunit to form phosphatidylinositol-3,4,5 trisphosphate (PIP3). The conversion 
of PIP3 to PIP2, and the subsequent inactivation of PI3K downstream signaling, is 
facilitated by the tumor suppressor PTEN located on chromosome 10167 (Figure 1.2).  
PTEN is a tumor suppressor gene, whose mutations promote the loss of function 
of the protein and are present in many cancers, including in ovarian cancer4,160,168–171. 
AKT activation is generally associated with processes of cell survival, growth, and 
proliferation172. Cell survival is regulated by inhibitory phosphorylation of the  forkhead 





apoptotic target gene Bim as well as by direct inactivation by phosphorylation of 
BAD173. 
Cell proliferation is regulated by activation of mTOR thereby promoting protein 
synthesis174. mTOR promotes cell growth and proliferation in association with the 
PI3K/AKT pathway166 through the  phosphorylation of AKT at the serine residue 473 by 
the mTOR complex 2 (mTORC2). The mTOR complex 1 (mTORC1) element raptor, and 
the mTORC2 element rictor, differ from each other in composition by a few elements 
that make up the respective complexes, accounting for the difference in resistance to 
rapamycin175. mTORC1 promotes proliferation by the activation of molecules involved 
in protein synthesis, mTORC2 promotes cell survival and proliferation through AKT 
activation176.  
Cell proliferation is stimulated via a number of mechanisms including inhibition 
of the FoxO-mediated transcription of the cyclin-dependent kinase inhibitor p27Kip1177. 
AKT also inhibits both p27Kip1 and p21 function by phosphorylation178 as well as by 
regulating D-type cyclins179. 
The FoxO factors function as downstream elements of the PI3K/AKT/PTEN 
signaling pathway and are essential for cell proliferation, differentiation, DNA damage 
repair and apoptosis180,181. Upon activation of the PI3K/AKT signaling pathway, FoxO 
proteins undergo AKT-mediated phosphorylation. Under conditions of stress or in the 
absence of growth or survival factors, the PI3K/AKT pathway is inhibited and FoxO3a 
proteins translocate to the cell nucleus, where they execute their transcriptional 
functions. By contrast, the dephosphorylation of activated FoxO3a induces cell cycle 
arrest and apoptosis. 
The cytostatic and cytotoxic effects of a variety of anti-cancer drugs182, such as 
paclitaxel183,184 doxorubicin185, lapatinib186, gefitinib187, imatinib188,189, and cisplatin190, 
are mediated through the activation of FoxO, particularly FoxO3a. The phosphorylation 







A number of studies have revealed FoxM1 to be a key cell cycle regulator in the 
transition from G1 to S phase and in the progression to mitosis192–194 and have 
demonstrated overexpression of the FoxM1 gene in human cancer cells and tissues, 
including in ovarian cancer31,195. In the study by TCGA31, 87% of the cases studied 
showed that elements of the FoxM1 pathway, such as baculoviral inhibitor of 
apoptosis repeat-containing 5 (BIRC5/survivin), cyclin B1 (CCNB1), aurora kinase-B 
(AURKB), cell division cycle 25 homolog B (CDC25B) and polo-like kinase 1 (PLK1) were 
consistently overexpressed but not altered by DNA copy number changes31. 
Inactivation of FoxO or overexpression of FoxM1 is associated with tumorigenesis and 
cancer progression.  
The integrated genomic analysis study of HGSC31 showed that at least 45% of the 
cases contained alterations in the PI3K and RAS signaling pathways, whereas PTEN 
deletions were found in 7%. PI3KCA amplifications (18%) and mutations (<1%), AKT 
isoform amplifications AKT 1 and AKT 2 (3 and 6% respectively), were observed in 
conjunction with KRAS amplification (11%)31. KRAS, independently, controls survival 
through BRAF but it can also activate PI3K, that induces activation of AKT, and cell 
cycle progression. Similarly, in the PI3K/AKT/mTOR signaling, a study by Kinross et 
al.196 using a mouse model demonstrated that PTEN double deletions with PI3K 
activation was necessary for HGSC and granulosa cell tumors development166. 
Therefore, a single event does not appear to influence ovarian tumorigenesis but 
multiple hits in the pathways that regulate growth, proliferation, and survival are 
required for tumorigenesis and progression.  
PI3K mutations in ovarian tumors are rare, but an increase in gene copy number 
has been observed more frequently. The amplifications are more pronounced in HGSC 
than LGSC tumors along with AKT phosphorylation contributing to survival, and 








1.2.2 Genes involved in ovarian cancer 
1.2.2.1 Tumor protein 53 (TP53) 
The TP53 gene codifies a sui generis tumor suppressor protein whose normal 
function is essential for cell normal physiology but when mutated p53 can exhibit 
oncogenic properties. Normal p53 function is anti-cancer and oncogenic p53 function 
is pro-cancer199. Hence, TP53 is a multifunctional tumor suppressor gene that is often 
altered in ovarian and other cancers199,200, plays a major role in regulating the cellular 
response to environmental and genotoxic stress, through cell cycle inhibition and 
promotion of programmed cell death and senescence.  
Mutation of the TP53 gene at the locus 17p13.1 is the most common single 
genetic alteration in sporadic human EOC. The p53 protein contains four functional 
domains – a transcriptional activation domain, a tetramerization domain and two DNA 
binding domains. In addition to possessing transcriptional activating properties, 
transcriptional repression has been described, although binding sites are less well 
characterized201,202. 
It has been estimated that the gene encoding p53 (TP53) is mutated in more 
than 50% of human cancers203. It appears that the loss of p53 normal function, by 
mutation or by other means, is highly advantageous and perhaps an absolute 
requirement for some cancers progression. This gene interacts with a variety of 
proteins involved in transcriptional regulation, DNA repair, cell cycle progression, 
apoptosis, and proteosome-mediated protein degradation204. De Graeff et al.205 
recently determined a prognostic value of p53 in ovarian cancer through a meta-
analysis of 62 previously published studies using a total of 9448 patients. The p53 
status was analyzed by IHC or mutational analysis. Out of 62 studies, 25 reported an 
association with poor survival while 4 were associated with improved survival. When 
the meta-analysis was restricted to serous tumors only, there was a significant 
association with poor prognosis205. Although, histotype heterogeneity and 
chemotherapeutic treatment were not taken into account and the analysis showed 
that the FIGO stage may influence the outcome predictive value of p53 and the 





 Some other studies suggested a correlation between p53 status and response to 
platinum-based chemotherapy, while strong discrepancies are noticed in clinical 
studies with paclitaxel-based treatment. These inconsistencies are likely due to 
different antibodies utilized, chemotherapeutic regimen and heterogeneity of 
histotypes, which render the interpretation of all these studies difficult206,207. 
TP53 is a canonical exception to Knudson hypothesis208, since a single mutation 
in one allele is enough to alter p53 tumor suppressor function, becoming 
advantageous for tumor survival. The majority of TP53 mutations are missense 
mutations that cause single residue changes, largely occurring in the DNA binding 
domain209. Mutant p53 protein has the ability to form a tetramer with wild type p53, 
acting as a dominant negative to repress normal physiological processes of p53, 
possibly by inducing an inactive conformation of the DNA binding domain and reducing 
the ability to transactivate/repress target genes210–212.  
The relevance of the normal function of p53 in a cell is showed up by the p53 
regulatory network, consisting of negative and positive feedback loops that modulate 
down and up p53 expression and activity213. The negative feedback loop established by 
p53 with MDM2 tightly controls both p53 and MDM2 levels in the cell. Tumor 
suppressor p53 activates targets in the MDM2 gene to be transcribed, ultimately 
causing production of the MDM2 protein, which then inhibits p53214,215. This negative 
feedback loop is vital for controlling p53 activity to prevent detrimental pathogenic 
effects of excessive p53 activity. 
Although TP53 mutations have been detected in all histological types of EOC, a 
number of studies have demonstrated higher frequencies of such mutations in HGSC. 
Point mutations, missense mutations and truncations have been observed, resulting in 
the overexpression of the p53 protein that has been detected in many of the 
immunohistochemical studies performed216,217. The accumulation of mutated and 
oncogenic p53 has been shown to affect the expression and interaction of the pro-
apoptotic BAX with the anti-apoptotic B-cell lymphoma 2 (BCL-2)218,219. 
The expression of mutated p53 results in the accumulation of the altered protein 





seems that p53 alterations in HGSC reduce BAX expression allowing the progression of 
solid tumors. However, immunohistochemistry studies in tumor tissue have not 
provided a definitive conclusion of a positive correlation with p53 expression and 
tumor prognosis and survival221,222. The expression of p53 vs BCL-2 and BCL-2 vs BAX 
have been shown to have a strong association with tumor grade and histopathological 
subtyping, factors that could be vital for identifying the specific epithelial ovarian 
carcinoma for adjuvant or combined therapies223. What has been observed is that the 
majority of ovarian tumors are initially very responsive to treatment but later become 
chemoresistant. Possibly the treatment itself may cause the selection of few cells 
within the tumor mass, harboring mutations in TP53 that, in addition to epigenetic 
silencing of promoter regions of apoptotic favorable genes such as p16 or Rb, may 
account for the relapse and progression of the tumor131.  
As previous described, mutations in TP53 are a common event in ovarian 
tumorigenesis, being particularly frequent in HGSC but are uncommon in CCC (10%)224. 
This implies that other anti-apoptotic mechanisms are likely to be involved in the 
development of CCC. HNF1β, a diagnosis marker for CCCs40, has been implicated in 
mediating apoptotic escape in tumor cells225.  
1.2.2.2 Hepatocyte nuclear factor 1β (HNF1β)  
Hepatocyte nuclear factor 1β (HNF1β) was originally described as a novel 
homeodomain-containing transcription factor isolated from a human liver library and 
found to be essential during organogenesis of the liver, kidney, and pancreas226. 
HNF1β gene (formerly known as TCF2) is located on 17q21.3, contains 9 exons227 and 
its expression is often altered in cancer228. CCC are usually positive for HNF1β 
(>90%)37,40. In addition, HNF1β is expressed in the majority of tumors with cytoplasmic 
clearing, including renal CCC and endometrial CCC69. 
HNF1β was found to be the most upregulated transcription factor in a gene 
expression analysis of four ovarian CCC cell lines when compared to non-CCC cell 
lines228. It was also subsequently reported to be positive in areas of endometriosis or 





hypothesis that the concurrent endometriosis seen in CCC may be linked as a 
precursor lesion67,229. 
HNF1β is involved in the glycogen synthesis67 and is also expressed in mid-to-late 
secretory and gestational endometrium (Arias-Stella reaction) and in atypical and 
inflammatory endometriosis. Studies confirm the identification of HNF1β as a 
susceptibility gene for CCC development and disclosed that promoter methylation 
plays a role in the regulation of  HNF1β expression229. 
Immunohistochemistry (IHC) analysis for HNF1β protein expression comparing 
CCC and HGSC in 1,149 ovarian tumors from the Ovarian Tumor Tissue Analysis 
Consortium, and DNA-methylation analysis on 269 of these tumors, revealed that the 
majority of CCC expressed the HNF1β protein, and were unmethylated at 
the HNF1β promoter, whereas the majority of HGSC lacked HNF1β protein expression 
and displayed frequent HNF1β promoter methylation228,229. This epigenetic 
inactivation of HNF1β seen in ovarian HGSC has also been detected in colorectal, 
gastric and pancreatic cancer cell lines70. 
HNF1β promoter hypomethylation has recently been detected in additional clear 
cell histology, including endometrial, cervical and renal clear cell cancers, 
suggesting HNF1β expression and promoter hypomethylation to be a general 
biomarker of cytoplasmic clearing69. HNF1β overexpression in immortalized 
endometriosis epithelial cells (putative precursors of CCC) led to altered morphology 
and multinucleation of cells228 while siRNA knock-down of HNF1β led to the induction 
of apoptosis in CCC cells lines229. 
1.2.2.3 Cyclins and Cyclin-dependent-Kinase inhibitors 
The cyclin and cyclin dependent kinase (CDK) elements, activators and inhibitors 
that have a major role in ovarian cancer are cyclin D1, p16INK4A, p27Kip1 and p21230–
232. Their regulation and function have been shown to be controlled in part by the 
tumor suppressor gene TP53, which is predominantly mutated in HGSC230,232. 
CDK activators and inhibitors are major co-regulatory proteins in the cell cycle 





target of p53234. In the presence of wild-type (WT) p53, p21 induction is followed by 
the inhibition of cyclin E/CDK2 preventing the G1-S transition, encouraging the 
quiescent or apoptotic phenotype of cells235. 
Although the roles of p21 and p27 have been discussed in many cancers, they 
appear to have secondary roles in the etiology of ovarian cancer rather than in the 
genesis236,237. Loss of function or accumulation of these proteins in ovarian cancers has 
not been reported. In some cases, the absence or low expression of p21 in p53 
expressing tumors appears to place patients at a higher risk for disease recurrence238. 
Studies have also shown that high p21 expression correlates with early stage ovarian 
tumors and that only high p27 expression was necessary for disease free survival239.  
1.3 Epigenetics and ovarian cancer 
Epigenetic mechanisms are essential for normal development and maintenance 
of tissue-specific patterns of gene expression in mammals240. Epigenetics is defined as 
a heritable change in gene expression without alteration of the primary DNA sequence. 
So, disruption of epigenetic processes can lead to altered gene function and malignant 
cellular transformation240,241. The current status of epigenomic research shows that 
epigenetic modifications among cancer cells result in aberrant gene expression via 
DNA methylation, histone modifications and post-transcriptional gene regulation by 
microRNAs (miRNAs)242,243. These modifications are also associated with initiation and 
progression of ovarian cancers241,244.  
In the last years, the importance of biomedical research towards epigenetics has 
increased, with the aim to discover the mechanisms that underlie the epigenetic 
regulation of cell physiology. From these studies the reversibility of epigenetic 
mechanisms showed promising targets to treat several diseases, through epigenetic 
targeted therapy. 
The structure of chromatin is complex, made up of DNA, histones, and non-
histones proteins245, these last two are primary targets of epigenetic regulation246. 
Chromatin is made of repeating units of nucleosomes, which consist of 146 base pairs 





proteins (H3, H4, H2A and H2B). This assembly is allowed by the negative charge of 
DNA and the positive charge of histone tails247. The histone octomer plays an 
important role in establishing interactions between the nucleosomes and within the 
nucleosome particle itself248. The N-terminal tails of core histones are flexible and 
unstructured, but the rest are predominantly globular and well structured. Depending 
on the epigenetic modifications that occur in DNA and in histone tails, chromatin can 
adopt different conformational changes that control the activation or repression of 
gene transcription. 
There are at least eight distinct types of histone post-translational modifications, 
namely acetylation, methylation, phosphorylation, ubiquitylation, sumoylation, ADP 
ribosylation, deamination and proline isomerization131. They can be viewed as a 
regulatory code that resides in the pattern of post-translational modifications for 
which the histone amino terminal tails are the target248. In this brief introduction we 
will mentioned the two main modifications: DNA methylation and histone acetylation. 
1.3.1 DNA methylation 
DNA methylation is the most studied epigenetic modification with regard to 
carcinogenesis, and has also been the major focus of pharmacological interventions in 
clinical trials. In normal cells, the human genome is not methylated uniformly, 
containing unmethylated segments interspersed with methylated regions. DNA 
methylation occurs on the cytosine residues of CpG dinucleotides, CpG enriched 
regions are so-called CpG islands that are usually regions greater than 200 bp in 
length249, that have more than 50 percent of CG content250 and frequencies above 
0.6% predominantly in the 5’ promoter regions of the genes251. Enzymes known as 
DNA methyltransferases (DNMTs) catalyze the addition of a methyl group (CH3) to the 






Figure 1. 3 – Cytosine metylation 
Chemical structure of cytosine base unmethylated and methylated. 
 
The methylation of CpG islands in gene promoters has been correlated with gene 
silencing, as it is an alternative pathway to the loss of tumor suppressor genes 
function, due to the lack of gene expression253. The epigenetic silencing of tumor 
suppressor genes has been associated with mechanisms such as uncontrolled cell 
division, the ability to infiltrate surrounding tissues, metastasis, avoiding apoptosis or 
sustaining angiogenesis, all of which are responsible for promoting tumor 
development. In ovarian cancer, a large number of tumor suppressor genes have been 
found to undergo promoter hypermethylation254. 
BRCA1 gene, as previous mentioned is one of the most studied genes, due to its 
role in inherited and sporadic forms of ovarian carcinomas255,256. It has been shown 
that promoter hypermethylation is a cause for BRCA1 silencing257 and has been 
reported in 15% of sporadic ovarian carcinomas255,258. 
In a study comparing the methylation status of BRCA1 among tumor samples 
obtained from patients with benign ovarian tumors, borderline tumors and 
carcinomas, promoter methylation of BRCA1 was detected in 31% of carcinomas but in 
none of the benign or borderline tumors259. Hypermethylation of BRCA1 was 
significantly higher in serous carcinomas than in tumors of other histological type260. 
Methylation of BRCA1, while frequent in sporadic ovarian cancer, has not been 
reported in the hereditary type of the disease, nor in samples from women with a 







BRCA2 does not exhibit a similar methylation profile in ovarian cancer263. 
According to Chan et al.264 methylated CpGs at the BRCA2 promoter were either 
absent or at very low levels in tumor DNA compared to normal tissues264. 
Tumor suppressor genes involved in DNA mismatch repair (MMR) have a distinct 
carcinogenic mechanism in ovarian tumors. MMR is an endogenous molecular 
mechanism that corrects replication errors that escape the proof reading system of 
replicative DNA polymerases. In MMR-defective cells with methylation of promoters of 
MMR genes, base-to-base mismatches and insertion/deletion loops, are left 
uncorrected265. This results in increased spontaneous somatic mutations, being 
particularly obvious in non-expressed sequences comprising multiple simple repeats 
(microsatellites)266. Approximately 10% of ovarian cancers are related to this molecular 
pathway267. Defective MMR is often a consequence of germline mutations in the 
MLH1, MSH2, or, occasionally, MSH6 or PMS2 genes. Hypermethylation of the MLH1 
gene accompanied by loss of the gene expression has been reported in 10–30% of 
ovarian malignancies. This phenomenon is more frequently found in cases with 
acquired resistance to platinum-based chemotherapy (56% )268,269. The methylation 
frequency of MSH2 promoters has also been reported to be as high as 57% in ovarian 
carcinomas, being higher in EC compared to other histological types268. Methylation 
grade of MSH2 has been correlated with tumor grade and lymphatic metastasis.  
Hypermethylation of tumor suppressor genes such as PTEN and p16INK4A have 
been observed contributing to the loss of function of these proteins in EOCs260,270 and 
the absence of these proteins contribute to deregulate pathways. 
DNA methyltransferases inhibitors have been proposed to be a promising 
strategy for epigenetic therapy in cancer treatment. The most commonly used DNMT 
inhibitors in clinical setting are nucleoside analogues, including 5-aza-2’-deoxycytidine 
(5-aza-dC)240,246. They are converted to deoxynucleotide triphosphates intracellularly 
and may be incorporated into replicating DNA instead of cytosine.  
These inhibitors act by different actions, namely the loss of DNA methylation 
resulting in the re-expression of the tumor suppressor genes; the inhibition of tumor 





In ovarian cancer, the recurrence of malignancy or the resistance to current 
therapies is one of the concerns in the treatment of these tumors. Epigenetic inhibitors 
hold the promise for overcoming chemoresistance through restoration of drug 
response genes and pathways246. Two clinical trials271,272 provided evidences that DNA 
hypomethylation agents can reverse platinum resistance in ovarian cancer patients, 
suggesting the clinical benefits of epigenetic drugs in the treatment of chemoresistant 
or recurrent advanced cancer. 
In summary, epigenetic alterations such as DNA methylation are involved in 
ovarian cancer initiation and progression. Hypermethylation has been found to be 
associated with the inactivation of almost every pathway involved in ovarian cancer 
development, including DNA repair, cell cycle regulation and apoptosis.  
1.3.2 Histone acetylation 
Histone modifications can alter histone-DNA interactions and consequent 
transcriptional activity due to changes in accessibility of the DNA to the transcriptional 
machinery. Histone tails are positively charged due to lysine and arginine amino acids. 
These positive charges allows the interaction and binding of the histone tails to the 
negatively charged phosphate groups on the DNA backbone273.  
Acetylation and deacetylation of histones play an important role in controlling 
chromatin activity and consequently transcription in eukaryotic cells273. The 
acetylation of histones and non-histone proteins is determined by the opposing 
activities of histone deacetylases (HDACs) and histone acetyltransferases (HATs). The 
balance between histone acetylation and deacetylation, mediated by HATs and HDACs, 
respectively, is usually tightly regulated, but this balance is often disturbed in diseases 
such as cancer273.  
Acetylation neutralizes the positive charges on the histone by changing amines 
into amides and decreasing the ability of the histones to bind to DNA. This decreased 
binding allows chromatin expansion, and genetic transcription takes place. 
On the contrary, histone deacetylases remove those acetyl groups, retrieving the 





histones and DNA backbone274. The increased histone and DNA binding condenses 
chromatin structure and prevents transcription.  
HDACs are a class of enzymes that remove acetyl groups (O=C-CH3) from an ε-N-
acetyl lysine amino acid on a histone, allowing the histones to wrap the DNA more 
tightly. A total of eighteen human HDACs enzymes are classified into four main groups 
depending on the homology of their catalytic domain245,275, their subcellular 
localization and their enzymatic activity276. 
Classes I, II, and IV require a zinc molecule as an essential cofactor in their active 
site and are inhibited by Zn2+-binding HDAC inhibitors277. Class I, includes HDAC1, 
HDAC2, HDAC3 and HDAC8. Class II, based on their sequence homology and domain 
organization, can be further subdivided into subclass IIa enzymes (HDACs 4, 5, 7 and 9) 
and subclass IIb enzymes (HDAC6 and HDAC10).  
HDAC11 is the only member of the forth HDACs class, localized in the nucleus. 
Besides sharing the homology with class I and class II HDACs278 and being a Zn2+-
dependent enzyme it does not have strong enough identity to be placed in either class. 
Class I HDACs are localized within the nucleus and are the most abundant and 
ubiquitously-expressed HDACs, whereas Class II localize between nucleus and 
cytoplasm depending upon the phosphorylation status, and their expression is tissue-
specific (Table 1.2)279–282.  
Unlike conventional HDACs, class III HDACs are composed of seven mammalian 
sirtuins (SIRT1-7)283. They use nicotinamide adenine dinucleotide (NAD+) as a cofactor 
instead of Zn2+, therefore; they are not inhibited by Zn2+-binding HDAC inhibitors. They 
are localized in the nucleus (SIRT1, SIRT6, and SIRT7), mitochondria (SIRT2, SIRT4, and 
SIRT5), and cytoplasm (SIRT2). The role of sirtuins in tumorigenesis is still controversial 









Table 1. 2 - Classes of histone deacetylases; localization in the cell, length, chromosomal 
localization and function 
 
Information retrieved from245,275276. 
1.3.3 HDAC inhibitors 
Epigenetic alterations, as described above, are involved in the repression of 
tumor suppressor genes and promotion of tumorigenesis in ovarian cancers, thus 
drugs with histone deacetylase inhibitory activity are an attractive therapeutic 
approach286. 
HDAC inhibitors (HDACI) are chemical compounds that inhibit HDAC enzymes 
activity, leading to an increased acetylation of histones, and consequently to an 
increased transcription activity and subsequently upregulation of specific genes 
HDAC family 
member





Class I  Zn2+
dependent
HDAC1 nucleus 483 1p34
Resistance to chemotherapy, proliferation, cell 
survival
HDAC2 nucleus 488 6p21 Proliferation
HDAC3 nucleus/cytoplasm 423 5q31 Proliferation, cell survival
HDAC8 nucleus 377 Xq31 Proliferation
Class IIa Zn2+
dependent
HDAC4 nucleus/cytoplasm 1084 2q37 Angiogenesis, gluconeogenesis
HDAC5 nucleus/cytoplasm 1122 17q21 Differentiation
HDAC7 nucleus/cytoplasm 855 12q13 Differentiation
HDAC9 nucleus/cytoplasm 1011 7p15-21 Angiogenesis
Class IIb Zn2+
dependent
HDAC6 cytoplasm 1215 Xp11 Migration




SIRT1 nucleus 747 --------





389 -------- Cell cycle control, lipid synthesis
SIRT3 nucleus 399 -------- ATP production, metabolism, apoptosis
SIRT4 mitochondria 314 -------- Insulin secretion, metabolism, apoptosis
SIRT5 mitochondria 310 -------- Urea cycle, metabolism, ATP regulation
SIRT6 nucleus 355 --------
DNA repair, chromosome stability, metabolic 
regulation
SIRT7 nucleus 400 -------- RNA pol I ,apoptosis transcription
Class IV Zn2+
dependent






involved in various cellular pathways including cell cycle, differentiation, DNA damage 
and repair, redox signaling, and apoptosis276,279,287,288. 
However, the complexity of the molecular network affected by the action of 
HDACIs does not allow the design of molecular pathways that may be predictive of 
therapeutic response. Hence, it remains unclear the molecular mechanisms underlying 
the response to HDAC inhibitors in cancer patients.  
HDACIs undergoing evaluation for the treatment of cancer can be divided into 
four classes based on their chemical structure. 
The classes include the short chain fatty acids (e.g., valproate and 
phenylbutyrate) that inhibit class I/IIa; hydroxamic acid derivatives (e.g., vorinostat, 
belinostat) that inhibit both class I and II enzymes; benzamides (e.g., entinostat,) that 
selectively inhibit a subset of class I enzymes and cyclic tetrapeptides (e.g., 
romidepsin)245,275,289. 
1.3.3.1 Mechanisms of action of HDACI 
HDACI induce cell cycle arrest in both normal and transformed cells287 and kill 
both proliferating and non-proliferating cells290. In vitro, the time of culture, 
concentration and type of HDACI used affect the number of genes detected with 
altered transcription in vitro. Short time points291,292 and low concentrations293 cause 
fewer changes in gene transcription and predominantly induce G1 arrest, while 
increased time of exposure in culture and concentration of HDACI induces several 
changes in genes and induces both G1 and G2/M arrests294. 
G1 and G2 arrests are largely associated with induction of cyclin-dependent 
kinase (CDK) inhibitor p21, which blocks cyclin E/CDK2 complexes, leading to cell cycle 
arrest and inhibiting differentiation294,295. HDACI-induced expression of p21 is 
independent of p53 and correlates with an increase in the acetylation of histones 
associated with p21 promoter region294,296. In cells cultured with HDACI, the increase 
of CDK inhibitors and the decrease of cyclins may act together to account for the 





through the inhibition of E2F activities in the transcription of genes for G1 progression 
and G1/S transition279.  
The action of HDACI cell cycle arrest in all cells is in contrast to the action of 
many chemotherapeutic drugs, which are only effective on proliferating cells. In some 
cells, the G1 arrest is associated with terminal differentiation294. Transformed cells 
sensitive to HDACI induced cell death are usually in a cell growth-arrested state with 
increase of p21 expression297. Loss of p21 abolishes HDACI-induced G1 arrest297,298, as 
observed in HCT116 cells without p21 expression299. In some cases, HDACI may induce 
other CDK inhibitors that may cause cell cycle arrest. For example, TSA induces 
G1 arrest in human colon HCT116 p21-/- cells associated with the induction of p15 
(INK4b), which is an inhibitor of the cyclin D-dependent kinases299. 
HDAC inhibition also modulates the balance between pro- and anti-apoptotic 
proteins, causing cell death300. Hyperacetylation stabilizes the p53 protein, promoting 
both cell cycle arrest and the expression of proapoptotic genes301. HDAC inhibition 
upregulates the intrinsic and extrinsic apoptosis pathways through the induction of the 
proapoptotic genes, Bmf and Bim302, and TRAIL and DR5, respectively279. 
HDACI activates the extrinsic apoptotic pathway by increasing expression of 
death receptors, including Fas (Apo-1 or CD95), tumor necrosis factor (TNF) receptor-1 
(TNFR-1), TNF-related apoptosis-inducing ligand (TRAIL or Apo2-L) receptors (DR-4 and 
-5), DR-3 (Apo3) and DR-6, and their ligands, such as FasL, TNF, TRAIL and TL1A 
(Apo3L), leading to activation of caspase-8 and caspase-10303. HDACI induces this 
pathway in vitro and in vivo, in transformed cells, but not in normal cells304,305. 
Upregulation of death receptors and/or reducing the inhibitory regulators of death 
receptors pathway by HDACI sensitize tumor cells to TRAIL279. 
HDACI activates the intrinsic apoptotic pathways through the release of 
mitochondrial proteins, such as cytochrome c, apoptosis inducing factor (AIF) and 
Smac, with the consequent activation of caspase-9279,281. These mechanisms are 
regulated, in part, by pro- and antiapoptotic proteins of BCL-2 family306. 
Overexpression of Bcl-2 or BCL-XL, which protect mitochondria, inhibits HDACI-induced 





BMF, BAX, BAK and BIK297,302 and decrease antiapoptotic proteins of Bcl-2 family, such 
as Bcl-2, BCL-XL, BCL-w and MCL-1297,307. The mechanism of this effect is not 
completely understood. It has been shown that vorinostat and TSA increase BIM 
transcription by increasing the activity of E2F1302. 
HDACI are also able to induce autophagy and at this process is expected to 
originate cell death and senescence308.  
The HDACI have shown synergistic or additive antitumor effects with a wide 
range of antitumor reagents, including chemotherapeutic agents such as 
antimetabolites 5-fluorodeoxyuridine and gemcitabine, antitubule agents paclitaxel 
and docetaxel, topoisomerase (Topo) II inhibitors doxorubicin, epirubicin,  etoposide309 
and DNA crosslinking agent cisplatin279,281,307. The synergistic effects in vitro may 
depend on the sequence of drug administration. 
Butyric acid and vorinostat (suberoylanilide hydroxamic acid or SAHA), two 
HDACIs will be further detailed. Vorinostat310, which was FDA approved in 2006 for the 
treatment of cutaneous T-cell lymphoma has shown interesting results in in 
vitro models of ovarian cancer311.  
1.3.3.2 Butyric acid 
Short chain fatty acids, in which butyrate (butyric acid) and valproate (valproic 
acid) are included, are carboxylate compounds that induce hyperacetylation through 
inhibition of HDAC, resulting in relaxation of chromatin, making DNA more accessible 
to transcription factors. 
Butyric acid is a product resulting from fibers degradation in colon by bacteria 
and the natural synthesis and breakdown of longer chain fatty acid in vivo. But, in 
addition of being a part of the metabolic fatty acid cycle312,313, butyric acid also 
functions as HDACI of class I and II enzymes to control cell proliferation and apoptosis 
in cancer cells314. Because cells are able to metabolize butyric acid, it is assumed that 







Vorinostat is a small molecular weight (<300) linear hydroxamic acid compound 
that inhibits the enzymatic activity of a subset of class I HDACs, (HDAC1, HDAC2 and 
HDAC3) and the class II HDAC (HDAC6) at low nanomolar concentrations (half maximal 
inhibitory concentration < 86 nM)245,281. 
The molecular mechanisms of vorinostat-induced cell cycle arrest, 
differentiation, apoptosis and autophagy are not fully understood but are believed to 
be due to the inhibition of HDAC activity. Inhibition of HDAC activity by vorinostat 
causes an increase in acetylation of all the four core nucleosomal histones245,281, 
induces the subsequent opening of DNA chain and promotes the expression of anti-
proliferation and pro-apoptotic genes.  
Many studies have found that the expression of approximately 5–10% genes is 
altered following exposure to vorinostat245,275. The genes regulated by vorinostat are 
dependent on the cell line under study and the study design (e.g, duration of 
vorinostat exposure and dose of vorinostat). 
Vorinostat also causes an increase in acetylation of other chromatin modifying 
proteins, including members of the SWI/SNF family.  
The exact molecular mechanisms how vorinostat induces apoptosis have yet to 
be fully clarified. It appears to occur through the interference in the intrinsic apoptotic 
pathway, characterized by the release of mitochondrial membrane proteins such as 
cytochrome C and the subsequent activation of caspases275,315, but several studies 
have demonstrated that both caspase-dependent and independent cell death275,308 can 
occur. 
Vorinostat may affect cancer growth independently of its direct action on tumor 
cell proliferation and survival by regulating the expression of genes involved in tumor 
angiogenesis316. 
Vorinostat has demonstrated anti-tumor activity in a variety of in vivo rodent 
tumor models whether administered by the  IP,  IV or oral route in carcinogen-induced 





inhibition is observed at doses of vorinostat that do not produce toxic side effects. 
Vorinostat has also been evaluated in preclinical safety studies and the identified 
toxicities are reversible and easily monitored in clinical studies321. 
Vorinostat induces cell cycle arrest, differentiation, apoptosis and autophagy in 
transformed cell lines derived from hematological malignancies and solid tumors as 
monotherapy and in combination with cancer chemotherapies322. Vorinostat is well 
tolerated as both monotherapy and combined therapy with the most common toxicity  
symptoms including fatigue, nausea, diarrhea, anorexia and thrombocytopenia323. 
Vorinostat can be given orally, with a maximum tolerated dose (MTD) of 400 mg 
once daily or 200 mg twice daily, for hematological malignancies, but the dose level 
can be increased up to 600 mg in solid tumors324.  
In summary, HDACs catalyze the removal of acetyl groups from lysine residues of 
proteins, including the core nucleosomal histones. HDACIs have anti-tumor activity in 
preclinical and clinical studies. Non-neoplastic cells are relatively resistant to HDACI-
induced cell death. The cell death pathways identified in mediating HDACI-induced 
transformed cell death include apoptosis by the intrinsic and extrinsic pathways, 
mitotic catastrophe/cell death, cell death as a consequence of autophagy, senescence 
and ROS-facilitated cell death.  
Although a large number of investigations carried out in the last years have made 
possible a broad knowledge about HDACIs, the molecular basis for the antitumoral 
effects of HDACIs is not completely understood as well as the mechanisms underlying 
the sensitivity and resistance of cancer cells to drugs with epigenetic regulatory 
activity. Further research to understand the mechanism(s) of action of vorinostat and 
other HDACIs may reveal the way to developing rational combinations with other 
chemotherapeutic agents and perhaps ultimately to optimizing chemotherapy 






























AIM AND THESIS OUTLINE 
 
Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy 
mainly due to late diagnosis, lack of specific therapy and resistance to conventional 
chemotherapy, based on platinum salts and taxanes. Hence, the discovery of new 
therapeutic strategies urges and the fact that histone deacetylases (HDACs) expression 
is increased in ovarian cancer points out HDAC inhibitors (HDACIs) as an attractive 
alternative. 
The identification of ovarian cancer biomarkers that serve as indicators of cell 
sensitivity for HDACs inhibitors will allow the design of a more effective therapy. 
Furthermore, the understanding of the mechanisms underlying the action of drugs 
involved in epigenetic regulation can give us guidelines for new and more specific 
therapeutic strategies.  
Our hypothesis is that HDACIs are useful drugs to treat ovarian cancer. 
So, the main goal of this study was to disclose the mechanisms underlying the 
effect of HDACIs, in ovarian cancer. In order to accomplish this, five specific aims were 
addressed: 
 To evaluate HDACs expression profiles in order to support the use of HDACIs in 
ovarian cancer (Chapter 2); 
 To access in vitro alterations in proliferation and cell death in EOC cell lines, due 
to exposure to HDACIs (butyric acid and vorinostat) alone and in combination 
with 5-aza-dC, a DNA methyltransferase inhibitor, and conventional 
chemotherapy (carboplatin and paclitaxel) (Chapter 3); 
 To evaluate the role of HNF1β in cell cycle arrest and apoptosis in CCC upon 
vorinostat exposure (Chapter 4); 
 To study the modulatory effect of vorinostat in Notch signaling pathway  
(Chapter 5); and 
 To establish human primary ovarian carcinoma cell lines, to be used as a tool to 




The expression of HDACs was evaluated in EOC tissues samples. The effects of 
HDACI in ovarian cancer were evaluated in vitro by analyzing the general effects of 
HDACIs (butyric acid and vorinostat) alone and in combination with a DNA 
methyltransferase inhibitor, 5-aza-deoxycytidine (5-aza-dC), and with conventional 
therapy (carboplatin and paclitaxel) in cell behavior. In depth it was also addressed the 
effect of vorinostat, in cell cycle and apoptosis and in the expression of key genes in 
ovarian cancer such as HNF1β and Notch elements. Considering the importance of cell 
lines in cancer research, we also established a human ovarian cancer cell line of HGSC. 
This thesis outline is organized in seven sections. In the 1st chapter there is a 
general introduction presenting all subjects and theoretical concepts concerning the 
thesis theme. The following sections include the results obtained in this PhD project 
(Chapter 2-6). Each chapter contains an abstract, a short introduction, methods, 
results and discussion. In the final chapter (chapter 7) the main conclusions enclosing 
all chapters are summarized and integrated, highlighting the major achievements that 




























Protein expression profile of histone deacetylases (HDAC) 1, 2, 
3, 4, 6 and PhosphoHDAC4/5/7 in ovarian cancer 
 







In cancer, histone acetylation was recognized has being involved in carcinogenesis and 
histone deacetylases (HDACs) play an important role in chromatin remodeling, gene 
repression, cell cycle progression, differentiation and therapy. 
The present study aimed to investigate the expression profile of histone deacetylases 
(HDAC), Class I (HDAC1, 2, 3) and class II (HDAC4, 6 and phosphoHDAC4/5/7) in ovarian cancer, 
in order to support the evaluation of HDACIs in ovarian cancer. HDACs expression was 
analyzed by immunohistochemistry on tissue microarrays (TMA) from 64 patients with ovarian 
cancer. HDACs expression was evaluated and correlated with clinicopathological parameters 
and cell cycle markers. 
Our results report that expression profile of HDACs were significantly associated with 
histological types of ovarian cancer. By immunohistochemistry, we found a high expression of 
HDAC1, 2, 3, 4, 6 and phosphoHDAC4/5/7 that was significantly associated with HGSC. The 
most expressed HDACs in CCC were HDAC1, 2 and 6.  
HDAC3 was associated with stage and metastasis, HDAC4c and pHDAC4/5/7 were 
associated with metastasis in EOC. Kaplan-Meier curves showed that HDACs expression was 
not associated with survival. 
Regarding the correlation with the cell cycle markers, we found that in HGSC HDAC1 
expression was statistically associated with p21 expression, and HDAC3, HDAC4c and 
pHDAC4/5/7 were associated with p53 expression.  
In addition, our results show that HDAC2, 3, 4 and phosphoHDAC4/5/7 were 
differentially expressed in HGSC and CCC. 
In conclusion, the panel of HDACs expressed in HGSC and CCC supports the use of 
HDACIs as an alternative to treat ovarian cancer. 











Epigenetic alterations including modifications of the acetylation status of 
histones in the development of human cancer have been recognized246,325. In the last 
years, several studies have highlighted the role of histone deacetylases (HDACs) in 
tumor progression and invasion and their potential use as therapeutic targets for 
cancer therapy and prognostic factors are recently emerging326.  
HDACs are regulators of gene expression by allowing the histones to wrap the 
DNA more tightly274. Histone acetylation is generally associated with increased 
transcription, while deacetylated histones are often associated with gene repression. 
Through these mechanisms, HDACs act as regulators of cell growth, differentiation and 
apoptotic programs and may favor neoplastic growth by allowing the aberrant 
transcription of key genes327. 
A total of eighteen human HDACs enzymes, classified in four main groups 
depending on the homology of their catalytic domain245,275, their subcellular 
localization and their enzymatic activities276 have been characterized in the literature 
and in Table 1.2, in Chapter 1.  
Class I HDACs has been the most systematically investigated group with respect 
to function and relevance for tumor formation. In general, class I HDACs (HDACs 1-3 
and 8) are primarily located in the nucleus and are associated with transcriptional 
repressors and cofactors, although there might be exceptions such as HDAC3, which 
are reported to be also located in the cytoplasm328. Class II HDACs (HDACs 4-7, 9 and 
10) are large proteins that shuttle between the cytoplasm and the nucleus depending 
upon the phosphorylation status279,282,287.  
In the last years, the expression of HDACs and its prognostic value has been 
analyzed in different kinds of human cancers329–331. HDAC expression seems to be 
associated with cell proliferation, angiogenesis, migration and invasion in cancer329. 
Based on these effects of HDAC new and different therapies were developed332,333. In 
vitro and in vivo assays showed that HDAC inhibition can limit growth of cancer cells 





unique roles in different cell types and tumors. At the present, HDACI in research and 
clinical use target class I and class II HDACs. 
In 2006, the HDAC inhibitor suberoylanilide hydroxamic acid–vorinosat (SAHA) 
was the first HDACI to be approved for cutaneous T-cell lymphoma334 therapy. In the 
last decade, different HDACI have being investigated in different types of cancers335–
337. These drugs have been more intensively studied in cancer types with poor 
prognosis. 
Epithelial ovarian cancers (EOC) are the leading cause of death in gynecological 
malignancies3–5 and the high mortality is mainly due to advanced disease at 
diagnosis5,13,338 and the lack of specific therapy. It is not clear which HDACs are active 
in these cancers and there is scarce information in the current literature about the 
expression profile of HDACs in ovarian carcinomas325,339.  
Our aim in this study was to evaluate expression profile of HDAC in human 
samples of ovarian carcinomas by immunohistochemistry and to find its potential 
relationship with tumor histology, clinical behavior and regulation of cell cycle proteins 
(p21, p16, p53 and cyclin D1). We also aimed to evaluate if its expression could help in 
the selection of HDACI. 
Material and Methods 
Patients and tissue samples 
Representative cases of high grade serous ovarian carcinoma (HGSC) and clear 
cell carcinomas (CCC) were retrieved from the archives of the Department of 
Pathology of the Instituto Português de Oncologia de Lisboa de Francisco Gentil 
(IPOLFG). Only tumors treated with primary surgery were selected. All cases were 
reevaluated to confirm the histopathological diagnosis and 49 cases of HGSC and 15 
cases of CCC were selected to construct a tissue microarray with 64 tumor samples of 
ovarian carcinoma and 2 commercial cell lines of ovarian carcinoma: OVCAR3 (a cell 





The study protocol was approved by the Ethics Committee of IPOLFG (reference 
number UC-938/2013) and approved by NOVA Medical School University Ethics 
Committee (reference number 01/2015). 
Cell lines 
Clear cell carcinoma (CCC) cell line ES2 (CRL-1978) and high grade serous 
carcinoma (HGSC) cell line OVCAR3 (HTB-161) were obtained from American Type 
Culture Collection (Manassas, VA, USA). The cells were incubated at 37°C in a 
humidified atmosphere containing 5% CO2 in McCoy’s 5A Modified Medium (Sigma-
Aldrich, St. Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS, S 0615, 
InvitrogenTM, Thermo Fisher Scientific, Inc., Waltham, MA, USA) and 1% antibiotic-
antimycotic (AA) (InvitrogenTM; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The 
cells were cultured to 80-100% confluence prior to detachment by incubation with 1X 
0.05% trypsin-EDTA (InvitrogenTM; Thermo Fisher Scientific, Inc.) at room temperature. 
Cells lines were collected and cytoblock was performed (according to manufacturer’s 
instructions). 
Tissue Microarray (TMA) 
Representative hematoxylin and eosin (H&E) stained slides of ovarian cancer 
cases were selected for tissue microarray construction and three cores of each case 
were collected. Four cores from each commercial cell line cytoblocks were included. 
Briefly, tissue cylinders with a diameter of 1.4 mm were punched from tumor 
areas of each donor tissue block and brought into a recipient paraffin block (tissue 
microarray–TMA), using a manual Tissue Puncher/Arrayer (Beecher Instruments, Silver 
Spring, MD, USA). Sections with normal (ovary, fallopian tube, tonsil, kidney) and 
cancer tissues (breast cancer, prostate cancer, mantle cell lymphoma) known to be 
positive for the different antibodies were used as positive controls. As negative 
controls, adjacent sections were processed as described above except that they were 








TMA sections (4m) were cut for immunohistochemical analysis and sections 
were deparaffinized in xylene and dehydrated through graded concentrations of 
ethanol. Antigen retrieval was performed by PT Link (Dako), with target retrieval 
solution high pH, for 20 min at 95ºC. Formalin-fixed paraffin sections were incubated 
for 1h at room temperature with the following antibodies described in Table 2.1: 
mouse anti-HDAC1, mouse anti- HDAC2, rabbit anti-HDAC6, mouse anti-p21, mouse 
anti-p53, anti-CINTec p16, rabbit anti-cyclin D1 and were visualized by EnVision/HRP 
rabbit/mouse (ChemMate Envision Kit, Dako, K5007, USA). The visualization signal was 
developed with 3,3’-diaminobenzidine (DAB) solution, and all the slides were 
counterstained with Mayer’s hematoxylin. 
Immunohistochemical staining of sections of TMA for HDAC3, HDAC4 and 
phosphoHDAC 4/5/7 was performed using the Ventana Ultra BenchMark Automatic 
staining platform (Ventana Medical Systems, Tuscon, Az, USA). The slides were 
automatically deparaffinized and rehydrated using an EZ Prep solution. Antigen 
retrieval was achieved with ULTRA CC1 solution for 92 min of incubation. Sections 
were then incubated in primary antibody for 20 min for both mouse anti-HDAC3 and 
rabbit phosphoHDAC4/5/7. For the antibody rabbit anti-HDAC4, antigen retrieval was 
achieved with ULTRA CC1 for 40 min and incubated for 12 min. For antibodies p53, p16 
and cyclinD1, antigen retrieval was achieved with ULTRA CC1 for 30 min and incubated 
for 20 min. The Benchmark platform uses a polymer detection system called OptiView 
to stain the antigen site brown. The sections were counterstained using Mayer´s 
Hematoxylin for staining contrast. Slides were then removed from the automated 
system, dry, covered, and analyzed by light microscopy. 
Evaluation of Immunohistochemistry 
The immunohistochemical evaluation was done by a pathologist and analyzed 
the nuclear and cytoplasmic expression of HDAC1, 2 and 3 (negative or positive) and 
the nuclear, cytoplasmic and/or membrane expression of HDAC4, 6 and 
phosphoHDAC4/5/7. A total of 64 cases of EOC and the two cell lines for HDACs with 





Tissue microarrays were assessed for HDAC1, HDAC2, HDAC3, HDAC4, HDAC6 
and phosphoHDAC4/5/7 staining. A two score system was used: 0 for negative cases, 
and 1 for positive cases. In all cores, at least some non-neoplastic cells, such as 
endothelial cells, lymphocytes or fibroblasts showed a weak and faint positivity with all 
HDAC antibodies. In total, only one case (2 %) of clear cell carcinoma was not 
interpretable for one marker. The staining for p53, p21, p16 and cyclin D1 was 
considered to be positive when there was a strong and widespread staining (>10%) of 
the nucleus of the tumor cells was found. Regarding p53 expression, three patterns 
were registered: positivity in >75% of tumor cells were stained; positive in ≤ 75% of 
cells; and the null pattern: when 0% of the neoplastic cells were positive.  
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For statistical analysis, IBM SPSS, version 21 (IBM Inc., Armonk, USA) was used. 
Associations between HDACs expression and clinical and pathological parameters were 
assessed by contingency tables and Fisher´s exact test to evaluate the distribution and 
the association of HDAC expression across tumors and by generalized linear models. 
Chi-square test was used to assess the associations of HDACs proteins expression with 
clinicopathological variables and cell cycle proteins. 
Univariate survival analysis was performed by the generation of Kaplan-Meier 
curves, and differences between groups were compared by the log-rank test. 
Multivariable survival analysis was performed using the Cox proportional hazards 
model. A p-value of 0.05 or less was considered statistically significant. Results were 
presented as hazard ratio (HR) and 95% confidence interval (CI). 
Clinical and pathological characteristics 
The main clinicopathological characteristics of ovarian cancer patients are 
presented in Table 2.2.  
The median age of patients diagnosed as HGSC was 62 years old (range 35 and 
82). Tumors stage was done using FIGO classification and 12% (6) of carcinomas were 
classified at stage I, 23% (11) were at stage II and the remaining 65% (32) patients were 
at stage III (table 2.2). The follow-up period was defined as the time interval between 
the surgery and last medical appointment or death. The median follow-up time was 58 
months (range, 1 to 167 months). All cases were treated with adjuvant chemotherapy 
but two cases. Recurrences were diagnosed in all but 2 patients, 31 (63%) were local 
recurrences and metastases were found in 96% of patients (47/49). At the end of the 
follow up a total of 37 patients died (37/49, 88 %) of disease progression, 3 patients 
were lost for follow up, 4 died from other causes and only 5 (12%) patients remain 







Table 2. 2 - Clinical and pathological characteristics of the EOC patients 
 
 
Regarding CCC, the median age of patients at the time of diagnosis was 61 
(range, 31-81 years). All tumors were stage I, except one diagnosed at stage IIIC (Table 
2.1). Follow up data was obtained and mean follow up was 56 months ranging from 17 
months to 140 months. All cases were treated with surgery and chemotherapy. 
Recurrences occurred in 5 patients and metastases occur in 3 of 15 patients (20%). At 
the end of follow up, 9 (64%) of patients were alive being one alive with disease; 
4(31%) patients died of disease’s progression; 1 died of another cause, and one was 
lost for follow up. 
Evaluating all cases included in this cohort, the median overall survival of 







No. of patients (%)
CCC (n=15)
No. of patients (%)
Age
≤ 61.5 years 22 (45) 8 (53)
> 61.5 years 27 (55) 7 (47)
median 62 61
Stage (FIGO)
I 6 (12) 14 (93)
II 11 (23) 0
III 32 (65) 1(7)
Metastasis
absent 2 (4) 12 (80)
present 47 (96) 3(20)
Status
alive 5 (12) 9 (64)
died of disease 37 (88) 4 (31)
others* 7 2






HDACs expression in EOC 
Immunostains were evaluated in all tissue cores of the TMA that included 
controls (normal and cancer tissues), tumor cases and cores from the commercial cell 
lines. HDAC1, HDAC2 staining was only present in the nucleus of cells. Regarding 
HDAC3, a nuclear staining was seen except in three cases diagnosed as HGSC, whereas 
HDAC3 had also a faint cytoplasmic expression in tumor cells. In all the previous TMA 
core samples, HDAC4 was expressed in the cytoplasm and in the membrane and 
phosphoHDAC4/5/7 and HDAC6 expression were present only in the cytoplasm.  
As regard to commercial cell lines HDAC1, 2, 3 and 6 was expressed in the 
nucleus of OVCAR3 cells (high grade serous carcinoma cell line) and ES2 (clear cell 
carcinoma cell line). Both cell lines cells did not exhibit HDAC4 or phosphoHDAC4/5/7 
staining, although rare ES2 cells exhibited phosphoHDAC4/5/7.  
Regarding the results of HDACs in the ovarian carcinoma’s samples, most cores 
showed an intermediate or high expression of the analyzed enzymes. The results of 
HDACs expression were registered in Figures 2.1., 2.2 and in Tables 2.3 to 2.6. 
 










Cell lines HDAC1 HDAC2 HDAC3 HDAC4m HDAC4c HDAC6 pHDAC4/5/7
OVCAR3 1 1 1 0 0 1 0
ES2 1 1 1 0 0 1 rare
0= negative; 1=positive; 





Table 2. 4 - Expression of HDACs in EOC samples and its association with the histological type 
 
 
Figure 2. 1- Representative pattern of HDACs protein expression in HGSC in tissue microarray 
(TMA) sections. 
Hematoxylin (H&E) and immunohistochemical stains for HDACs in TMA sections of HGSC. A, B- 
H&E; C, D- HDAC1; E, F- HDAC2; G, H- HDAC3; I, J- HDAC4; K, L- HDAC6; M, N- pHDAC4/5/7. 




patientspositive % 95% CI positive % 95% CI p-value
HDCA1 38 78 0.641-0.869 15 100 0.796-1.000 64 0.0540
HDAC2 49 100 0.927-1.000 12 80 0.548-0.929 64 0.0109
HDAC3 44 90 0.782-0.955 5 33 0.151-0.582 64 0.0001
HDAC4m 27 55 0.413-0.681 3 21 0.704-0.451 63 0.0349
HDAC4c 44 90 0.782-0.955 3 21 0.704-0.451 63 0.0001
HDAC6 41 84 0.709-0.914 13 87 0.621-0.962 64 1.000
phosphoHDAC4/5/7 45 92 0.808-0.967 6 43 0.198-0.642 63 0.0003
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In HGSC cases, a very high expression of HDACs was found (Table 2.4). HGSC 
expressed high levels of class I HDAC: 78% (38/49) for HDAC1; 100% (49/49) for HDAC2 
and 90% (44/49) for HDAC3. Regarding class II HDACs, HDAC4 expression in HGSC cases 
in the cytoplasm was more frequent than in the membrane, 90% (44/49) vs 55% 
(27/49), respectively. Cytoplasmic expression of HDAC6 and phosphoHDAC4/5/7 was 
also found in this tumor type in 84% (41/64) and 92% (45/49), respectively. 
 
 
Figure 2. 2 - Representative pattern of HDACs protein expression in CCC in tissue microarray 
(TMA) sections 
Hematoxylin (H&E) and immunohistochemical stains for HDACs in TMA sections of HGSC. A, B- 
H&E; C, D- HDAC1; E, F- HDAC2; G, H- HDAC3; I, J- HDAC4; K, L- HDAC6; M, N- pHDAC4/5/7. 
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In CCC cases (Table 2.4), HDAC1, 2 and 6 were strikingly expressed, 100% 
(15/15), 80% (12/15) and 87% (13/15), respectively. However, HDAC3 expression was 
moderate, being only present in 33% (5/15) of cases, and HDAC4 even lower in the 
membrane and in the cytoplasm, only 21% (3/15) of cases expressed. 
PhosphoHDAC4/5/7 expression was observed in 43% (6/15) of cases. 
The different expression of the HDACs and the tumor type were significant 
regarding HDAC2, HDAC3, HDAC4 and phosphoHDAC4/5/7 immunodetection, being 
more expressed in HGSC than in CCC. HDAC2 was present in all HGSC and only present 
in 80% of CCC being this difference significant with a p=0.0109 (CI=0.548-1.000). 
Nuclear HDAC3 expression was higher in HGSC compared to CCC, being this difference 
also significant (p<0.0001). Both membrane (p=0.0349) and cytoplasmic (p<0.0001) 
HDAC4 expression were associated with HGSC cases. PhosphoHDAC4/5/7 expression 
was also significantly associated (p=0.0003) with HGSC type as reported in Table 2.4. 
 
HDACs expression and clinicopathological parameters in EOC 
We analyzed the expression profile of HDACs and the clinicopathological data in 
separate groups for histological type and the all EOC.  
In univariate analysis of all cases of EOC the expression of some of these 

























negative positive negative positive negative positive
n (%) 11 n (%) 38 n (%) 0 n (%) 15 n (%) 11 n (%) 53
Age
≤61.5 5 (45) 17 (45)
1.000
0 9 (60) 5 (45) 26 (49)
1.0000
>61.5 6 (55) 21 (55) 0 6 (40) 6 (55) 27 (51)
Histological Type
HGSC 11 (100) 38 (72)
0.054
CCC 0 15 (28)
Stage
I-II 3 (27) 14 (37)
0.725
0 14 (93) 3 (27) 28 (53)
0.186
III 8 (73) 24 (63) 0 1 (7) 8 (73) 25 (47)
Metastasis
absent 1 (9) 1 (3)
0.402
0 12 (80) 1 (9) 13 (25)
0.431






p valuenegative positive negative positive negative positive
n (%) 0 n (%) 49 n (%) 3 n (%) 12 n (%) 3 n (%) 61
Age
≤61.5 0 27 (55) 1 (33) 8 (67)
0.525
1 (33) 30 (49)
1.000
>61.5 0 22 (45) 2 (67) 4 (33) 2 (67) 31 (51)
Histological Type
HGSC 0 0 49 (20)
0.010
CCC 0 3 12 (80)
Stage
I-II 0 17 (35) 2 (67) 12 (100)
0.200
2 (67) 29 (48)
0.607
III 0 32 (65) 1 (33) 0 1 (33) 32 (52)
Metastasis
absent 0 2 (4) 2 (67) 10 (88)
0.516
2 (67) 12 (20)
0.118






p valuenegative positive negative positive negative positive
n (%) 5 n (%) 44 n (%) 10 n (%) 5 n (%) 15 n (%) 49
Age
≤61.5 0 4 (5)
1.000
5 (50 4 (80)
0.580
7 (47) 24 (49)
1.000
>61.5 5 (100) 42 (95) 5 (50) 1 (20) 8 (53) 25 (51)
Histological Type
HGSC 5 (33) 44 (90)
0.0001
CCC 10 (67) 5 (10)
Stage
I-II 5 (100) 12 (27)
0.0032
9 (90) 5 (100)
1.000
14 (93) 17 (35)
0.0001
III 0 32 (73) 1 (10) 0 1 (7) 32 (65)
Metastasis
absent 0 2 ( 5)
1.000
8 (80) 4 (80)
1.000
8 (47) 6 (12)
0.002













negative positive negative positive negative positive
n (%) 5 n (%) 44 n (%) 12 n (%) 3 n (%) 16 n (%) 47
Age
≤61.5 4 (40) 18 (41)
0.160
5 (45) 2 (67)
0.209
9 (44) 21 (45)
0.564
>61.5 1 (20) 26 (59) 6 (55) 1 (33) 7 (56) 26 (55)
Histological Type
HGSC 5 (31) 44 (94)
0.0001
CCC 11 (69) 7 (6)
Stage
I-II 1 (20) 16 (36)
0.646
10 (91) 3 (100)
1.000
11 (69) 19 (40)
0.081
III 4 (80) 28 (64) 1 (9) 0 5 (31) 28 (60)
Metastasis




11 (69) 2 (4)
0.0001






p valuenegative positive negative positive negative positive
n (%) 22 n (%) 27 n (%) 11 n (%) 3 n (%) 33 n (%) 30
Age
≤61.5 9 (40) 13 (48)
0.774
5 (45) 2 (67)
1.000
15 (45) 15 (50)
0.803
>61.5 13 (59) 14 (52) 6 (55) 1 (33) 18 (55) 15 (50)
Histological Type
HGSC 22 (67) 27 (90)
0.034
CCC 11 (33) 3 (10)
Stage
I-II 10 (45) 7 (26)
0.228
10 (91) 3 (100)
1.000
20 (39) 10 (33)
0.044
III 12 (55) 20 (74) 1 (9) 0 13 (61) 20 (67)
Metastasis
absent 0 2 (7)
0.495
9 (82) 2 (67)
1.000
9 (27) 4 (13)
0.221






p valuenegative positive negative positive negative positive
n (%) 8 n (%) 41 n (%) 2 n (%) 13 n (%) 10 n (%) 54
Age




5 (50) 26 (48)
1.000
>61.5 3 (38) 24 (59) 2 (100) 4 (31) 5 (50) 28 (52)
Histological Type
HGSC 8 (80) 41 (76)
1.000
CCC 2 (20) 13 (24)
Stage
I-II 1 (12) 16 (39)
0.233
2 (100) 12 (92)
1.000
3 (30) 28 (52)
0.305
III 7 (88) 25 (61) 0 1 (8) 7 (70) 26 (48)
Metastasis
absent 0 2 (5)
1.000
2 (100) 10 (77)
1.000
2 (20) 12 (22)
1.000






p valuenegative positive negative positive negative positive
n (%) 4 n (%) 45 n (%) 8 n (%) 6 n (%) 12 n (%) 51
Age
≤61.5 3 (75) 19 (42)
0.314
5 (63) 3 (50)
1.000
8 (67) 22 (43)
0.202
>61.5 1 (25) 26 (58) 3 (37) 3 (50) 4 (33) 29 (57)
Histological Type
HGSC 4 (33) 45 (88)
0.0001
CCC 8 (67) 6 (12)
Stage
I-II 1 (25) 16 (36)
1.000
7 (88) 6 (100)
1.000
8 (67) 22 (43)
0.202
III 3 (75) 29 (64) 1 (12) 0 4 (33) 29 (57)
Metastasis
absent 1 (25) 1 (2)
0.471
6 (75) 5 (83)
1.000
7 (58) 6 (12)
0.001





In summary, HDAC3 expression was associated with stage (p=0.001), being 
present in high stage HGSC at presentation (p=0.002) and HDAC3, HDAC4c and 
phosphoHDAC4/5/7 expression was associated with the presence of metastasis 
(p=0.002), (p=0.001) and (p=0.001), respectively. No prognostic value of HDACs in 
overall survival (OS) was found using Kaplan-Meier method and log-rank test.  
Subsequently, we performed multivariate analysis and the results indicated that 
there is a trend of association between the histological type and metastasis and in our 
cohort the histological type is an independent factor. 
 
Table 2. 6 - Multivariate analysis of HDAC3, HDAC4c and phosphoHDAC4/5/7 expression for 
histological type and metastasis 
 
 
HDACs expression and cell cycle markers in EOC 
The results of the immunohistochemical study of cell cycle markers performed on 
commercial cell line and EOC samples are registered in figure 2.3 and table 2.7 and 2.8. 
Concerning the EOC cell lines, OVCAR3 expressed p53 and cyclin D1, and no 
expression for p16 and p21 was observed. ES2 exhibited p16, p53, Cyclin D1, however 
p21 was not present. 
 
 Table 2. 7 - Expression of cell cycle markers in EOC commercial cell lines 
 
 
Parameters HDAC3 HDAC4c pHDAC4
OR 95% CI p  value OR 95% CI p  value OR 95% CI p  value
Histological type (HGSC vs CCC) 0.045 0.004-0.494 0.011 0.149 0.19-1.148 0.68 0.112 0.013-0.956 0.045
Metastasis (absent vs present) 0.738 0.63-8.633 0.809 14.465 1.7-121.6 0.14 2.046 0.232-18.04 0.519
HDAC4c: cytoplasm, pHDAC4/5/7: phosphoHDACs/5/7, OR, odds ratio; CI, confidence interval
Cell lines p16 p21 p53 Cyclin D1
OVCAR3 0 0 1* 1
ES2 1 0 1* 1










In ovarian carcinoma cases, p21 was confined to the nucleus and was positive in 23 
(47%) of HGSC and in 11 (73%) of CCC. In spite of a higher p21 expression in clear cell 
carcinomas, the p21 status was not associated to the histological subtype.  Regarding 
p16 and cyclin D1 a very similar nuclear expression was found in both tumor types. In 
this cohort, the p53 status was related to histological type (p=0.001).  
We analyzed expression of cell cycle markers in EOC (Table 2.9) and HDAC 
expression and we observed significant association between the expression of HDAC1 
and p21 (p=0.002). We also observed significant association between p53 and some 
HDACs. We found that p53 positivity was correlated with HDAC3 (p=0.002), HDAC4c 
(p=0.033) and pHDAC4/5/7 (p=0.018). Cyclin D1 and p16 immunoexpression was not 






negative positive % positive negative positive % positive
p16 11 38 78 4 11 73 64 0.737
p21 26 23 47 4 11 73 64 0.085
p53 15 34 69 3 12 80 64 0.528














p53 4 45 92 11 4 27 0.001
p53*Negative – cases that show positive p53 stain in  <75%; Positive - cases that show positive p53 







Figure 2. 3 - Representative examples of immunostaining for p16, p21, p53 and cyclin D1 in 
different histological types of ovarian cancer 
Immunohistochemical stains for the cell cycle markers were performed in TMA sections. HGSC 




























negative positive negative positive negative positive
n (%) 11 n (%) 38 n (%) 0 n (%) 15 n (%) 11 n (%) 53
p16 expression
negative 3 (27) 8 (21)
0.692
0 4 (27) 3 (27) 12 (23)
0.710
positive 8 (73) 30 (79) 0 11 (73) 8 (73) 41 (77)
p21 expression
negative 10 (91) 16 (42)
0.006
0 4 (27) 10 (91) 20 (38)
0.002
positive 1 (9) 22 (58) 0 11 (73) 1 (9) 33 (62)
p53 expression
overexpressed/null 9 (82) 36 (95)
0.214
0 5 (37) 9 (82) 41 (77)
1.000
“wild type” 2 (18) 2 (5) 0 10 (67) 2 (18) 12 (23)
Cyclin D1 expression
negative 10 (91) 30 (79)
0.662
0 13 (87) 10 (91) 43 (81)
0.672






p valuenegative positive negative positive negative positive
n (% ) 0 n (%) 49 n (%) 3 n (%) 12 n (%) 3 n (%) 61
p16 expression
negative 0 11(22) 1 (33) 3 (25)
1.000
1 (33) 14 (23)
0.558
positive 0 38 (78) 2 (67) 9 (75) 2 (67) 47 (77)
p21 expression




positive 0 23 (47) 2 (67) 9 (75) 2(67) 32 (52)
p53 expression




“wild type” 0 4 (8) 2 (67) 8 (67) 2(67) 12 (20)
Cyclin D1 expression
negative 0 40 (82) 3 (100) 10 (83)
1.000
3 (100) 50 (82)
1.000






p valuenegative positive negative positive negative positive
n (% ) 5 n (%) 44 n (%) 10 n (%) 5 n (%) 15 n (%) 49
p16 expression
negative 2 (40) 9 (20)
0.311
3 (30) 1 (20)
1.000
5 (33) 10 (20)
0.315
positive 3 (60) 35 (80) 7 (70) 4 (80) 10 (67) 39 (80)
p21 expression
negative 3 (60) 23 (52)
1.000
4 (40) 0 (27)
0.231
7 (47) 23 (47)
1.000
positive 2 (40) 21 (48) 6 (60) 5 (73) 8 (53) 26 (53)
p53 expression
overexpressed/null 4 (80) 41 (93)
0.359
3 (30) 2 (40)
1.000
7 (47) 43 (88)
0.002
“wild type” 1 (20) 3 (7) 7 (70) 3 (60) 8 (53) 6 (12)
Cyclin D1 expression
negative 4 (80) 36 (82)
1.000
10 (100) 3 (60)
0.095
14 (93) 39 (80)
0.434














negative positive negative positive negative positive
n (%) 5 n (%) 44 n (%) 11 n (%) 3 n (%) 16 n (%) 47
p16 expression




4 (25) 11 (23)
1.000
positive 5 (100) 33 (75) 7 (64) 3 (100) 12 (75) 36 (77)
p21 expression
negative 4 (80) 22 (50)
0.353
2 (18) 1 (33)
1.000
6 (62) 23 (49)
0.564
positive 1 (20) 22 (50) 9 (82) 2 (67) 10 (38) 24 (51)
p53 expression




9 (56) 40 (85)
0.033
“wild type” 0 4 (9) 7 (64) 3 (100) 7 (44) 7 (15)
Cyclin D1 expression
negative 4 (80) 36 (82)
1.000
9 (82) 3 (100)
1.000
13 (81) 39 (83)
1.000






p valuenegative positive negative positive negative positive
n (%) 22 n (%) 27 n (%) 11 n (%) 3 n (%) 33 n (%) 30
p16 expression




9 (73) 6 (20)
0.564
positive 17 (77) 21 (78) 7 (64) 3 (100) 24 (27) 24 (80)
p21 expression
negative 11 (50) 15 (56)
0.778
2 (18) 1 (67)
1.000
13 (39) 16 (53)
0.317
positive 11 (50) 12 (44) 9 (82) 2 (33) 20 (61) 14 (47)
p53 expression




24 (73) 25 (83)
0.373
“wild type” 2 (9) 2 (7) 7 (64) 3 (100) 9 (27) 5 (17)
Cyclin D1 expression
negative 16 (73) 24 (89)
0.266
9 (92) 3 (100)
1.000
25 (76) 27 (90)
0.189






p valuenegative positive negative positivenegative positive
n (% )8 n (%) 41 n (%) 2 n (%) 13 n (%) 10 n (%) 54
p16 expression
negative 2 (25) 9 (22)
1.000
2 (100) 2 (15)
0.057
4 (40) 11 (20)
0.226
positive 6 (75) 32 (78) 0 11 (85) 6 (60) 43 (80)
p21 expression
negative 4 (50) 22 (54)
1.000
0 (40) 4 (31)
1.000
4 (40) 26 (48)
0.738
positive 4 (50) 19 (46) 2 (60) 9 (69) 6 (60) 28 (52)
p53 expression
overexpressed/null 7 (86) 38 (93)
0.522
2 (100) 3 (23)
0.095
9 (90) 41 (76)
0.437
“wild type” 1 (12) 3 (7) 0 10 (77) 1 (10) 13 (24)
Cyclin D1 expression
negative 8 (100) 32 (78)
0.322
2 (100) 11 (85)
1.000
10 (100) 43 (80)
0.188







negative positive negative positive negative positive
n (% ) 4 n (%) 45 n (%) 8 n (%) 6 n (%) 12 n (%) 51
p16 expression
negative 2 (50) 9 (20)
0.214
3 (37) 1 (17)
0.580
5 (42) 10 (20)
0.137
positive 2 (50) 36 (80) 5 (63) 5 (83) 7 (58) 41 (80)
p21 expression




5 (42) 24 (47)
1.000
positive 2 (50) 21 (47) 5 (63) 6 (100) 7 (58) 27 (53)
p53 expression
overexpressed/null 4 (100) 41 (91)
1.000
2 (25) 2 (33)
1.000
6 (50) 43 (84)
0.018
“wild type” 0 4 (9) 6 (75) 4 (67) 6 (50) 8 (16)
Cyclin D1 expression
negative 4 (100) 36 (80)
1.000
8 (100) 4 (67)
0.165
12 (100) 40 (78)
0.104






Ovarian carcinomas correspond to several different clinical and histological 
entities that are treated with the same therapeutic approach with very modest 
success340. Recently, genetic and molecular characterization of these entities, 
reinforced its individuality and the need to find more adequate therapeutics for each 
entity34,37.  
Over the 10 last years, HDACs have been reported to be involved in many human 
malignancies, including ovarian carcinomas325,341 and their expression has been 
associated with clinicopathological parameters such as patients’ survival and disease 
prognosis. The assessment of HDACs immunodetection profile and the biological and 
clinical significance of these markers in ovarian carcinomas remains scarce.  
In the view of above considerations, the present study assessed the expression 
of class I and II HDACs in ovarian carcinomas, pursued to find their association with 
clinicopathological parameters and with the expression of cell cycle proteins. Also, to 
contribute for HDAC immuno-profile that might establishes a rational for the use of 
HDAC inhibitors in ovarian cancer. 
Class I HDACs are mostly localized within the nucleus due to the lack of a nuclear 
export signal whereas class II HDACs shuttle between nucleus and cytoplasm in 
response to certain cellular signals339. 
In our panel of tumors, we observed a high expression of all HDACs in those 
cellular locations. All types of class I HDACs studied, HDAC1, 2 and 3, where present in 
the majority of HGSC and CCC cases. This result is in accordance with Hayashi et al.325 
that described an increased stepwise nuclear expression of HDAC1, HDAC2 and HDAC3 
proteins from benign, borderline and malignant ovarian tumors.  
In the analysis of our results, we observed a lower HDAC1 expression in HGSC 
(78%) than in CCC (100%), and a higher HDAC2 in HGSC (100%) than in CCC. These two 
HDACs have an opposite expression, being the HDAC2 significantly associated with the 
histological type (p=0.0109). The biological meaning of the different expression can be 





HDAC2 form homo-and heterodimers between each other342,343, which allows them to 
act together or separately from each other, so HDAC1 in the absence of HDAC2 is still 
able to interact with Co-REST and Sin3a (this is also true vice versa), demonstrating 
that the integrity of known HDAC containing corepressor complexes Co-REST and Sin3a 
is not affected in the absence of one of these two enzymes. In fact, no association was 
found regarding these two HDACs and the clinical parameters evaluated.  
HDAC3 protein expression in these two tumor type of ovarian carcinomas differs 
relevantly from the other two Class I HDACs proteins. The immunoexpression of 
HDAC3 in our set of CCC was low in comparison to previous reports325,339. HDAC3 in 
our series was highly express in the majority of HGSC (90%) and was seldom found in 
CCC (33%), being this difference statistically significant (p<0.0001). The low expression 
of HDAC3 in CCC might underlie different regulatory mechanisms of the three proteins 
in this tumor entity or might be dependent on the stage of disease. Hayashi et al.325 
found, in their series of cases of EOC, a correlation between HDAC3 expression on CCC 
and stage IV disease. In our series, all, but one case, were diagnosed at stage I and this 
might be the explanation for the lower expression of HDAC3 that we observed in our 
cohort of CCC. It is plausible that HDAC3 is associated with the biological 
aggressiveness. Although, we did not found an association between HDAC3 expression 
in CCC and stage or prognosis, in all the cohort of EOC cases, and in the HGSC group, 
HDAC3 was more frequently associated with advanced clinical stage (p=0.0001) and 
(p=0.0023), and presence of metastases (p=0.002) in EOC patients. Hayashi et al. also 
described the importance of HDAC3 expression for ovarian cancer cell migration325. 
Again, our cohort of CCC cases cannot be use to address this as only one case were at 
advance stage at presentation. 
The study of the role of HDACs in cancer has been mainly focused on the 
potential contribution of members of the class I HDACs subfamily. However, in recent 
year’s class II HDACs have started to be linked to several types of cancer344–346. Class II 
HDACs are regulated in part by shuttling the protein between the nucleus and 
cytoplasm.  Cytoplasmic location of class II facilitates gene activation by removing 





The HDAC4 nuclear localization seems to be important in cancer as HDAC 
inhibitors block its entrance to the nucleus347. In our series, we only found HDAC4 in 
the cytoplasm and/or in the cell membrane and was predominantly expressed in 
HGSC. Both membrane (p=0.0349) and cytoplasmic (p<0.0001) HDAC4 expression were 
associated with HGSC cases in comparison with CCC. The phosphorylation of HDAC4 
generates binding sites for the 14-3-3 protein, an HDAC chaperon, and promotes its 
export from the nucleus to the cytoplasm347. This protein has been also found highly 
expressed in some cancers such as esophageal carcinoma348 and breast cancer in 
comparison with others like renal, bladder and colorectal cancer346. HDAC4 has also 
been described in the cytoplasm of pancreatic adenocarcinoma349. In that series of 
pancreatic adenocarcinomas, the high cytoplasmic HDAC4 expression was associated 
with absence of metastasis. This is in contrast to our findings in ovarian carcinomas, 
where the HDAC4c was associated with the presence of metastasis (p=0.001). And also 
in contrast to Shen et al.350 findings, that also reported that EOC at stage III/IV had 
higher HDAC4 expression when compared to initial stages. It might be relevant to 
mention that this HDAC is missing in both cell lines by immunohistochemical 
evaluation. 
In our series of ovarian carcinomas phosphoHDAC4/5/7 expression was 
significantly associated with HGSC in comparison to CCC (p=0.003), corroborating the 
previous findings about HDAC4. The biological significant of this phospho-proteins is 
not clear in cancer but multiple cell stimuli, including VEGF-induced angiogenesis in 
endothelial cells, B cell and T cell activation, and differentiation of myoblasts into 
muscle fiber248 are known to induce phosphorylation of highly conserved HDAC4 
Ser632, HDAC5 Ser498 and HDAC7 Ser486 residues by CAMK and PKD kinases248.  
Among the HDACs family members, HDAC6 is overexpressed in many 
cancers351 and has been implicated in cell migration and invasion345,352,353. HDAC6 is a 
cytoplasmic resident protein, that deacetylates tubulin and alter microtubule 
stability354. Tubulin deacetylation is required for disposal of misfolded proteins in 
aggresomes355. During the last decade, HDAC6 has emerged as a master regulator of 
the cellular protective response to cytotoxic accumulation of toxic bioproducts351,356. 





Importantly, there are small molecule inhibitors for HDAC6 currently being tested in 
advanced clinical trials for other tumor types (myeloma and lymphoid malignancies)359. 
Although high levels of HDAC6 in HGSC (84%) and CCC (87%) were found, no 
associations with the histological type of EOC, nor with clinicopathological features 
were observed. Nevertheless, it might be interesting to explore the molecular 
mechanisms of this therapeutic approach in these tumor types.  
Because data from in vitro studies suggest a link between HDACs and cell cycle, 
we also aimed to verify the potential association to cell cycle markers in EOC325,360. 
HDAC1 and 2 act in concert to promote the G1-to-S progression329. And it has been 
observed that HDAC1 deacetylates p53 and modulates its effect on cell growth and 
apoptosis, and also mediates repression of p21 by deacetylating histones in the p21 
promoter region, resulting in inhibition of p21 gene expression329. The p21 gene is the 
primary mediator of p53-induced cell cycle arrest, and cells lacking functional p53 
express only low levels of p21.  
In our set of cases, by immunohistochemistry we observed that the majority of 
HGSC cases express high HDAC1 and p21. These apparently unexpected result can be 
explain by other mechanisms of regulation of the expression of p21, independent of 
p53, as for example the hyperacetylation of histones 3 and 4327,361. Lagger et al.362 
suggest that interactions of p53 and HDACs, likely result in p53 deacetylation, thereby 
reducing its transcriptional activity and increasing its ubiquitination and degradation 
rate.  
Recently, researchers reported that combination of HDACIs and anticancer 
agents, including conventional chemotherapeutic drugs, had synergistic effects279. In 
addition, HDAC3 has been associated with chemoresistance to etoposide363 and to 
paclitaxel in melanoma cells364. Furthermore, it has been reported that HDAC 
inhibitors increased the efficacy of chemotherapy and that administering agents in 
sequence is important for ovarian cancer treatment311.  
The present study corroborates previous findings that showed that elevated 
HDACs expression were associated with clinicopathological parameters such as 





ovarian carcinoma patient’s management and prognosis. These findings provided 
evidence for a potential role of HDACs in the biological mechanisms of ovarian 
malignant disease. The potential implication of HDACs in ovarian carcinomas, point out 
the necessity for further studies in order to clarify the potential role of the molecules 
and their possible use in the established therapeutic regimens of this types of 
malignancy.  
The elevated expression levels of HDAC1, 2 and 6 in ovarian carcinomas may 
reinforce the therapeutic utility of HDAC targeting in ovarian cancer, taking into 
consideration of HDACIs effect in cell proliferation and apoptosis. In this context, the 
cdk inhibitor p21 was shown to be the most commonly induced gene in various ovarian 
cancer cell lines by several HDACIs296, because deacetylation of histones represses the 
transcription of these tumor suppressor genes. 
Our study presents issues of strength and limitations in particular, it might be 
underpowered because of it is a small cohort and because it is not yet known if 
immunohistochemistry is useful to determine if HDAC protein expression as assessed 
by immunohistochemistry is a predictor of treatment response with HDACIs, Clearly, 
additional studies are needed to clarify this point. Although high rates of HDAC 
expression have been found to be prognostic markers in other tumor entities, in this 
cohort no survival value of these markers could be demonstrated but this study is 
useful to emphasize the difference between tumor types and the expression profile of 
HDACs. 
In conclusion, we demonstrated that the class I and II HDACs enzymes are highly 
expressed in HGSC and CCC and it is correlated with ovarian histological type. Although 
HDAC expression was not correlated with patient survival, the expression patterns of 
HDACs could hypothetically be important to predict the response of EOC patients to 
epigenetic therapies alone or in combination with conventional chemotherapy. 
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 Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy. Standard 
treatment for ovarian cancer patients is cytoreductive surgery, and in advanced disease 
chemotherapy, after debulking surgery, is a usual procedure.  
Our aim is to understand the effects of histone deacetylases inhibitors (HDACI) in 
ovarian cancer as well as the mechanisms underlying the sensitivity and resistance of cancer 
cells to drugs with epigenetic regulatory activity. Cancer cell lines (OVCAR3 and ES2) were used 
and exposed to HDACIs, butyric acid and vorinostat, 5-aza-2´-deoxycytidine (DNA methylation 
inhibitor) and carboplatin and paclitaxel (standard chemotherapy) alone and combined. 
Analysis of cell death, proliferation and migration in cancer cell lines was performed to 
evaluate the in vitro effects of the different therapeutic drugs. 
 Our results show, that the two distinct HDAC inhibitors, butyric acid and vorinostat 
induced cell death, mainly through apoptosis in the two cell lines. This result was further 
confirmed in ES2 cell line exposed to vorinostat, by the study of immunofluorescence of 
cleaved caspase 3 and the evaluation of the ratio of proteins BAX/BCL-2, which increased after 
vorinostat exposure. Cell migration is affected by vorinostat in both cancer cell lines. Our 
results also indicate that the association of different drugs types are able to potentiate the 
effect of standard chemotherapy, mainly in ES2 cell line (CCC), supporting that EOC treatment 
can benefit from combined chemical and epigenetic therapy.  







Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy3–5. 
Nearly 70% of patients present at advanced stage of ovarian cancer and the 5-year 
overall survival (OS) rates are around 20%11. The standard treatment for ovarian 
cancer patients includes cytoreductive surgery, during which adequate staging 
evaluation is performed, by pathological examination of ovarian and other abdominal 
tissues to define the nature of the tumor and its stage. In patients diagnosed with early 
cancer disease, surgery alone, or with adjuvant chemotherapy is usually sufficient, but 
in advanced disease, debulking surgery followed by chemotherapy is mandatory96. 
Current therapies for advanced ovarian cancer are limited and not curative and 
the search for new therapeutic agents to treat the primary disease and recurrences, 
have been disappointing22. New procedures of treatment based upon the knowledge 
of the mechanisms of carcinogenesis and new therapeutic targets are needed242. 
Recently, two new drugs have been introduced into the clinical practice as examples 
for the ‘‘proof-of-concept’’ approach to target cancers: Olaparib and Bevacizumab. 
Olaparib, a Poly (ADP-ribose) polymerase (PARP) inhibitor was approved for 
patients365 with inherent or acquired defects in DNA and Bevacizumab, a humanized 
monoclonal antibody that targets all isoforms of vascular endothelial growth factor 
(i.e. VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E). Unfortunately, although promising 
results were expected, till present these two agents are not routinely used as first- or 
second-line treatment of EOCs366. 
A different approach can be developed targeting epigenetic changes, as they are 
crucial for the development and progression of cancer, including in EOC. Significant 
progress has been made to understand how various epigenetic changes such as DNA 
methylation, histone modification, miRNA expression and other modulators of 
chromatin structure, affect gene expression. 
Histone acetyltransferases (HAT) and histone deacetylases (HDACs) are 
multifunctional enzymes that modify the acetylation status of both histone and 





apoptosis, and protein folding) and are often dysregulated in cancer273. HDACs (see 
Table 1.2 in Chapter 1) are classified into four main classes: I, II, III and IV. 
HDAC inhibitors are small molecules that directly interact with HDAC catalytic 
sites preventing the removal of acetyl groups, thereby counteracting the action of 
HDACs (Figure 3.1), leading to an increased transcription activity and subsequently 
upregulation of specific genes involved in regulation of gene expression and in various 
cellular pathways including cell growth arrest, differentiation, DNA damage and repair, 
redox signaling, and apoptosis276,279,287,288. 
Short chain fatty acids, in which butyrate (butyric acid) and valproate (valproic 
acid) are included312,313, also function as HDACI of class I and II enzymes to control cell 
proliferation and apoptosis in cancer cells314. Because cells are able to metabolize 
butyric acid, it is assumed as having a weak effect as HDACI. 
Vorinostat, a HDAC inhibitor, is a small hydroxamic acid compound that inhibits 
the enzymatic activity of a subset of class I HDACs, (HDAC1, HDAC2 and HDAC3) and 
the class II (HDAC6) at low nanomolar concentrations, and shows anti-proliferative 
activity in a variety of pre-clinical tumor models317,320 . It is currently in clinical use for 
the treatment of cutaneous T-cell lymphoma367. 
DNA methylation is another important process to regulate gene expression. DNA 
methylation occurs on cytosine residues of CpG dinucleotides. The methylation of CpG 
islands (regions greater than 200 bp in length, having more than 50 percent of CG 
content250 and frequencies above 0.6%) found in gene promoters has been correlated 
with the loss of gene expression and gene silencing through DNA methylation253. 
The inhibition of DNA methylation can regulate gene expression by "opening" 
the chromatin structure detectable as increased nuclease sensitivity. This remodeling 
of chromatin structure allows transcription factors to bind to the promoter regions, 
assembly of the transcription complex, and gene expression314. Hence, DNA 
methylation is a mechanism that affects all the cell functions. The strong inhibitor of 
DNA-methyltransferases, 5-aza-2'-deoxycytidine (5-aza-dC), has also been a subject of 





incorporated into DNA, irreversibly binds the methyltransferase enzymes as they 
attempt to methylate the cytosine analogue368. 
 
Figure 3. 1 - Mechanism of action of HDAC inhibitors (HDACI) 
Acetylation of histone proteins is catalyzed by the action of HATs and is reversed by the action 
of HDACs. The tight coiling of DNA results from the deacetylation of histones that inhibits the 
transcription of important tumor suppressor genes (up). With histone deacetylases (HDACs) 
inhibited, high levels of acetylated histones cause DNA relaxation, allowing tumor suppressor 
genes to be accessible for transcription (down).  
 
Our aim is to contribute to the study of the effects of HDACI in ovarian cancer 
cell lines as well as to disclose the mechanisms underlying the sensitivity and 
resistance of cancer cells to drugs with epigenetic regulatory activity. In this study we 
performed a set of experiments to evaluate the effect of HDACI and DNA methylation 
inhibitor alone or combined with conventional therapeutic agents in ovarian cancer 












class of enzymes that remove acetyl groups (O=C-CH3) allowing 






















Material and Methods 
Cell lines and cell culture conditions 
Clear cell carcinoma (CCC) cell line ES2 (CRL-1978) and high grade serous 
carcinoma (HGSC) cell line OVCAR3 (HTB-161) were obtained from American Type 
Culture Collection (Manassas, VA, USA). The cells were incubated at 37°C in a 
humidified atmosphere containing 5% CO2 in McCoy’s 5A Modified Medium (Sigma-
Aldrich, St. Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS, S 0615, 
InvitrogenTM, Thermo Fisher Scientific, Inc., Waltham, MA, USA) and 1% antibiotic-
antimycotic (AA) (InvitrogenTM; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The 
cells were cultured to 80-100% confluence prior to detachment by incubation with 1X 
0.05% trypsin-EDTA (InvitrogenTM; Thermo Fisher Scientific, Inc.) at room temperature.  
For the various assays, cell number was determined using a Bürker counting 
chamber. Prior to any experiment, cells were synchronized under starvation (culture 
medium without FBS), overnight at 37°C and 5% CO2. Preliminary assays were made to 
establish the concentrations of butyric acid, vorinostat and 5-aza-2´-deoxycytidine (5-
aza-dC) based in literature. Cell lines ES2 and OVCAR3 cells were seeded onto 24 plates 
at a density of 1x104, cultured with and without butyric acid, vorinostat and 5-aza-dC. 
Chemicals and Reagents 
Specifications on butyric acid, vorinostat, 5-aza-dC, paclitaxel (PTX) and 
carboplatin (CBP) are presented in Table 3.1. Vorinostat was dissolved in DMSO to 
produce a 50 mM stock solution and stored at -20°C. Paclitaxel and carboplatin were 
dissolved in sodium chloride and stored at room temperature and 4°C, respectively. All 










Table 3. 1 - Chemicals used in ovarian cancer cell lines 
 
Flow Cytometry analysis of cell death 
Cells were collected, followed by centrifugation at 1200 rpm for 2 min, at 
designated times (0, 6, 18, 30 and 72h). The cell pellet was incubated with 1 µl annexin 
V- fluorescein isothiocyanate (FITC BD-Pharmigen) and 1 µl propidium iodide (PI) (50 
µg/mL, Sigma-Aldrich, St. Louis, MO, USA) in 100 µl annexin V binding buffer 1X (10 
mM HEPES (pH 7.4), 0.14M sodium chloride (NaCl), 2.5 mM calcium chloride (CaCl2) at 
room temperature and in the dark for 15 min. After incubation, samples were rinsed 
with 0.1% (w/v) BSA (A9647, Sigma) in PBS 1X and centrifuged again at 1200 rpm for 2 
min. Cells were suspended in 200 µl of annexin V binding buffer 1X. 
Acquisition was performed in a FACScalibur flow cytometer (Becton Dickinson). A 
total of 10,000 cells per sample were acquired and data were analyzed with FlowJo 
software (http://www.flowjo.com/). 
Immunofluorescence 
Cells were cultured on glass slides with a 0.2% gelatin coating, until 80% of 
confluence and then fixed in 2% paraformaldehyde for 15 minutes at 4⁰C. Blocking was 
performed with 0.1% (w/v) BSA in PBS 1X for 1 h at room temperature, and incubated 
with rabbit polyclonal anti-cleaved caspase 3 (catalog no. 9661S, Asp175, Cell 
Signaling) antibody, overnight at 4°C (diluted in 0.1% (w/v) BSA in PBS 1X, 1:100). Cells 
were incubated with secondary antibody for 2 h, at room temperature. Secondary 
Chemicals Catalog no Supplier Dilution
Butyric acid B10 350-0 Sigma-Aldrich 1mM
Vorinostat CAS 149647-78-9







Paclitaxel Kabi 6mg/ml, L 
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antibody used was Alexa Fluor®488 anti-rabbit (A-11008, Invitrogen). The slides were 
mounted in VECTASHIELD media with DAPI (4'-6-diamidino-2-phenylindole) (H-1200, 
Vector Labs) and examined by standard fluorescence microscopy using an Axio 
Imager.Z1 microscope (Zeiss). Images were acquired with AxioVision software and 
processed with ImageJ software (imagej.nih.gov/ij/version 1.44p). 
Cell growth curves 
Cells were seeded at a cell density of 1x104 cells / well in a 12-well plate. Cell 
counting was determined by microscopy using the trypan blue exclusion method in a 
Bürker counting chamber at regular time intervals (0, 6, 18 and 30h). Each time point 
counting was performed in triplicate and growth curves were plotted. Prior to the 
experiment, cells were synchronized under starvation (culture medium without FBS) 
for eight hours at 37 °C and 5% CO2. 
Wound-healing assay 
For wound-healing assay, cell lines were previously treated with 5µg/mL of 
Mitomycin-C (Sigma) an anti-proliferative agent, for 3 hours at 37°C 5% CO2. A pipette 
tip was used to scratch a single wound in cells monolayer. Vorinostat (5μM) was added 
to medium and the plate was incubated at 5% CO2 at 37°C. PBS 1X was used to 
washout the cell debris three times. The wound closure was monitored by 
photography when the scrape wound was introduced (0h) and at designated times 
after wounding (6, 18 and 30h). 
Western blotting 
Total protein extracts were obtained after cell lysis in Radio-Immunoprecipitation 
Assay (RIPA) lysis buffer (20mM/L Tris (pH 7.5), 150 mM/L NaCl, 5 mM/L KCl and 1% 
Triton X-100) previously supplemented with protease and phosphatase inhibitors to 
the cell pellet (Complete, Mini, EDTA-free Protease Inhibitor Cocktail Tablet (catalog 
no. 11836170001, Roche), 1 mM Orthovanadate (Na3VO4) (450243, Sigma) and 1 mM 
Sodium fluoride (NaF) (catalog no. 201154, Sigma). Whole protein lysates were 





samples were then separated by electrophoresis in a 15% sodium dodecyl sulfate 
polyacrylamide gel (SDS-PAGE) and transferred to PVDF membranes (Bio-Rad). 
For protein immunodetection, membranes were incubated with the specific 
primary antibodies: rabbit polyclonal anti-BCL2 (1:1000, catalog no. SAB4300340, 
Sigma-Aldrich); rabbit polyclonal anti-BAX (1:100; catalog no.HPA027878, Sigma-
Aldrich) and mouse anti-β-actin (1:5000; catalog no., A5441, Sigma), overnight at 4°C, 
followed by incubation with peroxidase (HRP)-conjugated secondary antibodies (anti-
mouse; catalog no. 31430, Thermo Scientific and anti-rabbit; catalog no. 31460, 
Thermo Scientific).  
The peroxidase activity was detected by ECL method. Digital images were 
obtained in ChemiDoc XRS System (Bio-Rad) with Image Lab Software 
(imagej.nih.gov/ij/). Protein detection was quantified by digital analyses of the protein 
bands intensity that were normalized to β-actin, using ImageJ Software 
(http://rsbweb.nih.gov/ij/). 
Reverse transcription-quantitative polymerase chain reaction (qPCR) 
Total RNA was isolated from cells cultured with HDACI (butyric acid and 
vorinostat) or without HDACI (control condition), using RNeasy Mini Extraction Kit 
(catalog no., 74104, Qiagen, Inc., Valencia, CA, USA), according to manufacturer’s 
protocol. cDNA synthesis was performed with 1 µg of total RNA, using random 
hexamers (catalog no. 11034731001; Roche Diagnostics, Indianapolis, IN, USA) and 
SuperScript IITM (200 U; catalog no. 18064-014, InvitrogenTM, Thermo Fisher Scientific, 
Inc.), according to the manufacturer’s protocol. The PCR amplifications conditions 
were as follows: 95°C for 2 min, 95°C for 10 min followed by 45 cycles of 95°C for 15 
seconds, 60°C for 60 seconds. qPCR was performed using an ABI PRISM 7900HT 
Sequence Detection System (Applied Biosystems®; Thermo Fisher Scientific, Inc.) with 
Power SYBR Green PCR Master Mix (catalog no. 4367659, Applied Biosystems®, 
Thermo Fisher Scientific, Inc).  
The primers sequences used were as follows: BECLIN-1 
GGCTGAGAGACTGGATCAGG (forward), CTTCAGCTTATCCAGCTGCG (reverse), ATG-7 





AGGGAGGGCTGACCCAGAT (forward), GGCGGAAAACCCAAAACTTC (reverse), BCL-2 
ATGTGTGTGGAGAGCGTCAACC (forward), TGAGCAGAGTCTTCAGAGACAGCC (reverse). 
Data were analyzed in SDS 2.4.1 software (Applied Biosystems; Thermo Fisher 
Scientific, Inc.) and the relative expression of each gene was quantified 
by relative quantification (RQ) study module (∆∆Ct)369 using hypoxanthine 
phosphorribosyltransferase gene (HPRT) as an endogenous reference gene. 
Statistical analysis 
Statistical analysis was performed using Student’s t-test with GraphPad Prism 
software (GraphPad Software, Inc., La Jolla, CA, USA, version 5.03). P<0.05 was 
considered to indicate a statistically significant difference. 
Results 
Vorinostat induces cell death in ES2 and OVCAR3 cells, mainly through apoptosis 
ES2 cells exposed to HDACI and 5-aza-dC, revealed increased levels of apoptosis 
at different timepoints in comparison to control condition (untreated cells) (Figure 
3.2A). Butyric acid increased apoptosis in ES2 cells but in combination with 5-aza-dC 
apoptotic levels decreased (except for 18h). In contrast, vorinostat and 5-aza-dC 
showed a cumulative effect at 6, 30 and 72h of exposure and this was not observed for 
butyric acid and 5-aza-dC association.  
Regarding necrosis, ES2 cells exposed to vorinostat showed increased levels in all 
conditions comparing to control at 30 and 72h of exposure (Figure 3.2B). A cumulative 
effect with the combination of HDACIs and 5-aza-dC was observed for butyric acid at 






Figure 3. 2 - Cell death in ES2 cell line exposed to HDACIs and 5-aza-dC 
Cells were cultured in control conditions and in the presence or absence of HDACs inhibitors 
and 5-aza-dC. Cells were analyzed by flow cytometry: A. apoptosis (annexin V positive cells), 
and B. necrosis (PI positive cells). Data were acquired after 6, 18, 30 and 72h after 16h of 










































































Figure 3. 3 - Cell death in OVCAR3 cell line exposed to HDACIs and 5-aza-dC 
Cells were cultured in control conditions and in the presence or absence of HDACs inhibitors 
and 5-aza-dC. Cells were analyzed by flow cytometry: A. apoptosis (annexin V positive cells), 
and B. necrosis (PI positive cells). Data were acquired after 6, 18, 30 and 72h, after 16h of 
serum starvation. Data are mean ± standard deviation of triplicates. ***p ≤0.001 
 
Regarding, the effects of HDACIs and 5-aza-dC in OVCAR3 cells, at different 
timepoints, we observed that only cells exposed to vorinostat alone and in 
combination with 5-aza-dC showed a high percentage of apoptosis at 30h when 
compared to control (Figure 3.3A). At 6h, apoptosis levels were decreased when 
compared to control cells but it was significant only upon the exposure to vorinostat 
and 5-aza-dC. The following timepoints also indicate a decrease of apoptosis when 
cells were exposed to 5-aza-dC at 18h, and at 30h and 72h. A decrease in apoptosis 



































































The necrosis levels in OVCAR3 cells in all conditions were very low, having no 
significant differences in the overall cell death (Figure 3.3B). 
Vorinostat and 5-aza-dC decrease the expression of mRNA of BCl-2 and vorinostat 
decreases BAD in ES2 cell line 
In order to understand the mechanism through which vorinostat may exert cell 
death, we assessed the effect of vorinostat on the expression of genes related to 
apoptosis and autophagy in ES2 cell line. Two main pathways control apoptosis, the 
extrinsic and the intrinsic pathways. The extrinsic pathway was not evaluated because 
previous studies indicated that vorinostat induced apoptosis through the intrinsic 
pathway and the subsequent activation of caspases275,315. 
The intrinsic pathway is influenced by interactions between pro-apoptotic 
proteins such as BAX and BAD and anti-apoptotic proteins, such as BCL-2, BCL-XL, or 
IAP proteins370.  
We investigated the levels of BCL-2 and BAD mRNA expression in ES2 cell line 
exposed to HDACIs and 5-aza-dC. 
 
Figure 3. 4 - mRNA expression of BCL-2 and BAD in ES2 cell line 
Cells were grown in control conditions, in the presence and absence of HDACs inhibitors and 5-
aza-dC, and the expression of BCL-2 and BAD were evaluated by RT-qPCR. Hypoxanthine 
phosphoribosyltransferase gene (HPRT) was used as endogenous control. Data are mean ± 





























































































































BCl-2 and BAD mRNA expression levels (Figure 3.4) in cells treated with 
vorinostat were both reduced when compared to cells without vorinostat exposure. In 
addition BCL-2 expression also decreases when cells were exposed to vorinostat in 
combination with 5-aza-dC. Considering that there was no visible indications of 
effective apoptosis through mRNA, we used western blotting to examine the levels of 
expression of BAX and BCL-2 proteins to determine the changes in BAX:BCL-2 ratio 
(Figure 3.5) and in fact BAX/BCL-2 protein ratio was increased after vorinostat 





















Figure 3. 5 - Expression of BCl-2 and BAX by Western blot 
Cells were treated with and without vorinostat 5 μM. Cell extracts were analyzed in a 15% SDS-
PAGE and β-actin served as endogenous control. 
 
Vorinostat induce caspase activation in ES2 cell line 
Finally, to validate apoptosis as the predominant cell death mechanism, the 
cleavage of caspase 3 was evaluated in ES2 cell line. Caspase 3 belongs to the cysteinyl 
aspartate-specific proteases family involved in death cascade. Moreover, caspase 3 is a 
common final step of the extrinsic and intrinsic pathways of apoptosis, being its 









Figure 3. 6 - Expression of cleaved caspase 3 by immunofluorescence in EOC cell lines                                       
Representative staining for cleaved caspase 3 (green) in ovarian cancer cells, grown in control 
conditions and in the presence of HDACs inhibitors exposure. The nuclei are stained with DAPI 
(blue). 
 
Caspase 3 activation, evaluated by immunofluorescence staining for cleaved 
caspase 3, was induced by both HDACs inhibitors, being vorinostat more effective than 
butyric acid in caspase 3 cleavage when compared to control (Figure 3.6). Also, 
vorinostat induced higher expression of cleaved caspase 3 in ES2 cell line when 
compared to OVCAR3 cell line. This evaluation confirms that apoptosis occurs in 
ovarian cancer upon exposure to HDACI (butyric acid and vorinostat). 
 
Vorinostat increases the expression of autophagy genes in ES2 cell line 
Because autophagy besides being a survival mechanism, can promote cell death 
due to its extensive duration; the expression of autophagy genes BECLIN-1 and ATG-7 
was evaluated in cells treated with HDACI.  








Figure 3. 7 - mRNA expression of BECLIN-1 and ATG-7 in ES2 cell line 
Cells were grown in control conditions, in the presence and absence of HDACIs and 5-aza-dC 
and the expression of ATG7 and BECLIN-1 were evaluated by RT-qPCR. Hypoxanthine 
phosphoribosyltransferase gene (HPRT) was used as endogenous control. Data are mean ± 
standard deviation of triplicates.***p ≤0.001 
 
As shown in Figure 3.7, vorinostat induces the expression of BECLIN-1, required 
for the initiation of autophagy and ATG-7, which is necessary for the formation of 
autophagosomes. These transcripts are both upregulated in ES2 cells treated with 
vorinostat when compared with untreated cells (control). BECLIN-1 expression is 
downregulated with butyric acid and there is no difference in these markers in cells 
treated with 5-aza-dC during the whole duration of treatment.  
 
Effects of vorinostat and chemotherapy in ovarian cancer cell lines 
Combined therapy with platinum agents (carboplatin or cisplatin) and taxane 
(paclitaxel) are used as standard postoperative chemotherapy for the majority of 
EOC372. Recently, some therapeutic approaches and clinical trials proposed the use of 
epigenetic regulatory drugs with standard chemotherapy373,374. So, we also studied the 
combinatory effects of vorinostat, 5-Aza-dC and conventional chemotherapy 






























































































































Figure 3. 8 - Cell death in ES2 cell line exposed to vorinostat, 5-aza-dC, carboplatin and/or 
paclitaxel 
Cells were cultured in control conditions and in the presence of vorinostat, 5-aza-dC, 
carboplatin (CBP) and paclitaxel (PTX), alone or in combination, Cells were incubated for 30h 
with vorinostat and 5-aza-dC, and chemotherapy was added for 16h. Cells were analyzed by 
flow cytometry: A. apoptosis (annexin V positive cells), and B. necrosis (PI positive cells). Data 
are mean ± standard deviation of triplicates. ***p ≤0.001 
 
In Figure 3.8A, flow cytometry analysis of apoptosis confirmed that in ES2 cells 
the combined effect of carboplatin (CBP) and paclitaxel (PTX) is cumulative, but mainly 
due to the contribution of paclitaxel. Vorinostat (Vo) and 5-aza-dC (in separate) 


























































































































































































































































































































observed in the combinatory effect of CBP with PTX neither with the addition of 
vorinostat nor of 5-aza-dC. However, when the cells were exposed to all drugs 
together, cell death levels raised to 100%, both through apoptosis and necrosis (Figure 
3.8).  
 
Figure 3. 9 - Cell death in HGSC-OVCAR3 cell line exposed to vorinostat, 5-aza-dC, carboplatin 
and/or paclitaxel 
Cells were cultured in control conditions and in the presence of vorinostat, 5-aza-dC, 
carboplatin and paclitaxel, alone or in combination. Cells were incubated for 30h with 
vorinostat and 5-aza-dC, and chemotherapy was added for 16h. Cells were analyzed by flow 
cytometry: A. apoptosis (annexin V positive cells), and B. necrosis (PI positive cells). Data are 





















































































































































































































































































































In Figure 3.9A, flow cytometry analysis of apoptosis and necrosis of OVCAR3 cells 
showed that the higher levels of cell death was associated with the combination of 5-
aza-dC together with vorinostat when combined with the chemotherapeutic drugs 
alone or in combination, increased significantly the levels of apoptosis and necrosis 
(Figure 3.9B). Whereas 5-aza-dC without vorinostat did not alter the levels of apoptosis 
alone or in combination with CBP and/or PTX, so it seems that 5-aza-dC also 
potentiates the action of vorinostat. 
HDACIs inhibit cell proliferation in ES2 (CCC) cell line 
To investigate the effect of HDACs inhibitors and 5-aza-dC in cell proliferation, 
curves were done aiming to evaluate in vitro proliferation of the cells in the presence 
and absence of HDACIs and 5-aza-dC. Trypan blue exclusion assay was conducted to 
measure cell proliferation at 0, 6, 18 and 30 hours after seeding (Figure 3.10A and B). 
 
Figure 3. 10 - Cell proliferation curve for ES2 and OVCAR3 cells exposed to HDACIs and 5-aza-
dC 
Cells were grown in control conditions and in the presence and absence of HDACIs with and 
without 5-aza-dC. A. ES2 cell line and B. OVCAR3 cell line. Data were acquired at 0, 6, 18 and 
30 hours after 16h of serum starvation and are mean ± standard deviation of three cell counts. 
 
As shown in Figure 3.10A, the proliferation curve for ES2 cells treated with HDACI 
showed a decrease of proliferation rate; mainly in those cells under the exposure to 
vorinostat. In ES2 cells, the exposure to butyric acid, alone or in combination with 5-
aza-dC showed high proliferation, similar to the proliferation rate when cells are 













































of proliferation is verified even when there is a combined exposure with 5-aza-dC. 
Indeed, in this particular cell line, we verified that cells exposed in combined HDACI 
and 5-aza-dC have higher proliferation rate than when cells are exposed only to one.  
In Figure 3.10B, the proliferation curve for OVCAR3 cells showed no differences 
in proliferation rate in all conditions. However, cells exposed to 5-aza-dC exhibit a 
tendency (but not significant) to proliferate more in comparison to control condition.  
Vorinostat affects migration capacity mainly OVCAR3 cells 
To test the effect of vorinostat on cell migration, wound healing assay was 
performed. 
 
Figure 3. 11 - Wound healing assay in ES2 cells and OVCAR3 cells exposed to vorinostat. 
Mitomycin-C treated cells were grown in control conditions, with or without vorinostat. 
Wounds were made on monolayers of cells grown to 100% confluence. Effect of vorinostat on 
wound healing assays in A. ES2 cells and in B. OVCAR cells. Wound closure was photographed 
when the scratch wound was introduced (t=0 hours) and after 6h, 18h and 30h. Results 
presented here are representative of triplicate independent samples. Phase microscopy 
(original magnification: 200x).  


































As shown in Figure 3.11A, the wound healing assay showed that vorinostat 
inhibits cell migration in ES2 cell line after 6h. Despite the wound is almost completely 
closed at 30h in control and in vorinostat exposed cells, the cell density in control 
conditions is higher. Concerning OVCAR3 cell line (Figure 3.11B), the wound healing 
assay showed that vorinostat inhibits cell migration as seen at 18 and 30h after 
wounding.  
Discussion 
In clinical setting for the last 30 years, few improvements were done regarding 
treatment of ovarian cancer, being surgery and adjuvant chemotherapy the standard 
care in ovarian cancer patients. Many clinical trials have been testing different drugs 
and combined therapeutic schemes in advanced or recurrent disease, however, none 
of them proved to be better than the association of carboplatin and paclitaxel to 
increase overall survival and disease free survival375. Meanwhile, new therapeutic 
approaches, such as anti-VEGF and anti-PARP strategies376,377 for treatment of ovarian 
cancer where found to be very useful in some clinical contexts.  
As HDACs are overexpressed in cancer and represent a group of enzymes 
responsible for modifications of histones, conditioning epigenetic regulation, thus their 
action has been targeted in preclinical, clinical trials322,378 and clinical settings334,379,380. 
HDACIs, appeared has promising drugs in the last decade as anticancer agents332. They 
are known to restore the expression of silenced tumor suppressor genes in cancer cells 
through their ability to block histone deacetylation.  
HDACI have multiple actions in cells related to their ability of modulating gene 
expression, such as inducing programmed cell death in cancer cells through not very 
well understood mechanisms381. Other responses to these agents in cancer include cell 
cycle arrest, cell differentiation, autophagy and apoptosis, whereas normal cells are 
less affected318. HDACIs are currently in clinical use in the treatment of cutaneous T-
cell lymphoma alone and in combination with other anticancer therapies382. In vitro 
vorinostat anti-tumor activity has been reported in several hematological and solid 





pancreatic carcinoma, breast cancer, prostate cancer, colon cancer and ovarian 
cancer335,372,383,384. 
Our results allow us to confirm previous results in ovarian cancer cell lines 
regarding HDACIs335,360. We found that two distinct HDACIs, butyric acid and 
vorinostat, are able to induce cell death in ovarian cancer cell lines. Cell death is mainly 
through apoptosis, upon HDACIs exposure335,360 as it was confirmed in our study in ES2 
cell line, by the immunodetection of cleaved caspase 3 and the protein BAX/BCL-2 
ratio, which increased after vorinostat exposure as Takai et al.360 described. The same 
effect was reported in hematological malignancies320.  
Moreover, in ES2 cell line, we also study autophagy genes (BECLIN-1 and ATG-7) 
and observed that the levels of these genes were increased with exposure to 
vorinostat. The results are in agreement with recent studies, that have demonstrated 
that tumor resistance to anticancer therapies can be overlapped through upregulation 
of autophagy in different tumor cell lines385.  
The potential role of autophagy in the therapeutic response to anticancer agents 
has been controversial, as opposing results were obtained from different cancer cell 
lines, suggesting that autophagy may function as a stress response, helping to promote 
cell survival or demonstrating that increased autophagy leads to apoptosis385. 
According to Wirawan et al.371 in hematological cell lines, vorinostat induces 
autophagy that can change from a pro-apoptotic signal to a pro-survival function 
through acquired resistance. Autophagy is characterized by massive degradation of 
cellular contents, including essential organelles such as mitochondria, by means of 
complicated intracellular membrane/vesicle reorganization and lysosomal activity371.  
It has been purpose that autophagy allows the cell to survive in unfavorable 
conditions. It have been suggested, for example, that removal of apoptotic effectors 
(caspase 8), in the presence of which autophagy does not occur386, by degradation of 
aggregated proteins and damage organelles, restores metabolic homeostasis by 
recycling metabolites and prevents ROS accumulation387. In fact, the increased levels 
of autophagy effectors observed with exposure to vorinostat in ES2 cancer cell line 





autophagy regulators BECLIN-1 e ATG-7 are increased by vorinostat ( Figure 3.2 and 
3.7).  
Concerning cell proliferation, our results indicate that exposure to HDACIs have 
different outcomes regarding the two cell lines. ES2 cell line showed a decrease of the 
proliferation rate mainly in cells exposed to vorinostat, but this effect was not 
observed in HGSC cell line (OVCAR3). Regarding the response to other drugs and their 
association (figure 3.10), we also obtained different results in these cell lines, being the 
most relevant the increased proliferation rate of ES2 cell line, when exposed to 5-aza 
dC or to the combination of HDACIs and 5-aza-dC. This results allow us to postulate 
that hypomethylation seems to be an important inducer of cell proliferation in this cell 
line, not rescued by HDACIs.  
The cell line OVCAR3 behaves differently after the exposure to HDACIs and 5-aza-
dC. The proliferation rate is similar in all conditions indicating that these cells are not 
affected by those agents. However, previous studies report that ovarian cancer cell 
lines treated with methylation inhibitor, as decitabine, produced synergistic inhibition 
of cell proliferation by apoptosis and cell cycle arrest388. 
 Cell migration can be seen as a marker of cancer cells aggressive phenotype, 
since the ability of a cancer cell to invade the surrounding tissues and spread is 
determinant for disease progression and metastasis389,390. Our study on cell migration 
under HDACIs influence, demonstrated that vorinostat can diminished cell migration 
confirming previous reports335 using other ovarian cancer cell lines. It is important to 
mention that this effect was not evident in ES2 cell line as it was in OVCAR3. This 
underline another difference on vorinostat effect between these two cell lines. We are 
convinced that proliferation might not influence the results of wound healing assay 
because cells were previously exposed to mitomycin C, an inhibitor of proliferation. 
Previous studies have evaluated the action of vorinostat in ovarian cancer cell 
lines, and they have found that vorinostat suppress proliferation, migration and 
invasion in ovarian cancer cells, including cisplatin-resistant or highly-invasive ovarian 
cancer cells, by promoting histone acetylation335. Sonnemann et al.391 also report that 





cell lines and in patient-derived ovarian cancer cells. However, no previous report 
showed differences between different histological types of ovarian cancer. We would 
like to emphasize that our results may be relevant and highlight the need of studying 
different cell lines to fully understand the modulating effects of this type of drug and 
its use may not be applied to all histological types of ovarian cancer.  
Nevertheless, it is very important to remind that our results demonstrate that 
drugs commonly used in chemotherapy (carboplatin and paclitaxel) are still the most 
effective treatment to induce cell death, at least when applied in combination 
(carboplatin plus paclitaxel).  
Finally, the most interesting results is however the demonstration, in vitro, that 
vorinostat and 5-aza-dC are able to potentiate the effect of these chemotherapeutic 
drugs, since the acquisition of therapy resistance is an important clinical problem130. 
Importantly, this effect of the drug association was more evident in ES2 cell line, 
supporting that CCC treatment can benefit from combined cytostatic, cytotoxic and 
epigenetic therapy. This particular histological type is recognized as being intrinsically 
resistant to platinum salt-based therapies and new therapeutic approaches are 
urgently need72,392.  
Our results are in agreement with other studies72,393. showing that ES2 cells are 
resistant to carboplatin induced cell death72. Resistance mechanisms that limit the 
extent of DNA damage associated with chemotherapy include decreased intracellular 
drug accumulation, increased drug inactivation, and increased DNA damage repair100. 
Increased glutathione (GSH) levels, a ROS scavenger are also a mechanism of 
resistance72, since GSH reacts with carboplatin avoiding its contact with cell proteins 
and DNA and consequently decreasing carboplatin cytotoxic ability. According to 
Lopes-Coelho et al.72, ES2 cells expressed more GSH, which synthesis is regulated by 
HNF1β, the key gene in CCC, and the abrogation of GSH synthesis increases ES2 
sensitivity to carboplatin. Once carboplatin by itself does not induce cell death in ES2 






 Regarding OVCAR3 cells, we were able to document the benefit over the 
combination of carboplatin plus paclitaxel only if we submitted the cells in a tetra-
combination, joining carboplatin plus paclitaxel with vorinostat plus 5-aza-dC. Our 
results are in agreement to other studies that have reported that a combination of 5-
aza-dC or paclitaxel with vorinostat inhibited ovarian cancer growth while inducing 
apoptosis, cell cycle arrest and autophagy394,395.  
 HDACI potentiate platinum effect in cancer cells, possibly mediated by 
increasing platinum adduct formation, facilitated by the open of DNA configuration, 
induced by HDAC inhibition396,397 as well as by acetylation of other proteins such as 
transcription factors and tumor suppressor proteins. The synergy between HDACI, 
platinum agents and paclitaxel was also visible in HGSC cell lines, as reported in other 
studies311,391. But this effect was not observed in ES2 cells as previously discuss and it is 
another evidence of the heterogeneous nature of ovarian carcinomas. 
 Hence, ovarian cancer usually responds to chemotherapy but, in the majority of 
cases the cancer recurs resulting in the death of eventually half of patients77 as a 
consequence of the development of drug resistance99. To date, there are no reliable 
clinical factors that can properly stratify patients for suitable chemotherapy strategies. 
Upon cancer relapse, the only currently available treatment option is further 
chemotherapy.   
So, in vitro, the conjunction between conventional chemotherapy and epigenetic 
modulators can be a more effective therapeutic approach in EOC, and recent clinical 
studies report that combination of chemotherapeutic agents with vorinostat activity in 
relapsed platinum-sensitive ovarian cancer is more effective. We emphasize in our 
study the difference between cell lines of different histological types. It is important 
that studies consider that ovarian cancer is a heterogeneous entity and diverse 
histological types can respond differently to proposed therapies. Studies focusing on 
the histological type of ovarian cancer have never been made in previous approaches, 





















HNF1β acetylation a possible path for Vorinostat impairment of 
ovarian clear cell carcinoma (CCC) 
 








Ovarian clear cell carcinoma (CCC) is an unique clinical, histopathological and molecular 
entity within ovarian cancer, having HNF1β as a pivotal pro-survival gene. Moreover, the extra- 
ovarian stage at the time of diagnosis and the resistance to conventional therapy accounts for 
the very poor prognosis of CCC.  
Studies supporting the role of histone deacetylases (HDACs) in cancer progression, 
pointed out the use of HDAC inhibitors (HDACIs) as a promising therapeutic strategy.  
The present study aimed to evaluate the effect of the HDACI vorinostat at the functional 
and at the molecular level in CCC cells.  
Our results showed that vorinostat induced increased levels of HNF1β and at the same 
time cell cycle arrest and apoptosis in ES2 cells. This effect on HNF1β is associated with 
elevation on the acetylation load of HNF1β. 
This study confirms that epigenetic modulation affects not only the conformation of 
chromatin and gene expression, but also it may alter the function and the turnover of proteins 
other than histones.  






Clinical, histopathological and genetic features prove that ovarian clear cell 
carcinoma (CCC) is a distinct entity within epithelial ovarian cancer (EOC)398,399. In most 
cases, CCC is associated with ovarian endometriosis72,399. Hepatocyte nuclear factor 1β 
(HNF1β) overexpression is a biological mark of CCC400,401 and its considered to be 
responsible for cell survival, proliferation and chemoresistance72,402. As no mutations in 
HNF1β gene have been described to date in CCC, its overexpression in this tumor is 
thought to be probably under epigenetic control72,399. Resistance to standard 
treatment based in platinum salts and taxanes accounts for the very poor prognoses of 
advanced and recurrent CCC398. Hence, the discovery of therapeutic alternatives urges, 
target histone deacetylases (HDACs) seem to be a suitable and effective approach to 
treat cancer. 
HDACs are often overexpressed in cancer and they induce chromatin 
compression and consequently gene silencing. Furthermore, their action is pointed out 
to be responsible for the silencing of tumor suppressor genes along cancer 
development403–406, and the use of HDAC inhibitors (HDACIs) raised as new effective 
drugs. Previous studies show that HDACI action on the re-expression of certain 
silenced genes can result in cellular changes, including cell cycle arrest407, DNA repair 
and damage assessment408, and apoptosis407,409–411. This effect was mainly due to the 
restored expression of certain tumor suppressor genes supporting its use in cancer 
therapy. However, in most types of cancer the results of HDACIs application and trials 
fell short of expectations. Furthermore, most of the molecular mechanisms underlying 
the HDACIs failure remain not completely understood.  
In the present paper we intended to depict how vorinostat, an HDACI, interferes 
with HNF1β expression and cellular behavior in CCC and its potential use in this tumor 
type. In order to achieve this, we evaluated the effect of vorinostat in two cancer cell 
lines representing ovarian serous carcinoma (HGSC), the most prevalent type of 






Material and Methods 
Cell lines and cell culture 
Cell lines from CCC, ES2 ovarian clear cell carcinoma (CRL-1978, ATCC) and HGSC, 
OVCAR3 ovarian serous carcinoma (HTB-161, ATCC) were obtained from American 
Type Culture Collection (ATCC). Cells were cultured in Dulbecco's modified Eagle's 
medium (DMEM) 1X (41965-039, Invitrogen) containing 4.5 g/L of D-glucose and 0.58 
g/L of L-glutamine. Medium was supplemented with 10% Fetal Bovine Serum (FBS) 
(FBS, S 0615, Invitrogen, Thermo Fisher Scientific, Inc.) and 1% antibiotic-antimycotic 
(AA) (InvitrogenTM; Thermo Fisher Scientific, Inc.) at 37°C in a humidified atmosphere 
containing 5% CO2 environment. Cells were grown to 75 - 100% optical confluence 
before they were detached by incubation with 1X 0.05% trypsin-EDTA (25300-054, 
InvitrogenTM; Thermo Fisher Scientific, Inc.) at room temperature, and splited. The cell 
number was determined using a Bürker counting chamber. Prior to any experiment, 
cells were synchronized under starvation (FBS free culture medium), overnight at 37°C 
and 5% CO2.  
Cells were cultured with and without vorinostat at 5μM (suberoylanilide 
hydroxamic acid, Merck). For long time exposure, ES2 and OVCAR3 were stepwise 
exposed to vorinostat, first during 30 days, then vorinostat was removed for 20 days, 
which allows cells to proliferate again, and finally the cells were again exposed to 
vorinostat for more 20 days. 
Flow cytometry analysis of total cell death (apoptosis and necrosis) 
Cells were detached with trypsin, washed twice with cold PBS, and double 
stained with Annexin V- fluorescein isothiocyanate (FITC) (556420, BD-Pharmigen) and 
propidium iodide (PI) (P4864, Sigma-Aldrich) in Annexin-binding buffer, followed by 
analysis on FACSCalibur flow cytometer (Becton-Dickinson). All experiments were 








Flow cytometry analysis of cell cycle 
Cells were collected, washed twice with cold PBS and fixed in 70% ethanol 
(100983, Merck) at 4°C. Cells were centrifuged at 1500 rpm for 5 min and then stained 
with 100 µl of 50 µg/ml of propidium iodide (PI) and incubated at 37°C for 40 min. 
Analysis was performed immediately after staining using FACSCalibur flow cytometer 
(Becton-Dickinson). All experiments were performed in triplicates. Data were analyzed 
using FlowJo software (http://www.flowjo.com/). 
Reverse transcription-quantitative polymerase chain reaction (qPCR) 
 Ribonucleic acid (RNA) from ES2 and OVCAR3 was extracted using RNeasy Mini 
Extraction kit (74104, Qiagen, Inc.) according to the manufacturer’s protocol. RNA 
concentration was determined by measuring the absorbance at 260 nm in a Nanodrop 
2000 (Thermo Scientific). Reverse transcription polymerase chain reaction (RT-PCR) 
was performed with 1μg RNA and reversely-transcribed by SuperScript II Reverse 
Transcriptase (18080-44, 200 U; InvitrogenTM, Thermo Fisher Scientific, Inc.), according 
to the manufacturer’s protocol, in a T3000 thermocycler (Biometra). The PCR 
amplifications conditions were as follows: 95°C for 2 min, 95°C for 10 min followed by 
45 cycles of 95°C for 15 seconds, 60°C for 60 seconds. qPCR was performed using an 
ABI PRISM 7900HT Sequence Detection System (Applied Biosystems®; Thermo Fisher 
Scientific, Inc.) with Power SYBR Green PCR Master Mix (4367659, Applied 
Biosystems®, Thermo Fisher Scientific, Inc). 
The primers sequences used were as follows: HNF1β CCGACAATTCAACCAGACAG 
(forward), CAGAGCAGGCATCATCGGAC (reverse), p21 GAGACTCTCAGGGTCGAAAACG 
(forward), ATTAGGGCTTCCTCTTGGAGAAG (reverse). Data were analyzed in SDS 2.4.1 
software (Applied Biosystems; Thermo Fisher Scientific, Inc.) and the relative 
expression of each gene was quantified by relative quantification (RQ) study 
module (∆∆Ct)369 using hypoxanthine phosphoribosyltransferase gene (HPRT) as an 







Automated Sanger sequencing analysis 
Mutational analysis of TP53 was detected by polymerase chain reaction (PCR) for 
exon 7, followed by automated sequencing. PCR amplification was performed using 
specific primers (Forward: CCTCATCTTGGGCCTGTGTTA, Reverse: TGGAAGAAATCGGTA 
AGAGGTG) and DNA fragments with expected size were purified using Exonuclease I 
(20 U/µL) (EN0582, ThermoFisher)/FastAP Thermo-sensitive Alkaline Phosphatase (1 
U/µL) (EF0651, ThermoFisher), according to the manufacturer’s protocol. Sequencing 
reactions were performed using BigDye® Terminator v3.1 Cycle Sequencing kit, 
(catalog no. 4337456, Applied Biosystems) in a T3000 thermocycler (Biometra). 
Purification was executed with AutoSeq G-50 dye terminator removal kit (catalog no. 
27-5340-02, GE Healthcare Life Sciences) according to manufacturer´s instruction and 
then evaluated in an ABI Prism™ 310 Genetic Analyzer (Applied Biosystems). 
Western blotting 
Total protein extracts were obtained after cell lysis in Radio-Immunoprecipitation 
Assay (RIPA) lysis buffer (20mM/L Tris (pH 7.5), 150 mM/L NaCl, 5 mM/L KCl and 1% 
Triton X-100) previously supplemented with protease and phosphatase inhibitors to 
the cell pellet (Complete, Mini, EDTA-free Protease Inhibitor Cocktail Tablet (catalog 
no. 11836170001, Roche), 1 mM Orthovanadate (Na3VO4) (450243, Sigma) and 1 mM 
Sodium fluoride (NaF) (catalog no. 201154, Sigma). Whole protein lysates were 
quantified using standard Bradford protein assay, subsequently 100 µg protein 
samples were then separated by electrophoresis in a 15% sodium dodecyl sulfate 
polyacrylamide gel (SDS-  
For protein immunodetection, membranes were incubated with the specific 
primary antibodies: mouse monoclonal anti-p21 (1:1000; catalog no. 701151, Life 
technologies); mouse monoclonal anti-p53 (1:1000; catalog no. 453M-9, Sigma 
Aldrich); rabbit polyclonal anti-HNF1β (1:500; catalog no. HPA002083, Sigma-Aldrich); 
rabbit polyclonal anti-BCL-2 (1:1000; catalog no. SAB4300340, Sigma-Aldrich); rabbit 
polyclonal anti-BAX (1:100; catalog no. HPA027878, Sigma-Aldrich); rabbit polyclonal 
anti-acetyl-lysine (1:500; catalog no. AB3879, Millipore) and mouse monoclonal anti-β-





followed by incubation with peroxidase (HRP)-conjugated secondary antibodies (anti-
mouse; catalog no. 31430, Thermo Scientific and anti-rabbit; catalog no. 31460, 
Thermo Scientific).  
The peroxidase activity was detected by ECL method. Digital images were 
obtained in ChemiDoc XRS System (Bio-Rad) with Image Lab Software 
(imagej.nih.gov/ij/). Protein detection was quantified by digital analyses of the protein 
bands intensity that were normalized to β-actin, and acetylation of HNF1β was 
quantified using total levels of HNF1β, by using ImageJ Software 
(http://rsbweb.nih.gov/ij/).  
Immunoprecipitation 
To obtained total protein extracts cells pellets were lysed using phosphate buffer 
(0.1M, pH 7) with 1% Triton X-100 (catalog no. T8787, Sigma) and protease and 
phosphatase inhibitors (Complete, Mini, EDTA-free Protease Inhibitor Cocktail Tablet 
(catalog no. 11836170001, Roche), 1 mM Orthovanadate (Na3VO4) (catalog no. 
450243, Sigma) and 1 mM Sodium fluoride (NaF) (catalog no. 201154, Sigma)) followed 
by sonication (2 cycles of 10sec, 50% amplitude). Lysed cell pellets were incubated 
with anti-HNF1β (HPA002083, Sigma-Aldrich), overnight (ON) at 4°C followed by 
another incubation ON at 4°C with protein G-sapharose (51347800-EM, GE 
Healthcare). Samples (total protein extracts, anti-HNF1β and protein G-Sapharose) 
were then centrifuged and the pellet obtained ressuspended in glycine (0.1M) to 
obtain purified HNF1β and other proteins bound to HNF1β. HNF1β protein 
immunodetection were performed using western blotting (described above). 
Immunofluorescence 
Cells were cultured on glass slides coated with a 0.2% gelatin coating, until 80% 
of confluence and then fixed in 2% paraformaldehyde for 15 minutes at 4⁰C. Blocking 
was performed with 0.2% (w/v) BSA in PBS 1X for 1 h at room temperature, and 
incubated with primary antibody overnight (diluted 1:100 in 0.2% (w/v) BSA in PBS 1X). 
The primary antibody was anti-HNF1β (HPA002083, Sigma-Aldrich). After PBS 1x 
washing, samples were incubated with secondary antibody (Alexa Fluor® 488 anti-





VECTASHIELD media with DAPI (4'-6-diamidino-2-phenylindole) (Vector Labs) and 
examined by standard fluorescence microscopy using a Nikon Instruments Eclipse Ti-S 
Inverted Microscope (Hamamatsu digital camera C10600 ORCA-R2). Images were 
acquired and processed with NIS-Elements AR-3.2. 
Statistical analysis 
Data were analyzed using unpaired two-tailed student’s test and one-way/two-
way ANOVA with GraphPad Prim statistical software (San Diego, USA). A value of 
p<0.05 was considered statistically significant.  
Results 
Vorinostat effect in cancer cell proliferation, cell cycle status of EOC 
The evaluation of the effect exerted by vorinostat on the proliferation rate and 
cell cycle status showed that ES2 cells proliferate at a lower rate in the presence of 
vorinostat which is consistent with the G0-G1 cell cycle arrest observed after 30h of 
exposure to vorinostat (Figure 4.1A and B). OVCAR3 cells showed no alterations in 
growth curve and in cell cycle status due to vorinostat exposure (Figure 4.1A and B). 
Accordingly, the expression of p21, which is a cyclin dependent kinase (CDK) inhibitor  
and a canonical HDACI gene target412,413 is increased in ES2 cells exposed to vorinostat 
(Figure 4.1C).  
Upon a long term exposure to vorinostat, ES2 cells exhibit again a G0/G1 cell 
cycle arrest, which is reversed by the removal of vorinostat (Figure 4.2A). The levels of 
p21 mRNA were in agreement with the observed dynamics of cell cycle activity (Figure 
4.2B). In contrast, the OVCAR3 cells have no significant changes in cell cycle status 
after the long term vorinostat exposure as we observed in the 30h exposure (Figure 









Figure 4. 1 - Vorinostat affects cell proliferation of clear cell carcinoma (ES2) but not of 
serous carcinoma (OVCAR3) 
A. Vorinostat exposure induces a significant decrease in cell proliferation, in ES2 cell line; B. 
ES2 cells exposed to vorinostat show cell cycle arrest in G1-G0, at 30h, and C. In ES2 vorinostat 






























































































































































































































































































































Figure 4. 2 - Long term exposure of Vorinostat induces p21 expression and cell cycle arrest in 
clear cell carcinoma (ES2) 
A. Long term vorinostat exposure induces G0/G1 cell cycle arrest in ES2 cells but not in 
OVCAR3, and B. Vorinostat modulates the expression of p21 in clear cell carcinoma (ES2) 
 
As p53 is one of the main responsible for cell cycle regulation and is frequently 
mutated in cancer as it is in the ES2 (C.722 C>T) and OVCAR3 (C.743 G>A) cell lines, we 
were prompted to evaluate the expression of p53 upon vorinostat exposure. The 
expression levels of p53 at vorinostat short term (30h) exposure remained unaltered in 
both cell lines (Figure 4.3A). It is interesting to state that these cell lines only expressed 
the mutated p53, and the wild type p53 (Figure 4.3B) was not detected. In a long term 
exposure of ES2 to vorinostat, p53 levels are maintained but its levels are significantly 





































































































































































































































































































































Figure 4. 3 - The expression of mutant p53 increases in ES2 upon vorinostat removal, after 
long term exposure 
A. Exposure (30h) to vorinostat increases the levels of p53, in HGSC-OVCAR3 cells but nor in 
ES2 cells; B. p53 mRNA expressed in OVCAR3 and ES2 cells are mutated variants, having 
missense mutations in exon 7, respectively c.722 C>T and c.743 G>A, and C. Long term 
exposure (30 days) to vorinostat followed by 20 days without vorinostat increase the protein 
levels of p53 in ES2 cell line.  
 
Vorinostat effect in cell viability and HNF1β expression in CCC 
Vorinostat induces death of ES2 cells at 6, 18 and 30h of exposure as observed in 
figure 4.4A. This effect was also observed in OVCAR3 cells under vorinostat exposure, 
but only after 30h of treatment (Figure 4.4A). Moreover, the ratio of BAX (pro-
apoptotic) versus BCL-2 (anti-apoptotic) expression is increased in ES2 but not in 
OVCAR3, after 30h of vorinostat exposure, confirming the pro-apoptotic effect of 
vorinostat in CCC (Figure 4.4B). The levels of cleaved caspase 3 are consistent with 
apoptosis in both cell lines (Figure 4.4C). 



























Figure 4. 4 - Vorinostat increases cell death in clear cell carcinoma (ES2) 
A. Vorinostat induces death of ES2 cells at 6, 18 and 30h of exposure. This effect was observed 
in OVCAR3 cells under vorinostat exposure, only after 30h of treatment; B. The ratio BAX/BCL-
2 is increased in ES2, after 30h of vorinostat exposure, confirming pro-apoptotic effect of 
vorinostat in CCC, and C. After 30h of exposure vorinostat increases the levels of cleaved 
caspase-3. 
 
Since ES2 cells showed cell cycle arrest (Figure 4.1A and 4.1B) and increased cell 
death when exposed to vorinostat (Figure 4.4A), so it was mandatory to evaluate the 
effect of vorinostat exposure in HNF1β expression, once HNF1β is the key gene of CCC, 
contributing to cell survival and chemoresistance72,402. We observed that vorinostat 
exposure increased the expression of HNF1β in ES2 cells (Figure 4.5A and B) as well as 
the acetylation load of HNF1β (Figure 4.5B). As seen in Figure 4.5A, OVCAR3 does not 
express HNF1 β, even when exposed to vorinostat, so the following experiments were 
done only in ES2 cell line. 
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Interestingly, the levels of HNF1β mRNA also increase in vorinostat long term 
exposure of ES2 cells (Figure 4.5C). 
 
 
Figure 4. 5 - Vorinostat exposure increase the levels of HNF1β in clear cell carcinoma (ES2), 
both in short and long term exposure 
A. In ES2, vorinostat increases the levels of HNF1β; B. Vorinostat increases the protein levels of 
HNF1β and its acetylation (in lysine residues), and C. Long term exposure to vorinostat 










































































As mentioned, CCC in advanced stages is characterized by a poor prognosis due 
to intrinsic resistance to conventional therapy72. Therefore, the discovery of new 
therapeutic alternatives is of absolute importance.  
The emergence of HDACIs as therapeutic agents opened up novel perspectives 
for the treatment of cancer and particularly in ovarian cancer. In this work, we were 
able to document that vorinostat has different effects in ovarian cancer cell lines, CCC 
and HGSC. This result could be anticipated as these cancer cell lines derived from two 
different entities both in clinical and molecular terms.  
Overall, it is known that vorinostat induces cell cycle arrest and apoptosis in EOC 
as described in other cancer contexts upon exposure to HDACIs315,320,412. Furthermore, 
the cell cycle arrest in G0/G1 phases is supported on the molecular level by the 
increased expression of p21, an inhibitor of cyclin dependent kinases (CDK)414,415, thus 
not allowing the advance of cells throughout the cell cycle. 
The p53 mutant variants present in the cell lines (CCC-ES2; C.722 C>T and HGSC-
OVCAR3; C.743 G>A) used in this study were already described and these variants 
interfere with the p53 DNA binding capacity416,417. Gene CDKN1A (p21), is a main p53 
target gene and the fact that p21 is increased in cells exposed to vorinostat, probably 
means that p53 is activating its transcription. The mutations in exon 7 of p53 codifies 
p53 variants that are protected from degradation, having an increased half-life time 
and accumulating in the cell416,417. As a tumor suppressor gene, it was expected a loss 
of function in mutant p53, however its special condition is well known and mutated 
p53 variants are characterized by oncogenic gain of function that can be patent for 
instance in its action as a dominant negative abrogating normal p53 function in the 
tetramer, or by interacting with new partners being able to regulate the expression of 
a new setting of genes that are favorable to cancer development and progression418.  
The dramatically increased levels of p53 in ES2 cells that are cultured free of 
vorinostat after a long term exposure to vorinostat can indicate that p53 p.S241F 





resistant cells at least in this cancer cell line. As p21 gene is also described to be a 
target of p73, a transcription factor belonging to p53 family that can overcome p53 
function in cells with a mutated p53419, it might be a possible explanation for p21 
elevated levels. 
Interference of HNF1β in cell cycle was already describe by Shigetomi et al.402 
where they demonstrate the involvement of HNF1β in cell cycle of ovarian CCC lines 
using HNF1β knockdown cell lines. The study suggested that drug resistance of CCC cell 
lines may be caused by sustained activation of the G2 checkpoint, through HNF1β 
overexpression. Asides from studying checkpoint kinase 1(CHK1), important in G2 
checkpoint, no others proteins were investigated402.  
As demonstrated by our immunofluorescence experiments the HGSC cell line, 
OVCAR3 does not express HNF1β and therefore this type of carcinoma cannot help to 
explain the mechanism that cells use to survive through HNF1β action. 
The most important aspect of this work was the finding of HNF1β acetylation 
induced by vorinostat. This finding can underly a mechanism of modulation/abrogation 
of HNF1β function, which is an advance in the understanding of the CCC biology. Since 
HNF1β has a pro-survival activity, this work showed that its acetylation can be a route 
of HDACIs action in CCC cells, affecting cell proliferation and viability.  
Again, it became evident in this study that the action of HDACIs, although initially 
designed to affect the acetylation level of histones and therefore the conformation of 
chromatin; also affects the function of other proteins, which play crucial roles in cell 
function, since HDACs also deacetylate other proteins than histones. The HDACIs 
contribute for the overall increased levels of acetylation, interfering with proteins 
function420 and the turnover of proteins, not only histones, by affecting the labeling of 
proteins to be degraded, similar to what it is described for p53421–423. Acetylation can 
interfere with the proteosomic degradation of ubiquitinated proteins. So far, HNF1β is 
not described as being regulated by ubiquitination (http://www.ncbi.nlm.nih.gov/ 
ieb/research/acembly/av.cgi?db=human&term=HNF1B&submit=Go) but it may explain 





mechanisms of regulation of p53 activity and degradation with which acetylation 
interferes421–424.  
Hence, this work also opens new perspectives for studies to be further 
developed in order to better understand the function of HNF1β, especially in the 
context of cancer, since HNF1β is consistently de novo expressed or overexpressed in 
CCC from different organs such as ovary, pancreas, kidney and liver399,425–427.  
Unfortunately, clinical trials testing HDACIs, that have been proven inconclusive, 
due to toxic effects, or have classified HDACIs as not suitable therapeutic agents for 
the treatment of EOC; were essentially carried out in EOC with no identification of the 
tumor histological type324,374,428–430. This practically prevented the adjustment and use 
of HDACIs to treat CCC which is undoubtedly the histological type of EOC that requires 
a more urgent effective therapeutic action and bears molecular trait that seems to be 
more susceptible to this therapy.  
In light of our study, HDACIs are a group of drugs that could be a therapeutic 
alternative to the CCC. Possibly, its use also requires new strategies to deliver these 
drugs in a way to reduce the toxic effects already observed in clinical trials, since the 
structural changes are not indicated as they are inhibitors of the catalytic center of 



















Functional redundancy of the Notch pathway in ovarian cancer 
cell lines 
 
Work presented in this chapter corresponds to the following publication: 
Silva, F., Félix, A. & Serpa, J. Functional redundancy of the Notch pathway 








Epithelial ovarian cancer is the most lethal gynecologic malignancy, despite advances in 
treatment. The most common histological type, high grade serous carcinoma (HGSC) is usually 
diagnosed at an advanced stage, and although this type of tumors frequently respond to 
surgery and platinum-based chemotherapy, they usually recur. Ovarian clear cell carcinoma 
(CCC) is an unusual histological type, which is known to be intrinsically chemoresistant and is 
associated with poor prognosis in advanced stages.  
In recent years, genetic alterations and epigenetic modulation of signaling pathways 
have been reported in HGSC and CCC, including the overexpression of Notch pathway 
elements and histone deacetylases. Histone deacetylase inhibitors (HDACIs), including 
vorinostat (suberoylanilide hydroxamic acid), alter the transcription of genes involved in cell 
growth, survival and apoptosis, and have become an attractive therapeutic approach. 
However, no previous work has addressed the effect of HDACIs, and in particular vorinostat, 
on Notch signaling in ovarian cancer.  
Therefore, the present study aimed to investigate the modulation of the Notch pathway 
by vorinostat in ovarian cancer. Using immunofluorescence and quantitative polymerase chain 
reaction, the present results revealed that vorinostat activated the Notch pathway in CCC and 
HGSC cell lines, through different Notch ligands. In CCC, the activation of Notch pathway 
appeared to occur through Delta-like (Dll) ligands 1, 2 and 3, whereas in HGSC Dll1 and Jagged 
1 and 2 ligands were involved. The activation of Notch pathway by vorinostat, in CCC and HGSC 
cell lines, culminated in the increased expression of the same downstream transcription 
factors, hairy enhancer of split (Hes1) 1 and 5, and Hes-related proteins 1 and 2.  
In conclusion, vorinostat modulates the expression of several downstream targets of the 
Notch pathway and independent Notch receptors and ligands that are expressed in HGSC and 
CCC. This upregulation of the Notch pathway may explain why vorinostat therapy fails in 
ovarian carcinoma treatment, as shown in certain clinical trials.   







Epithelial ovarian cancer (EOC) is the most lethal and the seventh most common 
gynecologic malignancy in women worldwide3,4. EOC represents 90% of ovarian 
malignant tumors21 and it is an extremely  heterogeneous group of neoplasms that 
exhibit a wide range of tumor morphology, clinical manifestations and underlying 
genetic alterations25.  
The most common histological type, high grade ovarian serous carcinoma 
(HGSC), is characterized by tumor protein 53 (TP53) mutations and breast cancer 1 and 
2 dysfunction31. This type of tumor is aggressive and usually diagnosed at an advanced 
stage, and although HGSC frequently responds to surgery and platinum-based 
chemotherapy, it usually recurs55. 
Ovarian clear cell carcinoma (CCC) is a more unusual histotype of EOC, which is 
known to be intrinsically chemoresistant and is associated with poor prognosis in 
advanced stages55. Molecular alterations of CCC are not well known, presenting a 
challenge to treat this type of tumors. However, CCC is characterized by a unique 
histology, de novo expression of hepatocyte nuclear factor 1β transcription factor and 
somatic mutations of AT-rich interaction domain 1A gene, and loss of its 
expression61,62. 
In previous years, other genetic alterations and epigenetic modulation of 
signaling pathways have been reported in HGSC and CCC64, including the 
overexpression of Notch pathway elements and histone deacetylases (HDAC)339. The 
Notch pathway has multiple roles in cell fate determination, since it regulates cell 
proliferation, differentiation, survival and apoptosis135,136. This signaling pathway is 
deregulated in human hematological malignancies and solid tumors133,134, and it is also 
implicated in angiogenesis431,432. Notch signaling is a juxtacrine pathway composed by 
Notch receptors (Notch1-4) and two classes of ligands, Delta-like (Dll) 1, 3 and 4 and 
serrate-like Jagged1 and Jagged2137–140.  
Notch signaling is initiated by the binding of Delta/Jagged ligands to Notch 





(NICD) is released and activates the transcription of target genes, hairy enhancer of 
split (Hes) family proteins, Hes-related proteins (Hey)143 as well as cell cycle regulators, 
including p21135, cyclin D1 and 3144, c-myc145 and human epidermal growth factor 2146.  
Epigenetic alterations are also involved in the repression of tumor suppressor 
genes and promotion of tumorigenesis in ovarian cancers, and HDAC inhibitor (HDACI) 
drugs are an attractive therapeutic approach286. HDACIs inhibit cancer cell growth in 
vitro and in vivo, revert oncogene-transformed cell morphology, induce apoptosis, and 
enhance cell differentiation279. 
Vorinostat (suberoylanilide hydroxamic acid) is a HDACI310 that was FDA 
approved in 2006 for the treatment of cutaneous T-cell lymphoma, and it has 
demonstrated interesting results in in vitro models of ovarian cancer311. However, to 
the best of our knowledge, there has been no previous study addressing the effect of 
HDACIs, and in particular of vorinostat, on Notch signaling on ovarian cancer. 
Therefore, the aim of the present study was to investigate the modulation of the 
Notch pathway by vorinostat in ovarian cancer cell lines.  
Material and Methods 
Cell lines and cell culture conditions 
CCC-ES2 (CRL-1978) and HGSC-OVCAR3 (HTB-161) cell lines were obtained from 
American Type Culture Collection (Manassas, VA, USA). The cells were incubated at 
37°C in a humidified atmosphere containing 5% CO2 in McCoy’s 5A Modified Medium 
(Sigma-Aldrich, St. Louis, MO, USA), supplemented with 10% fetal bovine serum (FBS, S 
0615, Invitrogen) and 1% antibiotic-antimycotic (AA) (InvitrogenTM; Thermo Fisher 
Scientific, Inc., Waltham, MA, USA). The cells were cultured to 80-100% confluence 
prior to detachment by incubation with 1X 0.05% trypsin-EDTA (InvitrogenTM; Thermo 
Fisher Scientific, Inc.) at room temperature. For the various assays, cell number was 
determined using a Bürker counting chamber. Vorinostat (catalog no. CAS 149647-78-







Procedure already described in Chapter 3. 
The primary antibodies were as follows: rabbit polyclonal anti-human Notch1 
extracellular (catalog no., ABS90, EMD Millipore, Billerica, MA, USA), rabbit 
monoclonal anti-Notch1 cleaved (catalog no. 1744, Cell Signaling, Inc., Danvers, MA, 
USA), rabbit polyclonal anti-Notch2, cleaved (catalog no., 07-1234, EMD Millipore) and 
rabbit polyclonal anti-Notch4 (catalog no., N5163;  Sigma-Aldrich). The cells were 
incubated with Alexa Fluor® 488 goat anti-rabbit secondary antibody (catalog no., A-
11008; InvitrogenTM, Thermo Fisher Scientific, Inc.) for 2 h at room temperature. The 
slides were mounted in VECTASHIELD Anti-fade Mounting Medium with DAPI (catalog 
no., H-1200; Vector Laboratories, Inc., Burlingame, CA, USA) and examined by standard 
fluorescence microscopy using an Axio Imager microscope (Zeiss GmbH, Jena, 
Germany). Images were acquired with AxioVision software (version 4.5; Zeiss, GmbH) 
and processed with ImageJ software (version 1.44p; imagej.nih.gov/ij/). 
Reverse transcription-quantitative polymerase chain reaction (qPCR). 
Total RNA was isolated from cells cultured in complete McCoy’s with or without 
(control condition) vorinostat, using RNeasy Mini Extraction Kit (catalog no., 74104, 
Qiagen, Inc., Valencia, CA, USA), according to the manufacture’s protocol. Procedure 
already described in Chapter 3. 
The primers sequences used were as follows: Notch1: 
TGGCGGGAAGTGTGAAGCGG (forward), GTGCGAGGCACGGGTTGGG (reverse), Notch2: 
CCATATGCTTCAGCCGGGATAC (forward), GTCTCACATTTCTGCCCTGTG (reverse),  
Notch3: CTGCAAGGACCGAGTCAATGG (forward), CGTCCACGTTGCGAT CACAC (reverse), 
Nocth4: CCACCTTTCACCTCTGCCTC (forward), ACCTCACAG TCTGGGCCTAT (reverse), 
Dll1: ATGCCTTCGGCCACTTCAC (forward), CACATCCAGGCAGGCAGAT (reverse), 
Dll3:GAACCCGTGTGCCAATGGAG (forward), GTAGGCAGAGTAGGGTCTG (reverse), 
Jagged1: CGGCTTTGCCATGTGCTT (forward), TCTTCCTCCATCCCTCTGTCA (reverse), 
Jagged2: GTCGTCATCCCCTTCCAGTTC (forward), CTCATTCGGGGTGGTATCGTT (reverse), 
Hey1: GAAGTTGCGCGTTATCTGAG (forward), GTTGAGATGCGAAACCAGTC (reverse), 





CGGAGGTGCTTCACTGTCAT (forward), ACGACACCGGATAAACCAAA (reverse), Hes5: 
GAGAAAAACC GACTGCGGAAG (forward), GACAGCCATCTCCAGGATGTC (reverse), Hes6: 
GAAGTGCTGGAGCTGACGG (forward), CGAGCAGATGGTTCAGGAGC (reverse). All 
samples were run in triplicate. Data were analyzed in SDS 2.4.1 software (Applied 
Biosystems; Thermo Fisher Scientific, Inc.) and the relative expression of each gene 
was quantified by comparative quantification cycle (Cq) method (∆∆Ct)369 using 
hypoxanthine phosphoribosyltransferase gene (HPRT) as an endogenous reference 
gene.  
Statistical analysis 
Statistical analysis was performed using Student’s t-test with GraphPad Prism 
software (version 5.03; GraphPad Software, Inc., La Jolla, CA, USA). P<0.05 was 
considered to indicate a statistically significant difference.   
Results 
Effects of vorinostat treatment on Notch signaling in ovarian cancer cells 
In order to investigate the effect of HDACI vorinostat on the Notch signaling 
pathway, ES2 and OVCAR3 cell lines were exposed to vorinostat for various periods of 
time. The results demonstrated that vorinostat exposed ES2 cells express increased 
levels of Notch 2 (P<0.010), 3 and 4 (P<0.001) mRNAs, whereas Notch1 expression 
remained unchanged (Figure 5.1A). Increased levels of Notch1 NICD in control and 
vorinostat exposed cells was observed using immunofluorescence. In Fig. 5.1B, 
immunofluorescence revealed that vorinostat exposure increased Notch2 and 4 
protein expression but not extracellular Notch1. 
Concerning Notch ligands in ES2 cells, vorinostat induced an increased 
expression of Dll1, Dll3 and Dll4 (P<0.001), whereas Jagged1 and 2 levels remained the 
same compared to control cells (Figure 5.1C). The significant increase in mRNA levels 
of Notch downstream genes Hes1 (P<0.010), Hes5 (P<0.001), Hey1 (P<0.01), and Hey2 
(P<0.05), in cells exposed to vorinostat, confirmed the activation of Notch pathway in 







Figure 5.1 – Vorinostat increases the expression of mRNA of Notch receptors, Delta/Jagged 
ligands and Hey/Hes downstream target genes 
 















































































































































































Cells were grown in the absence and presence of vorinostat (5µM) and experimental 
conditions included exposures of 6, 18 and 30 hours, after starvation, with medium 
supplemented with 1% FBS; A. Notch receptors expression levels in ES2 cells. RQ-PCR showed 
that Notch2, Notch3 and Notch4 mRNAs are increased by vorinostat exposure, whereas 
Notch1 was not differentially expressed; B. Representative staining of Notch receptors by 
immunofluorescence. It was observed an increase of Notch2 and Notch4 protein after 
exposure to vorinostat (magnification 200x). Nuclei are stained with DAPI (blue), Notch 
receptors FITC (green); C. Notch ligands expression levels in ES2 cell line. RQ-PCR indicates that 
Dll1, Dll3, Dll4 mRNA expression levels in cells treated with vorinostat are higher than in cells 
without vorinostat. Jagged1 and Jagged2 mRNA expression levels were not significantly 
different; D. Notch downstream targets genes expression levels. RQ-PCR showed that Hes1, 
Hes5, Hey1 and Hey2 mRNA expression levels in cells treated with vorinostat are higher than in 
cells without vorinostat. Hes6 has similar expression in all conditions. The RQ-PCR was 
normalized to Hypoxanthine phosphoribosyltransferase gene (HPRT). Data are mean ± 
standard deviation of triplicates *p<0.05; **p<0.01; ***p ≤0.001.  
 
In OVCAR3 cells, vorinostat also significantly increased Notch2, Notch3 and 
Notch4 (P<0.010), and slightly decreased Notch1 mRNA levels (Figure 5.2A). Protein 
expression of Notch2 and 4 was also higher in cells exposed to vorinostat; however, 
extracellular and NICD of Notch1 levels were not increased (Figure 5.2B). For Notch 
ligands, it was observed that there was a significant increase in Dll1 (P<0.001), Jagged1 
and Jagged2 (P<0.001), mRNA levels in OVCAR3 cells exposed to vorinostat (Figure 
5.2C), whereas Dll3 and 4 mRNA expression was not increased. Regarding Notch 
downstream targets, it was observed that vorinostat statistically increased Hey1, Hey2 
(p<0.001), Hes1 (p<0.05), and Hes5 (p<0.001), mRNA levels compared with control 
cells (Figure 5.2D); however, Hes6 levels were not increased. 
Overall, the present results revealed that vorinostat activated Notch pathway in 
CCC and HGSC cell lines; however, this activation was through a different expression 
panel of Notch ligands in the two cell lines. In CCC, the activation of Notch pathway 
appears to occur through Dll1, Dll2 and Dll3, whereas in HGSC Dll1 and Jagged 1 and 2 
ligands families appear to be involved. Nevertheless, the present results revealed that 
the activation of Notch pathway by vorinostat, in CCC and HGSC cell lines, culminated 










Figure 5. 2 – Vorinostat increases the mRNA expression of Notch receptors, ligands and 











































































































































































The cells were grown in the absence and presence of vorinostat (5µM) for 6, 18 and 30 hours 
following starvation, with medium supplemented with 1% fetal bovine serum; A. Notch 
receptors expression levels in OVCAR3 cells. RQ-PCR indicated that Notch2, Notch3 and 
Notch4 mRNAs were increased following vorinostat exposure; B. Representative staining of 
Notch receptors by immunofluorescence. Vorinostat slightly increases the protein expression 
of Notch receptors 2 and 4, and decreased Notch1 expression following exposure to vorinostat 
(magnification 200x). Nuclei are stained with DAPI (blue), Notch receptors FITC (green); C. 
Notch ligands expression levels in OVCAR3 cell line. RQ-PCR showed that Dll1, Jagged1 and 
Jagged2 mRNA expression levels in cells treated with vorinostat are higher than in cells 
without vorinostat. Dll3 and Dell4 mRNA expression levels were not differentially express; D. 
Notch downstream targets genes expression levels. RQ-PCR showed that Hes1, Hes5, Hey1 and 
Hey2 mRNA expression levels in cells treated with vorinostat are higher than in cells without 
vorinostat. Hes6 mRNA expression levels were not affected by vorinostat. The RQ-PCR was 
normalized to Hypoxanthine phosphoribosyltransferase gene (HPRT). Data are mean ± 
standard deviation of triplicates *p<0.05; **p<0.01; ***p ≤0.001.  
 
Discussion 
The Notch signaling pathway is an important cell signaling system that is 
activated in various types of cancer, including ovarian carcinomas31,152,433.  Notch1 
overexpression has been demonstrated in several studies to promote ovarian cancer 
cell proliferation150,153,434 and this is primarily associated with increased levels of 
Notch1 NICD150. In the literature, Notch3 has also been demonstrated to be active in 
certain ovarian cancer cell lines and its overexpression was described in 20% of 
HGSC148,151. In addition, Notch3 was revealed to increase following tumor 
chemotherapy, and its overexpression is associated with tumor aggressiveness and 
poor prognosis of patients151. The present study aimed to investigate the effect of 
vorinostat, an HDAC inhibitor, on Notch signaling pathway in ovarian cancer cells. For 
this purpose, the present study used cell lines from two different histological types of 
EOC: HGSC, the most prevalent and aggressive EOC type; and CCC, which is a rare type 
of EOC that is highly resistant to chemotherapy435.  
No significant alteration in Notch1 mRNA levels following vorinostat exposure 
was identified in the two different ovarian cancer cell lines; however, high levels of 
cleaved Notch1 were detected in CCC cell line (ES2). In addition, Notch3 was 
demonstrated to be upregulated following vorinostat exposure in the two cell lines. 





through specific Notch ligands in CCC and HGSC cell lines; Dll1, 3 and 4 are activated in 
CCC, while Dll1 and Jagged1 and 2 are activated in HGSC. The present results are 
supported by a previous study that demonstrated altered Notch signaling in HGSC, due 
to increased expression of Jagged1 and 2 ligands31,149. 
The Hes and Hey gene families are the best characterized canonical Notch target 
genes, and the activation of Notch signaling upregulates their transcription436, 
therefore Hes and Hey mRNA expression may be considered as markers for Notch 
activation. The present study demonstrated that Hes and Hey Notch target genes are 
overexpressed in EOC cells following exposure to vorinostat. The present data reveals 
that vorinostat induces the overexpression of Hes and Hey Notch target genes in EOC 
cells, due to Notch signaling activation. In addition, the redundancy of Notch, Delta 
and Jagged elements expressed in EOC cell lines was shown (Figure 3). Hence, no 
matter which panel of receptors or ligands is expressed on the cell membrane, the 
downstream target genes are always expressed in the presence of vorinostat. This 
upregulation can aid our understanding of the mechanism underlying the failure of 
vorinostat therapy in ovarian carcinoma. 
In conclusion, the present findings illustrate the redundancy of Notch pathway in 
ovarian cancer, and suggest that disruption of histone acetylation may not be a useful 












Figure 5. 3 - Schematic representation of Notch pathway in ovarian cancer 
A. clear cell carcinoma ES2 and B. serous carcinoma OVCAR3 cells following exposure to 
vorinostat. NICD, Notch intracellular domain; CSL, Suppressor of Hairless; CoR, repressor; CoA, 




















Establishment and Characterization of a novel ovarian high 
grade serous carcinoma cell line - IPO-SOC43 
 






Epithelial ovarian cancer (EOC) is an aggressive and lethal malignancy and novel EOC cell 
lines with detailed characterization are needed, to provide researchers helpful resources of 
diverse EOC to study biological processes and cancer experimental therapy.  
The IPO-SOC43 cell line was established from the ascitic fluid of a patient with a 
diagnosis of high grade serous carcinoma (HGSC) of the ovary, previously treated with 
neoadjuvant chemotherapy. The cell immortalization was achieved as 2D cell culture and 
growth performed as 2D and 3D cell cultures. The morphological and molecular 
characterization of immortalized cells was done by immunocytochemistry, flow cytometry, cell 
proliferation and chromosomal Comparative Genomic Hybridization (cCGH).  
Characterization studies confirmed that IPO-SOC43 cell line is of EOC origin and 
maintains morphological and molecular features of the primary tumor. cCGH analysis showed  
a complex profile with gains and losses of specific DNA regions in both primary ascitic fluid and 
cell line IPO-SOC43. The cell line was successfully grown in a 3D system which allows its future 
application in more complex assays than those performed in 2D models. IPO-SOC43 is available 
for public research and we hope it can contribute to enrich the in vitro models addressing EOC 
heterogeneity, being useful to investigate EOC and to develop new therapeutic modalities.  








Cell lines provide a powerful model to clinical and basic research. In vitro models 
are suitable to study the molecular mechanisms underlying chemoresistance and 
cancer recurrence, being very helpful to clinical research, as the use of in vitro studies 
uncovered molecular pathways driving progression and metastatic spread of 
tumors437,438. 
As the development for precision medicine needs to account for tumor and 
microenvironment heterogeneity, the detailed characterization of in vitro models, 
representing the different histological and molecular types of ovarian cancer, is 
essential to accurate preclinical testing. There are at least 100 publicly available 
ovarian cancer cell lines but their origin and molecular characteristics are largely 
undescribed439. 
We described a new human high grade serous carcinoma (HGSC) cell line that 
represents the vast majority of ovarian carcinoma73. This tumor type is clinically 
aggressive, tumor relapse is frequent and most patients ultimately die due to the 
failure of current therapeutic regimes73.   
In this study, we presented the characteristics of immortalized cultured cells in 
two-dimensional (2D) monolayer culture and three-dimensional (3D) cell culture 
system, focusing on cell culture conditions, cell proliferation and the expression profile 
of biomarkers. 
Material and Methods  
Establishment of a primary cell line of ovarian carcinoma and culture conditions 
In our study, 130 ovarian tumor samples and 30 ascitic fluid were collected and 
cultivated for primary cell culture. Tumor samples were diagnosed as serous (90), clear 
cell (3), endometrioid (33) and mucinous (4) ovarian carcinomas and ascites from 





A successful primary cell culture was established from the ascitic fluid obtained 
from a caucasian female patient diagnosed with ovarian carcinoma, at Instituto 
Português de Oncologia Francisco Gentil de Lisboa.  The ascitic fluid was collected for 
therapeutic reasons and to cell culture, under patient’s formal consent. 
Clinical details were recorded and sample was assigned with a reference number 
to retain anonymity accordingly with the institutional approval for the research 
project, by our institutional Ethical Committee (UIC-772). This cell line was named IPO-
SOC43. 
Ascite-derived cells were isolated by centrifugation (1200 rpm, 2 minutes), and 
cells were stained with Giemsa for assessing the morphology of cells. Cells were also 
collected and suspended in culture medium, Dulbecco’s Modified Eagle Medium 
(catalog no. 41965-039, InvitrogenTM Life Technologies), supplemented with 1% 
Antibiotic-Antimycotic (catalog no. 15240062, InvitrogenTM Life Technologies) and 10% 
FBS (catalog no. S0615, InvitrogenTM Life Technologies) and placed directly into culture 
with little manipulation at 37°C in an incubator with humidified atmosphere containing 
5% CO2. Adherent cells were observed after 48h and once cultures reach 80-90% 
confluency, cells were detached. At each passage, cells were washed with PBS, 
trypsinized with 0.05% trypsin-ethylenediamine-tetraacetic acid (EDTA) and 
maintained in culture. Cell counting of viable cells was performed using trypan blue 
exclusion method as described below. Immortalization occurred spontaneously after 
six months in continuous culture. The established cell line is maintained in culture in a 
2D model for more than 100 passages. Cells, periodically, were collected and stored. 
The ability of cells to survive and proliferate in low serum conditions was 
assessed by plating cells in T25 cm2 flasks in DMEM  supplemented with 1% FBS and 
cultured for 20 days. The medium was changed every three days. The experiments 
were performed in duplicate.  
In summary, IPO-SOC43 was established from ascitic fluid of a patient diagnosed 







Characterization of the tumor was performed on formalin fixed paraffin 
embedded tissue (FFPE) from the primary ovarian tumor and confirmed by 
immunohistochemistry with the standard technique. Briefly, 3μm sections were 
heated at 60°C for 60 minutes, deparaffinized in xylene and rehydrated in an ethanol 
decreasing gradient. Antigen retrieval was performed using boiling citrate buffer (0.01 
M citric acid adjusted to pH 6.0) in a microwave for 10 min to retrieve antigens. 
The sections were incubated with primary antibodies (see Table 6.1) for 60 min 
at room temperature, after washing, the incubation of secondary antibody Dako 
RealTM, EnvisionTM/HRP (ChemMate Envision Kit, K5007; DAKO, USA) was at room 
temperature for 30 min and were developed by Peroxidase/DAB. Sections were 
counterstained with Mayer's hematoxylin. Phosphate buffered saline was used as a 
negative control and selected tissues for each antibody were used as positive control.  
Immunocytochemistry (ICC) and immunofluorescence 
Antigen expression was searched in original ascitic fluid cells preserved in a cell 
block, in the established cell line and in the corresponding formalin-fixed paraffin 
embedded tumor, using the antibodies listed in Table 6.1. 
IPO-SOC43 cells, in the exponential growth phase (2-3 days of growth) were 
removed from the surface of the flasks, cytospins prepared and the cell suspension, 
immediately fixed in ice-cold methanol at 4°C for 30 minutes and placed in 
polyethyleneglycol (PEG, P5402, Sigma-Aldrich) for 30 minutes and stored at room 
temperature (RT). Before ICC staining, PEG was removed by soaking in alcohol and 
incubated with several antibodies, indicated in Table 6.1. After incubation with primary 
antibody, slides were washed and then stained using Dako RealTM, EnvisionTM/HRP 
(ChemMate Envision Kit, K5007; DAKO, USA) at room temperature for 30 min and were 
developed by Peroxidase/DAB and counterstained with Mayer's hematoxylin and 
examined under a light microscope, Olympus Bx50F. Images were captured in Digital 
Microimaging Device (version 1.5, Leica Microsystems). Cytospin slides with no primary 





For immunofluorescence of the 2D cultures, permeabilization of cells was 
performed by incubation with 0.1% Triton X-100 for 10 min. Sections were blocked for 
30 min with 0.2% FSG (fish skin gelatin). Appropriate amount of primary antibody was 
diluted in blocking solution and incubated for 2h at room temperature. Secondary 
antibody was diluted in 0.125% FSG and incubated for 1h at room temperature (Table 
6.1). Sections were mounted with ProLong containing DAPI (Life Technologies). 
Samples were visualized using a fluorescence microscope (DMI6000 Leica 
Microsystems GmBH, Wetzlar, Germany).  
For 3D cultures of IPO-SOC43 cells, aggregates in suspension were dehydrated 
using 30% sucrose solution overnight. The sucrose solution was removed and the 
samples were transferred in Tissue Teck OCTTM (Sakura Finetek Europe B.V., 
Zoeterwoude, Netherlands) and stored at -80°C until cryosectioning in a cryostat 
(Cryostat I, Leica, Wetslar, Germany) to achieve sections of 10 µm thickness was 
performed. Immunofluorescence staining was then performed and visualized as 
indicated above for the 2D cultures.   
Flow cytometry 
Cells were collected to form a single cell suspension and washed in ice-cold 
phosphate buffered saline (PBS1X). Approximately, 1×106 cells were resuspended in 
100 μl of ice cold PBS/BSA 0,1% (bovine serum albumin, Sigma) and primary 
antibodies, anti-pan cytokeratin-FITC (catalog no. ab52460, Abcam) and anti-human 
vimentin-APC (catalog no. IC2105A, R&D systems) were added and incubated for 
60 minutes at 4°C in dark. At the end, cells labeled for the respective antigens were 
washed twice, centrifuged at 1200 rpm for 5 minutes, resuspended in 500 μl of 
PBS/BSA 0,1% and kept on ice until analysis. Appropriate controls have been used 
(unstained cells). Acquisition was performed in a FACScalibur (Becton Dickinson). Data 








Table 6. 1 - Antigens evaluated and antibodies used to characterize IPO-SOC43 cell line 
 
Proliferation curves 
Cells obtained from 2D cultures were plated at a cell density of 1x104 cells/well in 
a 12-well plate, in DMEM medium supplemented with 10% FBS and 1% antibiotic-
antimycotic. Cell counting was determined by microscopy using the trypan blue 
exclusion method. Total number of viable cells was determined by counting the 
colorless cells in a Fuchs-Rosenthal hemocytometer chamber after incubation with a 
solution of 0,1%(v/v) of Trypan Blue dye (Gibco, Invitrogen Corporation, Paisley, UK) in 
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in triplicate and proliferation curves were plotted and doubling time was calculated 
according to the following formula: 
doubling time =                        duration* log (2)_______________                                  
                Log (final concentration)-log (initial concentration) 
The crystal violet method was also used to determine the cell number. Cells were 
centrifuged for 5 min and then lysed using lysis solution (1% Triton X-100 in 0.1M citric 
acid), overnight at 37°C. Total cell number was determined after incubation with 0.1% 
(v/v) crystal violet in lysis solution. Nuclei density was assed using a Fuchs-Rosenthal 
hemocytometer and a microscope with phase contrast (DM IRB, Leica, Germany). 
Wound healing assay 
Cells were plated onto 12-well plates in DMEM medium supplemented of 10% 
FBS, and allowed to form a confluent monolayer. The cells were previously treated 
with 5µg/mL Mitomycin-C (Sigma), an antiproliferative agent, for 3 hours at 37°C in 5% 
CO2. The monolayer was then scratched in a straight line with a pipette tip. Dethatched 
cells were removed by washing with PBS1X. Images of closure of the wound were 
captured at 0, 24, 48 and 72h after scratching. 
Chromosomal Comparative genomic hybridization (cCGH) 
Genomic DNA isolated from the ascitic fluid and derived cell line was done using 
DNA Purification Protocol for 1-2 Million Cells (Citogene® DNA isolation kit) according 
to manufacturer’s protocol. cCGH technique was carried out according the method of 
the Kallioniemi et al.440 adapted as previously described by Roque et al.441. 
For image analysis a Zeiss epifluorescence microscope linked to a Cytovision CGH 
software program (Cytovision version 7.4, Leica Biosystems, Richmond, USA) was used. 
For both ascitic cells DNA and derived cell line DNA, at least, 15 metaphases were 
acquired for the establishment of the cCGH profile. The green (test DNA) to red 
(reference DNA) fluorescence ratio along the length of the chromosomes was 
calculated. This high resolution cCGH version uses dynamic standard reference 
intervals based in the systematic variation seen in normal samples. When the dynamic 
standard reference intervals do not overlap the confidence limits, the software 





regions in chromosomes 1, 9, 16 and Y, and the p arms of the acrocentric 
chromosomes were discarded from the analysis.   
Polymerase chain reaction, Sanger sequencing and conformation sensitive 
capillary electrophoresis (CSCE) 
The mutational status of TP53, BRCA1 and BRCA2 was evaluated as follow: 
genomic DNA was extracted using DNA Purification Protocol for 1-2 Million Cells 
(Citogene®DNA isolation kit) from cell line, according to manufacturer’s protocol. 
Mutational analysis of TP53 mutation was determinate by polymerase chain reaction 
(PCR) amplified products encompassing from exons 4, 5, 6, 7, 8 and 9 (Table 6.2) of the 
TP53 gene (which arbor mutational hotspots). 
The amplified PCR products were analyzed by electrophoresis, on a 2% (w/v) SEA 
KEM ® GTG ® agarose (50074, FMC BioProducts) gel (in TBE buffer 1x, diluted from TBE 
buffer 10 x, EC-860, National diagnostics) labelled with 0.05% (v/v) ethidium bromide 
10 mg/ml (15585-011, Invitrogen), under UV (BioDocAnalyse Transilluminator, 
Biometra).  DNA fragments with expected size were purified using Exonuclease I (20 
U/µL) (catalog no. EN0582, ThermoFisher)/FastAP Thermo sensitive Alkaline 
Phosphatase (1 U/µL) (EF0651, ThermoFisher), according to the manufacturer’s 
protocol. After purifying the DNA fragments were sequenced by automated 
sequencing. 
Automated sequencing reacting products were purified with Illustra AutoSeq G-
50 GFX (27-5340-03, GE Healthcare) according to manufacturer´s. Sequencing reaction 
was carried out in a T3000 thermocycler (Biometra), purified with AutoSeq G-50 dye 
terminator removal kit (27-5340-02, GE Healthcare Life Sciences), according to 
manufacturer’s instructions and analyzed in an ABI Prism™ 3130 Genetic Analyzer 
(Applied Biosystems). 
BRCA1 and BRCA2 mutations were screened by CSCE (conformation sensitive 
capillary electrophoresis).  This method is based on the principle that homoduplex and 
heteroduplex DNA have different mobility’s when subjected to electrophoresis. All 





sequencing kit v1.1 and DNA sequencing reactions were carried out on ABI Prism™ 
3130 Genetic Analyzer (Applied Biosystems). 
BRCA1 and BRCA2 large rearrangements were determined by Multiplex Ligation-
dependent Probe Amplification (MLPA) assay according to manufacturer's protocol. 
Amplification products were analyzed ABI Prism™ 3130 Genetic Analyzer (Applied 
Biosystems) using the GeneMapper software (Applied Biosystems) and data analysis 
was performed using Coffalyser software (MRC-Holland). 
Table 6. 2 - Primers for PCR of the TP53 gene (Exons 4-9) 
 
Generation of 3D tumor cell spheroids in stirred-tank culture systems 
Single cell suspensions of IPO-SOC43 cells (0.2 x 106 cell/mL) were inoculated in 
125 mL of culture media in stirred-tank vessels with flat centered cap and angled side 
arms (Corning® Life Sciences) and cultured on a magnetic stirrer in an incubator at 
37°C with humidified atmosphere containing 5% CO2. Stirring rates of either 40 rpm or 
60 rpm were tested. The culture media was the same used in the 2D cultures or 
supplemented with 10 µM of ROCK (Rho-associated coiled coil forming protein) 
inhibitor (highly potent, cell-permeable, and selective for ROCK I and II). Cultures were 
maintained for, at least, 72 hours.  
 
 















Cell membrane integrity assay 
Cell viability was evaluated using fluorescein diacetate (FDA; Sigma–Aldrich, Steinheim, 
Germany), an intracellular esterase substrate, at 10 μg/mL in PBS to label live cells, and 
TO-PRO-3 iodide (Invitrogen) at 1 μM in PBS to identify dead cells. Cultures were 
incubated for 5 min at RT with the fluorescent probes and then analyzed using a 
fluorescence microscope (DMI6000 Leica Microsystems GmBH, Wetzlar, Germany). 
Spheroid morphometry 
Aggregates were imaged in a fluorescence microscope (DMI6000, Leica 
Microsystems GmbH, Wetzlar, Germany). Ferret Diameter and the area of the 
aggregates were determined adjusting the threshold and applying the respective 
algorithm of FIJI open source software (Rasband, WS, ImageJ, U. S. National Institutes 
of Health, Bethesda, MD, USA, http://imagej.nih.gov/ij/, 1997–2012). In order to 
classify spheroid shape ‘Shape Parameters’ function of FIJI was used. The “solidity” 
function can be used as a measure of roughness of the spheroid surface and provides 
information about the regularity of the aggregate. A spheroid was considered as 
regular for solidity values higher than 0.9 on a scale from 0 to 1442. 
PicoGreen Assay 
Total cell quantification of DNA was assessed in samples collected from 3D 
cultures and washed once with PBS. The pellet was resuspended in milliQ water, 
frozen in liquid N2 and stored at -80°C until analysis. DsDNA quantification using 
Quant-iT™ PicoGreen® dsDNA Assay Kit (Life Technologies) was performed according 
to manufacturer’s protocol. Briefly, samples were thawed and subsequently sonicated 
for 30 min. Appropriate dilutions of samples and dsDNA standard were prepared in 
Tris-EDTA buffer. Addition of Quant-iT™ PicoGreen® and incubation for 5 min was 
followed measurement of fluorescence (excitation 480 nm; emission 520 nm; Infinite 








Establishment of a primary culture 
A successful primary cell culture was established from the ascitic fluid obtained 
from a caucasian female patient with 73 years old, diagnosed with ovarian high grade 
serous carcinoma, stage IIB (FIGO) with irressectable disease accordingly to imaging 
studies at Instituto Português de Oncologia Francisco Gentil de Lisboa. The patient 
underwent neoadjuvant standard chemotherapy (3 cycles), followed by surgery and 
was submitted to 3 more cycles. In the follow-up, 3 months after finishing 
chemotherapy, ascitic fluid was collected for therapeutic reasons and for cell culture, 
under patient’s formal consent.  The ascitic fluid was observed in cytospins and cell 
morphology assessed by Giemsa staining (Figure 6.1). Many cellular types were 
observed but malignant epithelial cells were predominant. These cells were present in 
large cell aggregates or isolated cells surrounded by inflammatory and mesothelial 
cells. Malignant cells expressed anti-cytokeratin type I and II (clone AE1/AE3) and 
CA125; vimentin was seldom positive in few malignant cells. 
 
Establishment of the histological type of ovarian carcinoma 
Residual tumor found in the ovary allowed the confirmation of the histotype as HGSC. 
Tumors cells aggregates show epithelial marker (cytokeratin), recognized by the 
antibody Cam 5.2. Mucin 16 (MUC16) recognized by anti-cancer antigen 125 (CA125) 
was observed in tumor cells (apical cell membrane). The cells showed strong nuclear 
staining for p53 and p16 protein and tumor cells aggregates were negative for WT1 
and vimentin (VIM). Some tumor cells exhibit expression for calretinin (CALRET). 















Figure 6. 1 – Morphological characterization of cells from ascitic fluid 
Cells were collected by cytospins. Smears of cells stained with Giemsa show aggregates and 
isolated cells with irregular size, abundant cytoplasm and large nuclei, confirming the presence 
of malignant cells; Immunocytochemical characterization of cells was done using cytokeratin 
(CK) AE1/AE3 (neoplastic cells are positive); Vimentin (neoplastic cells are predominately 




















Figure 6. 2 - Characterization of the primary ovarian carcinoma of the patient from whose 
ascitic fluid IPO-SOC43 was established 
Formalin fixed paraffin-embedded sections of patient tumor ovarian high grade serous 
carcinoma submitted to surgery and neoadjuvant chemotherapy (after 3rd cycle) stained with 
hematoxylin and eosin (H&E) and immunohistochemical staining. Tumor cells show positive 
expression of epithelial marker Cam 5.2 (CK type II). Apical cell membrane staining for CA125 
in tumor cells. Cells exhibited nuclear positive expression for p53, p16 and WT1. Tumor cells 
were negative with vimentin (VIM), calretinin (CALRET) and HNF1β, 100x. 
 
Expression of cell markers in IPO-SOC43 cell line   
After spontaneous immortalization, cell line was characterized by a panel of 
markers in order to confirm its nature by flow cytometry and immunohistochemistry. 
Cytokeratin (epithelial cell marker) and vimentin (mesenchymal cell marker) 
expression were evaluated. The epithelial origin of the cell line, IPO-SOC43 was 
confirmed by flow cytometry, showing a high expression for cytokeratin (85% of cells) 














Figure 6. 3 - Detection of cytokeratins and vimentin in IPO-SOC43 cell line by flow cytometry 
Cells were positive to, A. anti-pan cytokeratin-FITC, and negative to B. anti-human vimentin-
APC. 
 
The epithelial nature of IPO-SOC43 cells was also confirmed by 
immunocytochemical analysis through positive expression of anti-cytokeratins type I 
and II (clone Cam 5.2 and AE1/AE3).  Cells also show positive expression for vimentin 
and calretinin (Figure 6.4). 
Expression of biological markers relevant in ovarian cancer 
To further characterize this cell line we evaluated other biological markers such 
as the expression of cell cycle regulators and cell surface receptors relevant in ovarian 
carcinogenesis. 
We observed that the majority of cells exhibit nuclear staining for p53, nuclear 
and cytoplasmic staining for p16INK4a protein, a cyclin-dependent kinase-4 (CDK4) 
inhibitor that is expressed in a limited range of normal tissues and tumors such as 
HGSC443. Cells exhibited nuclear expression of the Wilm’s tumor 1 (WT1) protein and 
anti-cancer antigen 125 (Figure 6.4). The IPO-SOC43 cells were negative for HNF1β 











Figure 6. 4 - Ovarian biomarkers in IPO-SOC43 cell line 
Cells were collected, prepared in cytospins and stained with hematoxylin and eosin (H&E) and 
several biomarkers were tested; cells show positive reaction with anti-cytokeratins (CK) type II 
(clone Cam 5.2) and type I and II (clone AE1/AE3). Cells exhibited protein expression for CA125, 
p53 and p16. Cells were negative for WT1, and some exhibited positive expression for vimentin 
(VIM) and calretinin (CALRET), 100x. 
 
 
Other biological markers were also analyzed by immunofluorescence regarding 
cell-cell adhesion, cellular signaling, cell cycle status and tumor-stromal interactions as 
recreation of the tumor microenvironment is essential in cancer-related studies. We 
used immunofluorescence staining for cytokeratin 18, collagen IV, F-Actin, β-catenin, 
E-cadherin and Ki-67 (Figure 6.5). 
HE
WT1











Figure 6. 5 - Expression of biological markers in 2D cell culturing models in IPO-SOC43 cell 
line 
Cells exhibited positive expression for CK18, collagen IV, F-Actin, β-catenin, E-cadherin and Ki-
67, 400x. 
 
Cells showed positive expression for CK18, F-actin and collagen IV, a basement 
membrane component was detected in cytoplasm. Positive expression was observed 
for adherens junction protein E-cadherin and its partner β-catenin in cell membrane. 
Proliferation was evaluated by Ki-67 nuclear expression that was high, with more than 
70% of cells exhibiting nuclear expression. 
2D characterization of IPO-SOC43 cell line 
The cells were able to adhere to the flask surface forming cell aggregates with 
polymorphic appearance. At first, cells had irregular size and shape, were vacuolated 

















months, outgrowths developed and a monolayer of epithelial cells with a pavement-
like arrangement was established (Figure 6.6). At this time, cells were polygonal in 
shape and showed atypical nuclear features such as clusters of chromatin, thickened 
and convoluted nuclear membrane, and large nucleoli. Some multinucleated giant cells 
were also seen in cell culture.  
These cells are growing without interruption for more than 40 months and with 
more than 100 serial passages, exhibiting a continuous, permanent and stable 
proliferation rate. This cell line can be maintained in DMEM only with 1% of FBS 
(Figure 6.6A).  
 
Figure 6. 6 - Characterization of IPO-SOC43 cell line in 2D model 
The cell line presents cobblestone morphology or a pavement-like arrangement characteristic 
of epithelial cells in a confluent monolayer (cells with polygonal shape). A. Representative 
morphology of IPO-SOC43 cells in DMEM culture medium with 1% FBS, phase contrast 
microscopy, 100x. B. Representative morphological appearance of IPO-SOC43 cell line at 
passage 40, phase contrast microscopy, 100x; C. Representative morphology of IPO-SOC43 








Proliferation rate of IPO-SOC43 cell line 
The proliferative characteristics of the cell line were assessed (Figure 6.7) and the 
cell line exhibited a slow proliferation rate and a doubling time (37,3 hours) with a 
proliferation rate of 1,86% in the initial 72 hours (3 days). Continuous growth (more 
than 100 passages), led us to believe that IPO-SOC43 cell line behaves as an 
immortalized cell line. 
 
Figure 6. 7 - Proliferation curve of IPO-SOC43 cell line 
A. Cell counting was determined by microscopy using the trypan blue exclusion method, and in 
B. nuclei counting was determined by crystal violet staining, at regular time intervals (1 to 9 
days). 
 
Migration properties of IPO-SOC43 cell line 
The wound healing assay is a simple and reproducible method of measuring cell 
migration444. Scratch assays showed that the cell line have a low migration ability, 
taking 72h to close the wound area (Figure 6.8). 
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Figure 6. 8 - Wound healing assay to determine the migration rate of IPO-SOC43. 
Representative images of wound-healing assays performed in IPO-SOC43 cell. Cells were 
plated onto a 12 well dish and treated with mitomycin-C. Wounds were generated and cells 
migrate filling the wound after 72h. Pictures were taken at 0 h, 24h, 48h and 72h after the 
scratch was performed (bright field microscopy), 100x. 
 
Clonal selection was observed in IPO-SOC43 cells by cCGH 
For the establishment of the genomic profile by cCGH analysis was performed in 
the DNA extracted from the original ascitic fluid cells and subsequently in the 
corresponding cell line, at passage twenty (p20, Figure 6.9B) and forty-two (p42, Figure 
6.9C) after its initial establishment. We also tried to perform cCGH analysis with DNA 
extracted from paraffin sections of the primary tumor but the quality of the DNA was 
insufficient. 
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cCGH profiles showed gain and losses of chromosome regions as shown in Figure 
6.9 and chromosome alterations are described in Table 6.3.  
 
 
Figure 6. 9 - cCGH profiles of cells from ascitic fluid and IPO-SOC43 cell line 
A. Cells from ascitic fluid; B. IPO-SOC43 cell line p20; C. and p42; Red lines indicate loss and 
green lines indicate gain of chromosomal regions. 
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As shown in Table 6.3 and Figure 6.9, tumor cells from ascitic fluid showed a 
complex genomic profile by cCGH with several gains, including amplifications, and 
losses of chromosome regions. The cell line cCGH profile was quite similar exhibiting 
most of the alterations present in the original ascetic fluid but also showing some de 
novo alterations.  
Table 6. 3 - Description of cCGH chromosome alterations in IPO-SOC43 cell line 
 
 
The cells from the ascetic fluid present alterations in TP53 gene, namely deletion 
of the region where TP53 gene is located, verified by cCGH (Figure 6.9). 
 
 
Gain of entire chromosomes/partial gains of 
chromosome regions
Loss of entire chromosomes/partial 
losses of chromosome regions
Cells from
ascitic fluid
20/                                                           
1p34.3-q23, 1q31-q32.1, 1q32.3-q44, p25-
p11.2, 3p12-q29, 4q28.q35, 5p15.3-p13, 
7p22-q34, 8p21-q24.3 with amplification
8q11.2-q23, 11p14-p11.2, 12p12-p11.2, 
13q21-q31, 14q11.2-q13, 17q24-q25, 
18p11.3-p11.2, 18q12, 19p13.3-q13.2 with
amplification 19q12-q13.1
9, 15, 16, X/                                 
3p24-p14, 4p16-q28, 5q11.2-q31, 





7, 12, 20/                                               
1p36.3-q23, 1q32-q44, 2p25-q13, 2q21.1, 
2q24-q32, 3p12-q29, 4q28.q35, 5p15.3, 
8q11.2-q24.3, 11q13-q14, 13q21-q31, 
14q11.2-q21, 17q22-q25, 18p11.3, 
19p13.3-q13.2 with amplification of
19q13.1.
9, 15, X/                                      
1q25-q31, 3p23-p21, 4p16-q27, 





20/                                                           
1p36.1-p31, 1q22-q23, 1q41-q42, 2p25-
p21, 3q13.1-q29, 4q28.q35, 5p15.3-p13, 
5q32, 7p22-q31, 9q22-q31, 10p13-p12, 
14q11.2-q13, 17q22, 19p13.1-q13.1 with
amplification of 19q13.1, Xq21.3-q25
15, 18/                                       
1q31.1, 3p26-p13, 4p16-q27, 
5q11.2-q22, 6p21.3-p12, 7q35-q36, 
8p23-p12, 9p24-p13, 17p13-q21.1, 






Other alterations, also frequently found in ovarian cancer and also reported in 
TGCA31, such as 1p36.3, 8q11.2 and 14q11.2 were observed in IPO-SOC43 cell line. The 
acquisition of changes not seen in the in the original ascitic fluid cells, possibly led to its 
spontaneous immortalization.  
cCGH analysis of the cells from passage twenty showed gains of chromosome 7, 
12 and 20 and partial gains on several chromosomes as reported in Table 6.3. The IPO-
SOC43 cell line presented a total loss of chromosomes 9, 15 and X. 
We also found that 19q 13.1 was amplified, this feature is maintained 
throughout all cell line passages and was reported in other studies445,446. 
In the passage 42, IPO-SOC43 showed gain of chromosome 20 and partial gains 
of 1p36.1-p31, 1q22-q23, 1q41-q42, 2p25-p21, 3q13.1-q29, 4q28.q35, 5p15.3-p13, 
5q32, 7p22-q31, 9q22-q31, 10p13-p12, 14q11.2-q13, 17q22, 19p13.1-q13.1, Xq21.3-
q25 and again amplification of 19q13.1 (Figure 6.9). Loss of chromosome 15 and 18 
was observed, at this passage, and the cell line also maintained partial losses of some 
chromosome regions. cCGH analysis revealed that IPO-SOC43 cells at passage 42 
contained more genetic changes than the original tumor cells from ascitic fluid, 
however these data are consistent with the acquisition of genetic change with cell line 
passage and clonal evolution.  
Mutational status of TP53, BRCA1 and BRCA2 of IPO-SOC43 cell line 
In order to further characterize the cell line, mutation analyses of TP53 and 
BRCA1 and BRCA2 were performed. As mentioned above, IPO-SOC43 cell line has the 
deletion of the region where TP53 is located in the short arm of chromosome 17, 
detected by cCGH and indicating the loss of one allele (Figure 6.9).  By automate 
Sanger sequencing a missense mutation in exon 5, codon 172 (p.V172F; GTT>TTT, 
c.514G>T) was detected in the other allele, with the substitution of Valin (Val) to 
phenylalanine (Phe), also identified in the hemizygotic histogram in Figure 6.10. This 
c.514G>T mutation in TP53 is associated with an advantage for tumor growth in a 
variety of  neoplasms and it might have an pathophysiological effect, as reported in 
V80 COSMIC database (http://cancer.sanger.ac.uk/cosmic/mutation)447–452. Thus IPO-





The TP53 mutation status of IPO-SOC43 is consistent with IHC results, showing 
intense nuclear positivity for p53 protein, corresponding to aberrant expression mainly 
due to stabilization of the protein and a longer half-life453. 
Analysis of mutations in BRCA1 and BRCA2 genes was performed by CSCE. No 
mutation or polymorphism was identified in the BRCA1 gene. Regarding BRCA2 
gene, three polymorphisms with no recognized clinical significance were 




Figure 6. 10 - Sanger sequencing histogram of TP53 exon 5 
IPO-SOC43 cell line has a mutation in codon 172 (p.V172F;GTT>TTT) on exon 5 in hemizygosity 
since the cell line has the loss of the short arm of chromosome 17 in one allele, resulting in 
substitution of Valin (Val) to phenylalanine (phe) (IARC TP53 mutation database). 
 
Establishment and characteristics of 3D cell culture  
3D cell cultures of IPO-SOC43 cells were established in stirred-tank culture 
systems. Two approaches were pursued to induce cell aggregation and compaction of 
cell aggregates: with and without ROCK inhibitor supplementation. We observed that 
IPO-SOC43 cells in 3D are heterogeneous and when cultured without ROCK inhibitor 
arranged in aggregates with irregular shape (grape-like shape, Figure 6.11). Addition of 
ROCK inhibitor improved cell aggregation reversibly as, when it was removed 
aggregates reacquired their original organization. On the other hand, cells with ROCK 
inhibitor maintained the conformation in aggregates (Figure 6.11); and after 72h of 
culture the levels of cell death were lower in aggregates with ROCK inhibitor than 





Culture progression was evaluated by measuring the area of the tumor 
aggregates. Cell aggregates had an average area of approximately 2761 ± 1986 µm2 at 
day 1 of culture and 2970 ± 2401 µm2 at day 3 (Figure 6.12A). We also assessed the cell 
concentration, by quantification of DNA and, after day 3, cell concentration decreased 
in 3D cultures (Figure 6.12B).  
These results show that IPO-SOC43 cells are suitable to establish 3D cultures and 




Figure 6. 11 - Aggregation of IPO-SOC43 with and without ROCK Inhibitor in 3D culture 
system 
Aggregates in suspension were cultured on a magnetic stirrer (40 rpm) and supplemented with 
and without ROCK Inhibitor, during several time points. Aggregates with ROCK Inhibitor 














Figure 6. 12 - 3D Culture progression with measurement of aggregates area and growth curve 
of IPO-SOC43 cells with ROCK Inhibitor 
A. IPO-SOC43 aggregates area and B. growth curve, determined by PicoGreen analysis. Values 
are mean±SD. Area increased with culture time, but growth tends to be lower. 
 
Regarding the imunoprofile of IPO-SOC43 cultured in 3D, cells express a similar 
profile as in 2D cell culture (Figure 6.13). Cells are positive for anti-cytokeratin type II 
(clone Cam 5.2), and CA125. Cells exhibit positive expression with p53 and are negative 
for WT1 as in 2D model and some cells express vimentin. IPO-SOC43 in 3D culture 
maintains the same biological markers (Figure 6.14) as cultured in 2D (Figure 6.5). 
In 3D configuration, IPO-SOC43 cells exhibited loose aggregates. Cells continue to 
produce cytokeratin 18 and collagen IV. Cells exhibited β-catenin, mainly in the 
cytoplasm, and fewer cells exhibited positive expression for E-cadherin, with a more 
peripheral distribution in cell aggregates. Proliferation activity is maintained has seen 

























































Figure 6. 13 - Characterization of IPO-SOC43 cell line in 3D model 
Cryosections of 3D aggregates stained with hematoxylin and eosin (HE) and 
immunohistochemical staining panel. Cells show positive expression for cytokeratin (CK) type II 
(clone CAM 5.2), vimentin and p53. Cells were negative for WT1 and had positive expression 




Figure 6. 14 - Expression of biological markers relevant for the establishment of 3D cell 
culturing models in IPO-SOC43 cell line 
Cryosections of 3D aggregates show positive expression for CK18, collagen IV and β-catenin. 
























In this paper we characterized a new EOC cell line, IPO-SOC43 (Instituto 
Português de Oncologia - High Grade Serous Ovarian Carcinoma 43), established in our 
laboratory that can used as an important experimental tool in cancer research of EOC.  
Cancer cell lines, besides their well-known limitations, are still useful in vitro 
models to study molecular mechanisms underlying cancer biology, chemoresistance 
and tumor recurrence, providing that they are well characterized454. There are many 
benefits in using primary cell cultures with little or no laboratory-induced 
transformation as the behavior of these cells reflects better the original tumor cells.  
Our cell line was established from a patient (73 years old) receiving neoadjuvant 
chemotherapy treatment for advanced HGSC, not manageable by surgery up front. 
Ovarian cancer is recognized as a disease with distinct molecular backgrounds28 and 
not a single clinical entity. Seventy percent of EOC are HGSC, making this tumor type 
an important research focus455. Although considerable progress has been made in 
cancer research, the survival rate of ovarian cancer has not improved over the past 
several decades7, demonstrating the urgent need for understanding the mechanisms 
underlying the development of ovarian cancer.  
In this study a detailed characterization of this cell line was done in order to 
establish the similarities and differences between the cell line and the original ascitic 
fluid456.  
The evaluation of the morphological features and immunohistochemistry 
confirm that the IPO-SOC43 cell line resembles the original cells from the ascitic fluid 
cells and also from the patient’s ovarian primary tumor. The 2D model cell line 
expresses ovarian carcinoma markers and its epithelial origin has been confirmed by 
immunohistochemistry and immunofluorescence. Although a positive expression of 
vimentin was observed using techniques of immunocytochemistry, the result of flow 
cytometry indicates that the cell line does not express vimentin. We believe that the 
process of fixation of the cells can interfere with the antibody vimentin and this may 





Dynamical chromosomal gains and losses in the cell line support the evidence of 
clonal selection. The cCGH profile of passage 42 of cell line showed less variability of 
numerical alterations apparently due to clonal adaptation to in vitro conditions and 
hopefully the stabilization of the cell line. Nevertheless, IPO-SOC43 cultured cells 
showed gains and losses similar to the parental cells as well as additional chromosomal 
alterations in clones compared with the parental cells suggesting that IPO-SOC43 cell 
line was undergoing clonal selection.  
It is suggested that certain genetic alterations that emerge in a cancer cells 
confer a selective advantage over the others, and cancer progression results from the 
expansion of clone(s) that collectively acquires the following characteristics: self-
sufficiency in growth signals, evasion to apoptosis, sustained angiogenesis, limitless 
replicate potential and capacity of tumor invasion and metastasis458.  
Through cCGH we verified that the cell line has the deletion of the region where 
TP53 is located in the short arm of chromosome 17 and IPO-SOC43 cells contains a 
missense mutation in TP53 in exon 5, codon 172 (p.V172F;GTT>TTT, c.514G>T. This 
c.514G>T mutation is associated with an advantage for tumor growth in a variety of 
neoplasms and it might have an pathophysiological effect, as reported in V80 COSMIC 
database (http://cancer.sanger.ac.uk/cosmic/mutation)447–452. Thus IPO-SOC43 cells do 
not have wild type p53 protein.   
IPO-SOC43 cell line harbors alterations in chromosome 19, specifically gain of 
chromosome regions 19p13.1-19q13.2 with amplification at 19q13.1, that has been 
reported as a frequent cytogenetic change observed in ovarian carcinomas by other 
studies338,445,459. We believe that our cell line may has become immortalized through 
these alterations as reported for other cell lines338,445,459.  
The study of the cCGH of our cell line revealed several other cytogenetic 
alterations that were already described as highly frequent in HGSC by Kim et al.456, 
such as the gain of 1p36, Xq21 and loss of 8p23. The same authors claimed that gains 
of 5p15 and 14q11, and loss of 22q12, which we also find in IPO-SOC43 are associated 





Finally, IPO-SOC43 cell line does not present BRCA1 mutations although in BRCA2 
three polymorphisms were identified:  5’UTR 1-26 G/A; p.N372H and p.V1269V. These 
alterations are not associated with clinical significance. 
In summary, the genetic main characteristics of this cell line match the “classical 
features” described by Cancer Genome Atlas Research Network (TGCA)31 such as 
alterations in DNA regions copy number and TP53 mutation (reported in 96% of cases). 
3D cultures of tumor cell lines are considered to be better models than 2D for 
evaluation of tumor characteristics. For this reason we started by establishing a 3D 
culture of IPO-SOC43 and compared to the characteristics of neoplastic cells cultured 
in 2D culture. IPO-SOC43 cells in 2D were able to produce adhesion molecules such as 
E-cadherin and β-catenin; and extracellular matrix macromolecules as collagen IV. 
Their epithelial origin was proved by cytokeratin 18 positivity and expression of F-actin 
very similar with original tumor. Our cell line persists in 3D, in irregular and loose 
aggregates, and maintains the phenotypical features of the original tumor. This allow 
us to explore the advantages of the use of stirred-tank culture systems for 3D cultures 
in process scale-up over the standard two-dimensional (2D) static culture460; and by 
reproducing better the effects of the tissue microenvironment, including cell 
morphology, polarity and junctions.  
In both models, we observed a similar proliferation activity (by Ki-67). In our 3D 
model, expression of adhesion molecules such as E-cadherin or extracellular matrix as 
collagen IV, indicates that cell aggregates maintained cell–cell interactions and 
expression of ECM components. We hope to use this 3D culture system in more 
complex assays, and to provide better and more complete answers regarding 
neoplastic cells and their microenvironment460. 
In conclusion, we describe the characteristic of an established cell line, IPO-
SOC43, isolated from ascitic fluid of HGSC patient using different techniques and 
approaches (morphology, phenotype, genetic) and confirm its use as a stable cell line 
suitable to investigate on HGSC of ovary, fallopian tube and peritoneum.  































Epithelial ovarian cancer (EOC) is a heterogeneous disease composed by 
different histological types with distinctive patient outcomes3–5. EOC diagnosed while 
still limited to the ovaries, allow that 90% of patients can be cured with conventional 
surgery but cure rates decrease substantially after tumor dissemination to the pelvic 
organs or beyond the peritoneal cavity2,26. 
The standard chemotherapy procedure involving cytotoxic drugs has been 
established and optimized for ovarian cancer treatment (such as the combination of 
taxane and platinum); however, the overall cure rate has remained between 20-40% 
for the last 30 years4,461–463. Therefore, these therapeutic options are not effective, 
leading to therapy resistance and metastasis. 
We focus our study in the most common histological type, high grade serous 
carcinoma (HGSC), usually diagnosed at an advanced stage, and although these tumors 
frequently respond to surgery and platinum-based chemotherapy, they usually recur55; 
and in ovarian clear cell carcinoma (CCC), less frequent histological type, known to be 
intrinsically chemoresistant and associated with poor prognosis in advanced stages55. 
New approaches are needed and epigenetic therapies raise as a possible route. 
Histone deacetylases (HDACs) are responsible for many functions, they regulate 
the acetylation of a variety of histone and nonhistone proteins, controlling the 
regulation of transcription and function of genes involved in cell cycle control, 
proliferation, survival/cell death, DNA repair, differentiation and therapy274,325,326. 
Hence, HDACs expression is frequently altered in hematologic and solid tumor 
malignancies329–331,334 and they can represent ideal targets for new therapeutic 
strategies.  
In the perspective of better understanding the role of HDACs in ovarian 
carcinoma, we evaluated the expression profile of HDACs in our ovarian series, using 
immunohistochemistry (IHC). Although many studies have been carried out to 
elucidate the role of these enzymes in the context of ovarian cancer, their expression 





We evaluated the expression by immunohistochemistry of class I enzymes, 
HDAC1, 2, 3, and class II enzymes, HDAC4, 6 and phosphoHDAC4/5/7 in HGSC and CCC. 
The results in both EOC types, revealed that HDACs were significantly associated with 
the histological type of ovarian cancer. In HGSC, it was verified a high expression of 
HDAC1, 2, 3, 4, 6 and pHDAC4/5/7. Regarding evaluation of clinical parameters and cell 
cycle markers only HDAC1 expression was associated with p21 expression and HDAC3 
was associated with disease stage at presentation in HGSC.  
In CCC, high expression of HDAC1 and 2 was verified, whereas HDAC3 expression 
was only present in 30% of cases. Also the low expression of HDAC4 (in only 21% of 
cases) seems to be characteristic of this tumor type. In this cohort no other HDAC 
expression was associated with any of the analyzed molecular and clinical parameters. 
As mentioned above, other studies report the expression of these enzymes in 
ovarian cancer, however, this is the first time the difference of HDACs expression 
profile between different histological types of ovarian carcinomas is highlighted. 
However, since we show that HDACs are expressed in EOC at higher levels than 
in normal tissue counterparts, independently of which the enzyme is, we consider that 
HDACIs can be a putative therapeutic strategy for ovarian carcinoma. 
Assuming that the expression profiles of HDACs were different between 
histological types we observed that HDACs are linked to the expression of cell cycle 
molecules as reported by other studies296,299,325,421,465. However, further investigation is 
required to clarify which of the identified biomarkers or whether they will ultimately 
be useful in the diagnosis and monitoring of patients with ovarian carcinomas.  
 Hence, we evaluated the effects of HDACI in proliferation and cell death in EOC 
cell lines with exposure to HDACI, DNA methyltransferases inhibitors (5-aza-dC) and 
conventional chemotherapy (carboplatin and paclitaxel).  Our results report that HDAC 
inhibitors, butyric acid and vorinostat, induced cell death, mainly through apoptosis in 
ES2 cell line, confirmed by immunofluorescence of cleaved caspase 3 and the ratio of 
protein BAX/BCL-2 which increases after vorinostat exposure. Also, vorinostat and 5-
aza-dC were able to potentiate the effect of chemotherapeutic drugs mainly in ES2 cell 
line (CCC), supporting that CCC treatment can benefit from combined chemical and 




epigenetics directed therapy. Whereas in HGSC we verified that only tetra-
combination of HDACIs, 5-aza-dC, carboplatin and paclitaxel would be profitable to 
induce cell death.  
In this work it was interesting to note that vorinostat has differential effects 
between CCC and HGSC as it would be expected since they are different entities in 
clinical and molecular terms. Regrettably, clinical trials have been proven inconclusive 
or have classified HDACIs as not suitable therapeutic agents for the treatment of EOC, 
mainly due to toxic effects. Unfortunately, we cannot make a point on histological type 
response between our in vitro results and the literature on clinical assays, since the 
clinical trials were labeled as being carried out in EOC with no identification of the 
tumor histological type324,374,428–430. 
Further studies are needed to understand how and why the different cancer cell 
types respond to HDACIs differently and the mechanistic basis underlying resistance as 
well as the secondary and adverse effects in patients, in order to develop more 
effective and harmless HDACIs. 
As mentioned above, CCC is an unique clinical, pathological and molecular entity 
within ovarian cancer, having HNF1β as a key pro-survival gene400,401, being considered 
as responsible for cell survival, proliferation and chemoresistance72,402. So, we 
evaluated the effect of HDACI in HNF1β expression and CCC cells viability and the 
results showed that the increased levels of HNF1β by vorinostat induced cell cycle 
arrest and apoptosis in CCC cells. The increased expression of p21 supports the 
evidence observed of the cell cycle arrest in G0/G1 phases414,415. In our work we 
proved that increased levels of HNF1β by vorinostat is associated with cell cycle arrest 
and apoptosis in CCC cells. This observation was deeply related with increased 
acetylation load of HNF1β. The increased acetylation levels related to HDACIs exposure 
was already described for other proteins that are not histones, for example the tumor 
suppressor p53421–424, although it is a completely new concept in HNF1β that we are 
currently experimentally depicting. However, since HNF1β has a pro-survival activity, 
this work showed that its acetylation can be a route of HDACIs action in CCC cells, 





becomes evident that the action of HDACIs, although initially they have been designed 
to affect the acetylation level of histones, also affects the function of other proteins 
which play crucial roles in cell function420 421–423.    
Together, our study provided new evidences of HNF1β role in CCC. Further 
studies are needed in order to unravel the function of HNF1β, especially in the context 
of cancer, since HNF1β is consistently de novo expressed or overexpressed in CCC from 
different organs such as ovarian, pancreas, kidney and liver399,425–427. 
At the light of our findings we can raise two more questions: 1) What is the role 
of HNF1β in tumor progression?, and 2) Would an acetylation of HNF1β-target therapy 
be efficient in clear cell carcinomas? 
According to TGCA31, genetic alterations and epigenetic modulation of signaling 
pathways have been reported in EOC, including the overexpression of Notch pathway 
elements and histone deacetylases. However, no previous work has addressed the 
effect of HDACIs, and in particular vorinostat, on Notch signaling in ovarian cancer. 
In this PhD thesis we aimed to investigate the modulation of the Notch pathway 
by vorinostat, since it was already knew the involvement of Notch pathway in ovarian 
cancer biology148,152,153,310,466. With our study we revealed that vorinostat activated the 
Notch pathway in both CCC and HGSC cell lines, through different Notch elements. In 
CCC, the activation of Notch pathway appeared to occur through Delta-like (Dll) ligands 
1, 2 and 3, whereas in HGSC Dll1 and Jagged 1 and 2 ligands were involved. Also, our 
results ensure the activation of Notch pathway in EOC cells by vorinostat because it 
induces the overexpression of Hes and Hey Notch target genes. Moreover, it was 
shown the redundancy of Notch, Delta and Jagged elements expressed in EOC cell 
lines; thus, whatever is the panel of receptor or ligands expressed on the cell 
membrane, the downstream target genes were always expressed in the presence of 
vorinostat. This upregulation can shed a light on the mechanism underlying the failure 
of vorinostat therapy in some ovarian carcinoma subsets, as shown on clinical 
trials372,379,380. Again, the fact that the published clinical trials do not present the 
results considering the histological type of tumor limits the confrontation of our results 
with the literature.    




 The final aim of this study was to establish and characterize a human cell line. 
We described a HGSC cell line (IPO-SOC43) immortalized without any induced 
transformation, which represents the most frequently occurring histopathological 
subtype of ovarian carcinomas, the HGSC. 
The cell line is maintained in 2D and 3D model exhibiting protein expression 
profile similar to the primary tumor. The expression of adhesion molecules indicating 
that the established cells closely mimic the natural environment found in vivo, 
resembling the primary tumor. 
The cell line arbors some classical features described by TGCA31,  such as 
alterations in DNA copy number, TP53 mutation and BRCA2 mutation. The IPO-SOC43 
cell line established is a suitable model to investigate the molecular mechanisms 
underlying the progression, treatment, resistance and recurrence of HGSC. We hope 
this new cell line can contribute to enlarge the panel of cell lines uncovering ovarian 
cancer heterogeneity, however, considering in vitro models and the development of 
cell technology some questions remain to be answered: Do 3D models have an 
advantage on 2D models, giving a more real picture of an ovarian cancer?, and Can 3D 
models be useful tools to predict sensitivity to therapy, allowing an accurate screening 
of drugs to be used individually in each patient- precision medicine?  
Conclusions 
In this study, our results confirmed previous reports that HDACs are expressed in 
ovarian cancer, involved in tumor progression and cancer metastasis and the 
epigenetic changes found could potentially serve as biomarkers for disease 
progression. The research of class I and II of HDACs expression profiles evidenced their 
association with different histological types of ovarian cancer. Moreover, we 
demonstrated that HDACIs inhibit cell proliferation and induced cell death in ovarian 
clear cell carcinoma (CCC) and in high grade serous carcinoma (HGSC), especially in 
combined therapy with 5-aza-dC, carboplatin and/or paclitaxel. Our data specified 
some of the putative mechanisms for apoptosis induced by HDACIs. Also, we reported 





action from pro-survival to anti-survival upon exposure to vorinostat or other HDACI. 
So, the description of HNF1β acetylation can constitute a mechanism of 
modulation/abrogation of HNF1β pro-survival function in CCC, which can contribute 
for the design of a new CCC therapy. 
Furthermore, we reported that vorinostat modulates the expression of 
downstream targets of the Notch pathway whatever is the panel of Notch receptor or 
ligands expressed in EOC cell lines. Hence, the downstream target genes are always 
expressed in the presence of vorinostat. This regulation may explain the mechanism 
underlying the failure of vorinostat therapy in ovarian carcinoma, but our results did 
not show a route to impair Notch pathway in ovarian cancer by using HDACIs. 
In the course of this work, we demonstrated the successful establishment of a 
cell line of HGSC, cultured in 2D and 3D, without lab immortalization, which can be a 
new tool to study ovarian cancer biology. So far, due to the high heterogeneity of EOC 
the existing models have been insufficient to accurately mimic all disease cases. This 
new cell line will contribute to enrich the current panel of cell lines available for 
scientific and clinical use. Moreover, in vitro models, transient/perishable or 
stable/immortalized, will be for sure the most suitable tools to select more efficient 
drugs and predict chemoresistance allowing an increasingly individualized medicine, in 
which cells of a patient can be manipulated in vitro to select a more beneficial 
therapeutic program.   
In conclusion, our findings reinforced the putative efficiency of HDACs in a 
combined therapy to treat ovarian cancer and we believe this thesis work contributes 
with new molecular insights on how HDACIs disturbs the biological functioning of these 
two different histological types of ovarian cancer (CCC and HGSC) and opens new 










In the last decade, the surgical approach and the standardization of 
chemotherapeutic modalities have slightly improved survival of epithelial ovarian 
cancer (EOC) patients, however EOC still has a poor prognosis. Since the histological 
types of EOC corresponds to different diseases, future developments in the 
understanding of these diseases and treatment should focus on histology and its 
specific molecular alterations.  
Based on the fact that histone deacetylases (HDACs) expression is increased in 
EOC, the research presented in this thesis contributes with some inputs to disclose the 
molecular mechanisms underlying the action of histone deacetylases inhibitors 
(HDACIs) in EOC. We reported that the expression profile of HDAC, class I (HDAC1, 2, 3) 
and class II (HDAC4, 6 and phosphoHDAC4/5/7) in ovarian cancer is intimately 
associated with the histological type. Considering this, in the future it would be 
interesting to perform in vitro knockdown studies aiming the relevance of each HDAC 
in the different histological types of EOC, to disclose their real role as epigenetic 
biomarkers. 
This thesis open up for a wide range of further investigation to explore the role 
of HDACs in cancer cells pathophysiology that might have an impact on cancer therapy. 
Clear cell carcinoma (CCC) is by far the most interesting and challenging EOC biological 
model. 
Regarding the HNF1β in CCC, we showed that Vorinostat induces both the 
increased of HNF1β levels and its acetylation load concomitantly with a decreased cell 
survival. This evidence is new since high levels of HNF1β are correlated to increased 
cell survival. So, the meaning of HNF1β acetylation must be clarified in order to know 
the role of HDACs and/or other deacetylases in the modulation of HNF1β function as 
well as their relevance in CCC biology. Moreover, our group have shown recently that 
HNF1β regulates the production of glutathione (GSH) which constitutes a mechanism 
of resistance to carboplatin. Hence, HNF1β is still a very interesting gene/protein which 
function deserves to be depicted in cancer, not only in EOC but also in other 





established by HNF1β and other molecular elements, such as p53 and BAF250a 
(encoded by ARID1A) is for sure a challenge. 
In our study it was not possible to include TP53 wild type CCC cell lines but it 
would be interesting to evaluate how the function of HNF1β is affected (abrogated or 
potentiated) by p53. Since HNF1β is a pro-survival gene in CCC and TP53 mutation is 
uncommon in CCC, we believe the modulation of the action of HNF1β will be rather 
different than in TP53 mutated CCC cell lines.    
ARID1A is a gene that codifies BAF250a protein that belongs to a chromatin 
remodeling complex and has recently been pointed out as a marker for CCC. In our 
cohort we saw a perfect match between HNF1β and BAF250 expression and their 
interaction remain unknown in CCC biology. Disclosing their relationship we can go 
forth into a relevant step to understand CCC unique biological behavior. 
The redundancy of epigenetic modulation of Notch pathway elements by 
Vorinostat in EOC was also shown, indicating that Notch pathway is really central in 
EOC carcinogenesis and progression and this fundamented by the way their elements 
are able to overcome each other functions and sustain the expression of downstream 
targets. In this point, it would be interesting to find a way other than through HDACS 
to effectively disturb Notch pathway in EOC. 
The results in vitro proved that there is benefits of combined therapy, using 
drugs with action of epigenetic modulation and conventional therapy. Future analyses 
of both primary and relapse tumors from the same patient would be an ideal way to 
study chemotherapy resistance in EOC as well as new combined therapeutic regimes. 
However, since secondary surgery is rarely performed, ascitic fluid which is collected 
for a palliative purpose can be a good alternative to collect cancer cells, as we have 
shown with the establishment of a primary cell line from a HGSC patient. Additionally, 
ex vivo transient experiments using tumor explants can be an useful approach to be 
optimized in order to serve as a screening platform to analyze individualized responses 
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